Jack A. Roth, M.D., F.A.C.S.

Peer-Reviewed Articles

1. Deboever, N, Al Tashi, Q, Eisenberg, M, Saad, M, Antonoff, MB, Hofstetter, WL, Mehran, RJ, Rice, DC, Roth, JA, Swisher, SG, Vaporciyan, AA, Walsh, GL, Wu, J, Rajaram, R. Machine Learning Prediction of Financial Toxicity in Patients with Resected Lung Cancer. Journal of the American College of Surgeons 241(2):107-116, 2025. e-Pub 2025. PMID: 40028915.
2. Deboever, N, Al Tashi, Q, Eisenberg, M, Saad, M, Antonoff, MB, Hofstetter, WL, Mehran, RJ, Rice, DC, Roth, JA, Swisher, SG, Vaporciyan, AA, Walsh, GL, Wu, J, Rajaram, R. Machine Learning Prediction of Financial Toxicity in Patients with Resected Lung Cancer. Journal of the American College of Surgeons 241(2):107-116, 2025. e-Pub 2025. PMID: 40028915.
3. Lei G, Sun M, Cheng J, Ye R, Lu Z, Horbath A, Huo D, Wu S, Alapati A, Aggarwal S, Xu Z, Mao C, Yan Y, Yao J, Li Q, Chen X, Lee H, Zhuang L, Jiang D, Pataer A, Roth JA, Navin N, Koong AC, You MJ, Lin SH, Gan B. Radiotherapy promotes cuproptosis and synergizes with cuproptosis inducers to overcome tumor radioresistance. Cancer Cell 43(6):1076-1092.e5, 2025. e-Pub 2025. PMID: 40215978.
4. Wang Y, Meraz IM, Qudratullah M, Kotagiri S, Han Y, Xi Y, Wang J, Akdemir KC, Roth JA, Lissanu Y. Mutation of SMARCA4 Induces Cancer Cell-Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy. Cancer Res 85(11):1997-2013, 2025. e-Pub 2025. PMID: 40080526.
5. Meraz, I, Majidi, M, Song, R, Meng, F, Gao, L, Wang, Q, Wang, J, Shpall, E, Roth, JA. NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model. eLife 13, 2025. e-Pub 2025. PMID: 39932765.
6. Deboever N, Eisenberg MA, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Rajaram R. Relationship of Surgical Approach With Financial Toxicity in Patients With Resected Lung Cancer. J Surg Oncol 131(2):303-309, 2025. e-Pub 2025. PMID: 39257253.
7. Araujo HA, Pechuan-Jorge X, Zhou T, Do MT, Hu X, Rojas Alvarez FR, Salvatierra ME, Ibarguen HP, Lee R, Raghulan R, Shah H, Moreno Ayala MA, Chen K, Tovbis Shifrin N, Wu S, Solis Soto LM, Negrao MV, Gibbons DL, Hong DS, Roth JA, Heymach JV, Zhang J, Jiang J, Singh M, Smith JAM, Quintana E, Skoulidis F. Mechanisms of response and tolerance to active RAS inhibition in KRAS-mutant NSCLC. Cancer Discov, 2024. e-Pub 2024. PMID: 38975897.
8. Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbo F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Leighl NB, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Janne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature 635(8038):462-471, 2024. e-Pub 2024. PMID: 39385035.
9. Zhou, N, Leung, CH, William Jr, WN, Weissferdt, A, Pataer, A, Godoy, M, Carter, B, Fossella, FV, Tsao, A, Blumenschein, GR, Le, X, Zhang, J, Skoulidis, F, Kurie, JM, Altan, M, Lu, C, Glisson, BS, Byers, LA, Elamin, YY, Mehran, RJ, Rice, DC, Walsh, GL, Hofstetter, WL, Roth, JA, Tran, HT, Wu, J, Solis Soto, LM, Kadara, HN, Swisher, SG, Vaporciyan, AA, Gibbons, DL, Lin, HY, Jack Lee, J, Heymach, JV, Vailati Negrao, M, Sepesi, B, Cascone, T. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. Journal for immunotherapy of cancer 12(10), 2024. e-Pub 2024. PMID: 39448200.
10. Zhou N, Leung CH, Wiliam WN, Weissferdt A, Pataer A, Fossella FV, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Wu J, Kadara H, Swisher SG, Vaporciyan AA, Gibbons DL, Lin HY, Lee JJ, Heymach JV, Negrao MV, Sepesi B, Cascone T. Impact of Actionable Genomic Aberrations on Efficacy of Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. J Immunother Cancer, 2024. e-Pub 2024.
11. White BS, Woo XY, Koc S, Sheridan T, Neuhauser SB, Wang S, Evrard YA, Chen L, Foroughi Pour A, Landua JD, Mashl RJ, Davies SR, Fang B, Raso MG, Evans KW, Bailey MH, Chen Y, Xiao M, Rubinstein JC, Sanderson BJ, Lloyd MW, Domanskyi S, Dobrolecki LE, Fujita M, Fujimoto J, Xiao G, Fields RC, Mudd JL, Xu X, Hollingshead MG, Jiwani S, Acevedo S, Davis-Dusenbery BN, Robinson PN, Moscow JA, Doroshow JH, Mitsiades N, Kaochar S, Pan CX, Carvajal-Carmona LG, Welm AL, Welm BE, Govindan R, Li S, Davies MA, Roth JA, Meric-Bernstam F, Xie Y, Herlyn M, Ding L, Lewis MT, Bult CJ, Dean DA 2nd, Chuang JH. A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis. Cancer Res 84(13):2060-2072, 2024. e-Pub 2024. PMID: 39082680.
12. Deboever N, Correa AM, Feldman H, Eisenberg M, Antonoff MB, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Hofstetter WL. Early Interventional Treatment of High Output Chyle Leak following Esophagectomy is Associated with Improved Survival. Ann Surg 280(1):91-97, 2024. e-Pub 2024. PMID: 38568206.
13. Meric-Bernstam F, Lloyd MW, Koc S, Evrard YA, McShane LM, Lewis MT, Evans KW, Li D, Rubinstein LV, Welm AL, Dean DA, Srivastava A, Grover JW, Ha MJ, Chen H, Huang X, Varadarajan K, Wang J, Roth JA, Welm BE, Govindan R, Ding L, Kaochar S, Mitsiades N, Carvajal-Carmona LG, Herlyn M, Davies MA, Shapiro GI, Fields RC, Trevino JG, Harrell JC, Doroshow JH, Chuang JH, Moscow JA. Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations. Mol Cancer Ther, 2024. e-Pub 2024. PMID: 38641411.
14. White BS, Woo XY, Koc S, Sheridan T, Neuhauser SB, Wang S, Evrard YA, Chen L, Foroughi pour A, Landua JD, Mashl RJ, Davies SR, Fang B, Rosa MG, Evans KW, Bailey MH, Chen Y, Xiao M, Rubinstein JC, Sanderson BJ, Lloyd MW, Domanskyi S, Dobrolecki LE, Fujita M, Fujimoto J, Xiao J, Fields RC, Mudd JL, Xu X, Hollingshead MG, Jiwani S, Acevedo S, Consortium P, Davis-Dusenbery BN, Robinson PN, Moscow JA, Doroshow JH, Mitsiades N, Kaochar S, Pan C, Carvajal-Carmona LG, Welm AL, Welm BE, Govindan R, Li S, Davies MA, Roth JA, Meric-Bernstam F, Xie Y, Herlyn M, Ding L, Lewis MT, Bult CJ, Dean II DA, Chuang JH. A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis. Cancer Res 84(13):2060-2072, 2024. e-Pub 2024.
15. Tan X, Wang S, Xiao GY, Wu C, Liu X, Zhou B, Yu J, Duose DY, Xi Y, Wang J, Gupta K, Pataer A, Roth JA, Kim MP, Chen F, Creighton CJ, Russell WK, Kurie JM. Chromosomal 3q amplicon encodes essential regulators of secretory vesicles that drive secretory addiction in cancer. J Clin Invest 134(12), 2024. e-Pub 2024. PMID: 38662435.
16. Deboever N, Feldman H, Eisenberg M, Antonoff MB, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Hofstetter WL. Octreotide's role in the management of post-esophagectomy chylothorax. Dis Esophagus 37(6), 2024. e-Pub 2024. PMID: 38391198.
17. Haderk F, Chou YT, Cech L, Fernández-Méndez C, Yu J, Olivas V, Meraz IM, Barbosa Rabago D, Kerr DL, Gomez C, Allegakoen DV, Guan J, Shah KN, Herrington KA, Gbenedio OM, Nanjo S, Majidi M, Tamaki W, Pourmoghadam YK, Rotow JK, McCoach CE, Riess JW, Gutkind JS, Tang TT, Post L, Huang B, Santisteban P, Goodarzi H, Bandyopadhyay S, Kuo CJ, Roose JP, Wu W, Blakely CM, Roth JA, Bivona TG. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. Nat Commun 15(1):3741, 2024. e-Pub 2024. PMID: 38702301.
18. Feldman H, Sepesi B, Leung CH, Lin H, Weissferdt A, Pataer A, William WN, Walsh GL, Rice DC, Roth JA, Mehran RJ, Hofstetter WL, Antonoff MB, Rajaram R, Gibbons DL, Lee JJ, Heymach JV, Vaporciyan AA, Swisher SG, Cascone T. Surgical Outcomes After Chemotherapy plus Nivolumab and Chemotherapy plus Nivolumab and Ipilimumab in Patients with Non-Small Cell Lung Cancer. J Thorac Cardiovasc Surg 167(4):1444-1453.e4, 2024. e-Pub 2024. PMID: 37816395.
19. Deboever N, Bayley EM, Eisenberg MA, Hofstetter WL, Mehran RJ, Rice DC, Rajaram R, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Bednarski BK, Morris VK, Antonoff MB. Lung surveillance following colorectal cancer pulmonary metastasectomy: Utilization of clinicopathologic risk factors to guide strategy. J Thorac Cardiovasc Surg 167(3):814-819.e2, 2024. e-Pub 2024. PMID: 37495170.
20. Deboever N, Eisenberg MA, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Rajaram R. Perspectives, Risk Factors, and Coping Mechanisms in Patients with Self-Reported Financial Burden following Lung Cancer Surgery. J Thorac Cardiovasc Surg 167(2):478-487.e2, 2024. e-Pub 2024. PMID: 37356476.
21. Mitchell KG, Bayley EM, Ikoma N, Antonoff MB, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Maru DM, Erasmus JJ, Weston BR, Ajani JA, Badgwell BD, Hofstetter WL. Gastric extent of tumor predicts peritoneal metastasis in Siewert II adenocarcinoma. Ann Thorac Surg 117(2):320-326, 2024. e-Pub 2024. PMID: 37080372.
22. Deboever N, Bayley EM, Eisenberg MA, Hofstetter WL, Mehran RJ, Rice DC, Rajaram R, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Bednarski BK, Morris VK, Antonoff MB. Do resected colorectal cancer patients need early chest imaging? Impact of clinicopathologic characteristics on time to development of pulmonary metastases. J Surg Oncol 129(2):331-337, 2024. e-Pub 2024. PMID: 37876311.

Professional Educational Materials

1. Roth J. Gene therapy for lung therapy. (Videoconference). Satellite patient information network, 1996.
2. Roth J. p53 gene therapy for lung cancer. (Audio Journal of Oncology), 1996.
3. Roth J. The technique of esophagectomy does not influence survival after resection of esophageal carcinoma. (Video Library). International Society for Diseases of the Esophagus (ISDE, 1995.
4. Roth J. Results of esophagectomy for severe dysplasia in Barrett‘s esophagus. (Video Library). International Society for Diseases of the Esophagus (ISDE), 1995.
5. Roth J. Biology of non-small cell lung cancer. The Current Perspectives in the Treatment of Non-Small Cell Lung Cancer, The University of Colorado Health Sciences Center, 1994.
6. Roth J. Commentary and Review of presentations on lung cancer. (Audio Cassettes). American Society of Clinical Oncology - IASLC Update: Commentary on Lung Cancer Presentations, 1994.
7. Roth J. Surgical and neoadjuvant approaches to locally advanced, potentially resectable non-small cell lung cancer. Recent Advances in the Management of Lung Cancer, The University of Texas Southwestern Medical Center, 1993.
8. Roth J. Brief Report: Modulation of oncogene and tumor suppressor gene expression for prevention and therapy of lung cancer. Invited Symposia Speaker, 4th IASLC Lung Tumor Biology Workshop, 1993.
9. Roth J. Molecular biology of NSCLC. Advances in the Diagnosis and Treatment of Lung Cancer, University of California, Los Angeles, School of Medicine, 1992.
10. Roth J. Esophageal cancer (multidisciplinary). American Society of Clinical Oncology Fall Educational Conference, 1992.
11. Roth J. The biology and therapy of adenocarcinoma of the esophagus and cardia. American Society of Clinical Oncology Educational Program, 1992.
12. Roth J. Surgical therapy for stage I and stage II non-small cell lung cancer. American College of Chest Physicians, Postgraduate Course, Lung Cancer: Internist and Surgeon, 1991.
13. Roth J. Tumor biology. American College of Chest Physicians, Postgraduate Course, Lung Cancer: Internist and Surgeon, 1991.
14. Roth J. Practical reviews in cancer management: Cancer of the esophagus (Audio Cassette Tape). Albert Einstein College of Medicine, 1991.
15. Roth J. Adjuvant therapy for esophageal carcinoma. (Manual). Southern Thoracic Surgical Association 37th Annual Meeting Postgraduate Course, 1990.
16. Roth J. New insights into selecting patients likely to benefit from resection of pulmonary metastases. (Manual). American College of Surgeons Postgraduate Course, 1990.
17. Roth J. Carcinoma of the esophagus. (Manual). Educational Symposium for the American Society of Clinical Oncology, 1990.
18. Roth J. Symposium on thoracic surgical oncology (September 1989) Educational Report of Proceedings of the 25th Anniversary Meeting of the Society of Thoracic Surgeons held by the Thoracic Surgery Directors Association. (Manual). Ann Thorac Surg, 1990.
19. Roth J. New developments in management of lung cancer. (Audio tape with CME Credit, 120 minutes). Oncology Update, 1990.
20. Roth J. Prognostic indicators for soft tissue sarcoma in patients with pulmonary metastases. (Manual). American College of Surgeons Postgraduate Course, 1989.
21. Roth J. Cancer-induced immunosuppression: Implications for therapy. (Manual). American College of Surgeons Postgraduate Course, Seminars in Surgical Oncology, 1988.
22. Roth J. Obliteration of bronchopleural fistula in a pneumonectomized lymphoma patient by tailored thoracoplasty and muscle transposition. (Motion Picture). American College of Surgeons, New Orleans, LA, and Society of Thoracic Surgeons, 1987.
23. Roth J. Resection of the unresectable chest wall rhabdomyosaroma following multi-modality treatment. (Motion Picture). American College of Surgeons, Chicago, IL, and Society of Thoracic Surgeons, 1985.

Other Articles

1. Skoulidis, F, Araujo, HA, Do, MT, Qian, Y, Sun, X, Cobo, AG, Le, JT, Montesion, M, Palmer, R, Jahchan, NS, Juan, J, Min, C, Yu, Y, Pan, X, Arbour, KC, Vokes, N, Schmidt, S, Molkentine, D, Owen, D, Memmott, R, Patil, P, Marmarelis, ME, Awad, MM, Murray, J, Hellyer, JA, Gainor, J, Dimou, A, Bestvina, CM, Shu, CA, Riess, JW, Blakely, CM, Pecot, CV, Mezquita, L, Tabbò, F, Scheffler, M, Digumarthy, S, Mooradian, MJ, Sacher, A, Lau, SC, Saltos, A, Rotow, JK, Johnson, RP, Liu, C, Stewart, TF, Goldberg, SB, Killam, J, Walther, Z, Schalper, K, Davies, KD, Woodcock, MG, Anagnostou, V, Marrone, KA, Forde, PM, Ricciuti, B, Venkatraman, D, Van Allen, EM, Cummings, AL, Goldman, JW, Shaish, H, Kier, M, Katz, S, Aggarwal, C, Ni, Y, Azok, J, Segal, J, Ritterhouse, LL, Neal, JW, Lacroix, L, Elamin, YY, Vailati Negrao, M, Le, X, Lam, VK, Lewis, WE, Kemp, HN, Carter, B, Roth, JA, Swisher, S, Lee, R, Zhou, T, Poteete, A, Kong, Y, Takehara, T, Paula, AG, Parra Cuentas, ER, Behrens, MC, Wistuba, II, Zhang, J, Blumenschein, GR, Gay, CM, Byers, LA, Gibbons, DL, Tsao, A, Lee, JJ, Bivona, T, Camidge, DR, Gray, JE, Leighl, NB, Levy, BP, Brahmer, JR, Garassino, MC, Gandara, D, Garon, EB, Rizvi, NA, Scagliotti, G, Wolf, J, Planchard, D, Besse, B, Herbst, RS, Wakelee, HA, Pennell, N, Shaw, AT, Jänne, PA, Carbone, DP, Hellmann, MD, Rudin, CM, Albacker, LA, Mann, H, Zhu, Z, Lai, Z, Stewart, RA, Peters, S, Johnson, M, Wong, KK, Huang, A, Winslow, MM, Rosen, MJ, Winters, IP, Papadimitrakopoulou, VA, Cascone, T, Jewsbury, P, Heymach, JV Correction to. Nature 639(8054):E19, 2025. PMID: 40016449.

Abstracts

1. Eisenberg MA, Deboever N, Hofstetter WL, Mehran RJ, Rice DC, Rajaram R, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Antonoff MB. Pulmonary Surgical Margins for Metastatic Osteosarcoma: Is Negative Margin Enough?. STSA 2023, 2023. e-Pub 2023.
2. Eisenberg MA, Deboever N, Antonoff MB, Mehran RJ, Rice DC, Rajaram R, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Hofstetter WL. A Propensity Matched Analysis. STSA 2023, 2023. e-Pub 2023.
3. Deboever N, Eisenberg MA, Hofstetter WL, Mehran RJ, Rice DC, Rajaram R, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Antonoff MB. Extent of Resection in Stage IV Non-small Cell Lung Cancer: Does it Even Matter?. International Thoracic Surgical Oncology Summit, 2023. e-Pub 2023.
4. Deboever N, Bayley EM, Eisenberg MA, Hofstetter WL, Mehran RJ, Rice DC, Rajaram R, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Bednarski BK, Morris VK, Antonoff MB. Lung surveillance following colorectal cancer pulmonary metastasectomy: Utilization of clinicopathologic risk factors to guide strategy. International Thoracic Surgical Oncology Summit, 2023. e-Pub 2023.
5. Graber W, Deboever N, Niu J, Eisenberg M, Antonoff M, Hofstetter W, Mehran R, Roth J, Sepesi B, Swisher S, Walsh G, Vaporciyan A, Giordano S, Rajaram R, Rice D. Evaluating The Conditional Survival Benefit Of Minimally Invasive Lobectomy In Early-stage Non-small Cell Lung Cancer. 2023 Annual Meeting of the International Society for Minimally Invasive Cardiothoracic Surgery, 2023. e-Pub 2023.
6. Deboever N, Eisenberg MA, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Rajaram R. Perspectives, Risk Factors, and Coping Mechanisms in Patients with Self-Reported Financial Burden following Surgical Management of Non-Small Cell Lung Cancer. AATS 2023, 2023. e-Pub 2023.
7. Sepesi B, Feldman H, Walsh GL, Rice, DC, Roth JA, Mehran RJ, Hofstetter WL, Antonoff MB, Rajaram R, Gibbons DL, Heymach JV, Vaporciyan AA, Swisher SG, Cascone T. Surgical Outcomes After Chemotherapy plus Nivolumab and Chemotherapy plus Nivolumab and Ipilimumab in Patients with Non-Small Cell Lung Cancer. AATS 2023, 2023. e-Pub 2023.
8. Deboever N, Al-Tashi Q, Eisenberg M, Hofstetter W, Mehran R, Rice D, Roth J, Sepesi B, Swisher S, Vaporciyan A, Walsh G, Mara A, Wu J, Rajaram R. Machine learning prediction of financial toxicity in patients with resected lung cancer. AACR 2023, 2023. e-Pub 2023.
9. White B, Woo XY, Koc S, Sheridan T, Neuhauser S, Wang S, Evrard Y, Chen L, Landua J, Mashl R, Davies S, Fang B, Rasco MG, Evans K, Bailey M, Chen Y, Xiao M, Rubinstein J, Sanderson B, Foroughi pour A, Dobrolecki L, Fujita M, Fujimoto J, Xiao G, Rields R, Mudd J, Xu X, Hollingshead M, Jiwani S, Acevedo S, Davis-Dusenbery B, Robinson P, Wallace T, Moscow J, Doroshow J, Mitsiades N, Kaochar S, Pan CX, Chen M, Carvajal-Carmona L, Welm A, Welm B, Govindan R, Li S, Davies M, Roth J, Meric-Berstam F, Xie Y, Herlyn M, Li D, Lewis M, Bult C, Dean D, Chuang J. A pan-cancer PDX histology image repository with genomic and pathological annotations for deep learning analysis. AACR Annual Meeting 2023, 2023. e-Pub 2023.
10. Ries SA, Qing Y, Sun R, Eisenberg MA, Mitchell KG, Mehran RJ, Rice DC, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB. Disparities in Lung Cancer Surgery Permeate Evolving Paradigms in Stage IV Disease. AATS 2023, 2023. e-Pub 2023.
11. Deboever N, Khanduri I, Eisenberg M, Mehran RJ, Rajaram R, Rice DC, Roth J, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Antonoff MB, Maru DM, Hofstetter WL. Mucosal Lymphovascular Invasion in Early Esophageal Cancer; Depth of LVI Affects Outcome. AATS 2023, 2023. e-Pub 2023.
12. Deboever N, Bayley, EM, Eisenberg MA, Hofstetter WL, Mehran RJ, Rice DC, Rajaram R, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Bednarski BK, Morris VK, Antonoff MB. Optimal Timing for Surveillance Imaging in Colorectal Pulmonary Metastatic Disease: Evidence for a Clinicopathologic-driven Algorithm. International Thoracic Surgical Oncology Summit, 2022. e-Pub 2022.
13. Deboever N, Bayley EM, Feldman HA, Hofstetter WL, Mehran RJ, Rice DC, Rajaram R, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Bednarski BK, Morris VK, Antonoff MB. Do Resected Colorectal Cancer Patients Need Early Chest Imaging? Impact of Clinicopathologic Characteristics on Time to Development of Pulmonary Metastases. American College of Surgeons Clinical Congress, 2022. e-Pub 2022.
14. Deboever N, Bayley EM, Feldman HA, Hofstetter WL, Mehran RJ, Rice DC, Rajaram R, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Bednarski BK, Morris VK, Antonoff MB. Lymph Node Ratio is Associated with Time to Pulmonary Metastasis in Patients with Resected Colorectal Cancer. American College of Surgeons Clinical Congress, 2022. e-Pub 2022.
15. Deboever N, Eisenberg M, Hofstetter W, Mehran R, Rajaram R, Rice D, Roth J, Sepesi B, Swisher S, Vaporciyan A, Walsh G, Antonoff M. Circulomic Variables may Predict Pathologic Staging Preoperatively in Treatment-Naïve Non-Small Cell Lung Cancer. 2022 North America Conference on Lung Cancer, 2022. e-Pub 2022.
16. Deboever N, Bayley EM, Eisenberg MA, Hofstetter WL, Mehran RJ, Rice DC, Rajaram R, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Bednarski BK, Morris VK, Antonoff MB. Surveillance following Colorectal Cancer Pulmonary Metastasectomy should be Dependent on Clinicopathologic Factors. International Thoracic Surgical Oncology Summit 2022, 2022. e-Pub 2022.
17. Deboever N, Mitchell KG, Eisenberg MA, Hofstetter WL, Mehran RJ, Rice DC, Rajaram R, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Antonoff MB, Sepesi B. Aspirin’s Protective Effect in Resectable Non-Small Cell Lung Cancer is Marginally Mediated by Circulomics. International Thoracic Surgical Oncology Summit, 2022. e-Pub 2022.
18. Eisenberg MA, Deboever N, Hofstetter WL, Mehran RJ, Rice DC, Rajaram R, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Antonoff MB. The Pre-Operative Inflammasome Predicts Infectious Complications Following Lung Resection in Patients with NSCLC. International Thoracic Surgical Oncology Summit, 2022. e-Pub 2022.
19. Bayley EM, Ivy ML, Ge PS, Shewale JB, Antonoff MB, Francis AM, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Vaporciyan AA, Walsh GL, Lee JJ, Louie BE, Swisher SG. High-Risk Features of Esophageal Adenocarcinoma Following Neoadjuvant Chemoradiation: Patients for whom Surgery Should Not Be Delayed. Digestive Diseases Week Annual Meeting 2022, 2022. e-Pub 2022.
20. Mitchell KG, Bayley EM, Ikoma N, Antonoff MB, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Maru DM, Erasmus JJ, Weston BR, Ajani JA, Badgwell BD, Hofstetter WL. Gastric Extent of Tumor Predicts Peritoneal Metastasis in Siewert II Adenocarcinoma. 102nd Annual Meeting of the American Association for Thoracic Surgery, 2022. e-Pub 2022.
21. DiPeri TP, Evans K, Kong K, Raso G, Rizvi Y, Zheng X, Ha MJ, Chen H, Korkut A, Buchold G Kirby B, Dumbrava EI, Pant S, Ajani JA, Roth JA, Rowse G, Rodon J, Meric-Bernstam F. Co-Clinical Trial of Patient-Derived Xenograft Models from the Phase I Trial of Bispecific Anti-HER2 Antibody Zanidatamab. SSO 2022, 2022. e-Pub 2022.
22. Deboever N, Correa A, Feldman HA, Eisenberg MA, Antonoff MB, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Hofstetter WL. Early Interventional Treatment of High Output Chyle Leak following Esophagectomy is Associated with Improved Survival. STS 2022, 2022. e-Pub 2022.
23. Feldman HA, Zhou N, Deboever N, Hofstetter W, Mehran R, Rajaram R, Rice D, Roth JA, Sepesi B, Swisher S, Vaporciyan A, Walsh G, Godoy M, Strange C, Antonoff MB. Intraoperative Challenges After Induction Therapy for NSCLC: Impact of Nodal Disease on Technical Complexity. AATS 2022, 2022. e-Pub 2022.
24. Deboever N, Bayley EM, Bednarski BK, Morris VK, Antonoff MB, Group MD. Lymph Node Ratio is Associated with Time to Pulmonary Metastasis in Patients with Resected Colorectal Cancer. American College of Surgeons Clinical Congress 2022, 2022. e-Pub 2022.
25. Hubert SM, Li Z, Zhang R, Song X, Karpinets T, Weissferdt A, Little L, Mohammad M, Gumbs C, Negrao M, Zhang J, Pataer A, Swisher S, Vaporciyan A, Roth J, Heymach J, Sepesi B, Gibbons D, Fang B, Zhang J. Molecular Parameters Impacting the Success Rate of a Lung Cancer PDX Model. ASCO 2022, 2022. e-Pub 2022.
26. Deboever N, Feldman H, Vaporciyan A, Hofstetter W, Roth J, Mehran R, Swisher S, Walsh G, Rajaram R, Rice D, Antonoff M. The Role of Surgery in the Treatment of Pulmonary Melanoma Metastases Amidst Modern Systemic Therapies. Academic Surgical Congress 2022, 2022. e-Pub 2022.
27. Blumenthaler AN, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Strange CD, Antonoff MB. Preoperative Maximum Standardized Uptake Value Associated with Recurrence Risk In Early Lung Cancer. STS 2022, 2022. e-Pub 2022.
28. Frank ML, Shah P, Forget MA, Federico L, Jiang P, Khairullah R, Wistuba II, Chow CW, Long Y, Fujimoto J, Lin SY, Maitra A, Negrao MV, Mitchell KG, Weissferdt A, Vaporciyan AA, Cascone T, Roth J, Zhaing J, Sepesi B, Gibbons DL, Heymach JV, Haymaker C, McGrail DJ, Bernatchez C, Reuben A. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. SITC 2021, 2021. e-Pub 2021.
29. Chang JY, Mehran RJ, Feng L, Balter P, McRae S, Berry DA, Roth JA, Trials Group SC. Stereotactic ablative radiotherapy in operable stage I NSCLC patients: Long-term results of the expanded STARS clinical trial. ASCO 2021, 2021. e-Pub 2021.
30. Faron M, Cheugoua-Zanetsie AM, Nankivell MG, Winter KA, Law S, Van Der Gaast A, Ychou M, Mauer M, Valmasoni M, Roth JA, Blanchard P, Thirion PG, Tierney JF, Gebski V, Burmeister BH, Paoletti X, Yang H, Van Sandick JW, Ducreux M, Michiels S. Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery in esophageal or gastro-esophageal carcinoma. ASCO 2021, 2021. e-Pub 2021.
31. Li D, Ha MJ, Evrard YA, Chen H, McShane LM, Grover J, Wang J, Fang B, DiPeri T, Lewis MT, Rubinstein L, Roth JA, Chuang JH, Doroshow JH, Moscow JA, Meric-Bernstam F. A systematic review of the tumor growth metrics of patient-derived xenograft (PDX) models in the literature and in NCI PDXNet centers. AACR 2021, 2021. e-Pub 2021.
32. Gay CM, Stewart CA, Diao L, Nabet BY, Fujimoto J, Solis LM, Lu W, Xi Y, Cardnell RJ, Vokes NI, Ramkumar K, Swisher SG, Roth JA, Glisson BS, Shames DS, Wistuba II, Wang J, Minna J, Heymach JV, Byers LA. A novel, inflamed small cell lung cancer transcriptional subtype, SCLC-I, defines a subset of patients with distinct immunotherapy vulnerability. AACR 2021, 2021. e-Pub 2021.
33. Zhou N, Hofstetter WL, Esophageal Squamous Cell Carcinoma Working Group, Mitchell KG, Bayley EM, Ajani JA, Antonoff MB, Betancourt SL, Blum-Murphy M, Feldman HA, Lin SH, Maru DM, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Weston BR. Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers. 57th Annual Meeting of The Society of Thoracic Surgeons, Virtual Meeting, 2021. e-Pub 2021.
34. Feldman HA, Pedroza C, Zhou P, Antonoff MB, Hofstetter W, Mehran R, Rice D, Roth JA, SepesiB, Swisher S, Vaporciyan A, Walsh G, Rajaram R. Signet Ring Cell Esophageal Adenocarcinoma: A Conditional Survival Analysis. STS 2021, 2021. e-Pub 2021.
35. Zhou N, Feldman HA, Corsini EM, Antonoff MB, Mehran RJ, Rajaram R, Rice RC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Ajani JA, Hofstetter WL. Definition of Salvage Esophagectomy Influences Survival for Trimodality and Bimodality Therapy for Esophageal Squamous Cell Carcinoma. STS 2021, 2021. e-Pub 2021.
36. Blumenthaler AN, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Strange CD, Antonoff MB. Maximum Standardized Uptake Value (SUVmax) on Preoperative PET: Role in Guiding Postoperative Surveillance for Patients with Stage I NSCLC. STS 2021, 2021. e-Pub 2021.
37. Zhou N, Feldman HA, Corsini EM, Antonoff MB, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Ajani JA, Hofstetter WL. Definition of Salvage Esophagectomy Influences Survival for Trimodality and Bimodality Therapy in Esophageal Squamous Cell Carcinoma. STS 2021, 2021. e-Pub 2021.
38. Girard L, Drapkin B, Fang B, Farago A, Dyson N, Xi Y, Huffman K, Gao B, Park H, Timmons B, Stastny V, Covington K, Davis C, Wang Y, Hanash S Wistuba I, Byers L, Lam S, Wheeler D, Heymach J, Wang J, Roth J, Minna J. Molecular Comparison (DNAseq, RNAseq) of Patient-derived Lung Cancer Preclinical Models with Lung Tumor Specimens in Public Databases. SCLC Meeting, 2021. e-Pub 2021.
39. Corsini EM, Weissferdt A, Pataer A, Zhou N, Antonoff MB, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Cascone T, Heymach JV, Swisher SG, Sepesi B. Timing And Patterns Of Recurrence In Lung Cancer Patients With Major Pathologic Response Following Neoadjuvant Chemotherapy – The Influence Of Persistent Pathological Nodal Disease. ESTS 2020, 2020. e-Pub 2020.
40. Corsini EM, Mitchell KG, Zhou N, Mena GE, Rajaram R, Sepesi B, Swisher SG, Roth JA, Walsh GL, Antonoff MB, Vaporciyan AA, Mehran RJ, Rice DC, Hofstetter WL. Intercostal Liposomal Bupivacaine Is Associated with Reduction in Postoperative Pulmonary Complications. AATS 2020, 2020. e-Pub 2020.
41. Zhou N, Mitchell KG, Corsini EM, Jones D, Bott M, Wilshire CL, Swisher SG, Antonoff MB, Rice DC, Walsh GL, Mehran RJ, Hofstetter WL, Roth JA, Vaporciyan AA, Vallieres E, Park BJ, Sepesi B. Predictors of Overall Survival Following Surgical Resection of Small Cell Lung Cancer. AATS 2020, 2020. e-Pub 2020.
42. Corsini EM, Foo WC, Mitchell KG, Correa A, Zhou N, Rajaram R, Sepesi B, Swisher SG, Roth JA, Walsh GL, Antonoff MB, Vaporciyan AA, Mehran RJ, Rice DC, Lin SH, Maru DM, Ajani JA, Hofstetter WL. Even Scant Signet Ring Cell Component Portends Dismal Prognosis after Resection of Esophageal Adenocarcinoma. AATS 2020, 2020. e-Pub 2020.
43. Sepesi B, Corsini E, Weissferdt A, Pataer A, Altan M, Antonoff M, Blumenschein GR, Elamin YY, Fossella F, Glisson BS, Hofstetter W, Kurie J, Le X, Leung CH, Lin H, Lu C, Mehran R, Mott F, Rice D, Roth J, Skoulidis F, Swisher SG, Tsao A, Vaporciyan AA, Walsh G, Zhang J, Gibbons DL, Heymach JV, Cascone T. Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy. SITC 2020, 2020. e-Pub 2020.
44. Stewart CA, Gay CM, Xi Y, Sivajothi S, Fujimoto J, Hartsfield PM, Tran H, Swisher SG, Roth JA, Zhang J, Glisson B, Heymach JV, Wistuba I, Robson P, Wang J, Byers LA. Paired, single-cell profiling of circulating tumor cell-derived xenograft models of small cell lung cancer reveals intratumoral heterogeneity and emergence of new cell clusters following treatment relapse. AACR 2020, 2020. e-Pub 2020.
45. Bayley EM, Zhou N, Mitchell KG, Antonoff MB, Mehran RJ, Rice DC, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Cinciripini PM, Karam-Hage M, Roth JA, Hofstetter WL. Modern Perioperative Practices May Mitigate Effects of Continued Smoking Among Lung Cancer Patients. 100th Annual Meeting of the American Association for Thoracic Surgery, 2020. e-Pub 2020.
46. Zhou N Mitchell KG, Corsini EM, Hofstetter WL, Mehran RJ, Rice DC, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Roth JA, Antonoff MB. Impact of Psychiatric Comorbidities on Surgical Outcomes for Non-Small Cell Lung Cancer. General Thoracic Surgery Club 33rd Annual Meeting, 2020. e-Pub 2020.
47. Williams LA, Chen TH, Malveaux D, Sulihem S, Hirschmann M, Griffin D, Sui D, Garcia Gonzalez A, Cleeland CS, Rinsurongkawong W, Rinsurongkawong V, Lewis J, Lee J, Roth J, Swisher S, Zhang J, Elamin Y, Simon G, Heymach J. Does symptom burden at diagnosis predict survival in metastatic non-small cell lung cancer in the age of immunotherapy?. WCLC 2020, 2020. e-Pub 2020.
48. Gay CM, Stewart CA, Diao L, Fujimoto J, Solis LM, Lu W, Xi Y, Cardnell RJ, Robson P, Swisher SG, Roth JA, Glisson BS, Wistuba II, Wang J, Minna J, Heymach JV, Byers LA. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. SCLC 2020 Annual Workshop, 2020. e-Pub 2020.
49. Saddoughi SA, Mitchell K, Fruth KM, Taswell J, Mounajjed T, Harmsen WS, Allen MS, Cassivi SD, Nichols FC, Shen KR, Wigle DA, Walsh GL, Mehran RJ, Hofstetter WL, Swisher SG, Roth JA, Sepesi B, Vaporciyan AA, Rice DC, Antonoff MB, Blackmon SH. Re-resecting to a Negative Margin after an Initial Positive Esophagectomy Margin Enhances Progression Free Survival. STSA 2019, 2019. e-Pub 2019.
50. Datar SS, Corsini EM, Mitchell KG, Mehran RJ, Rice DC, Sepesi B, Walsh GL, Swisher SG, Roth JA, Vaporciyan AA, Hofstetter WL, Loree JM, Morris VK, Antonoff MB. High Mutational Concordance Between Next Generation Sequencing Profiles of Colorectal Cancer and Pulmonary Metastases. STSA 2019, 2019. e-Pub 2019.
51. Corsini E, Mitchell K, Mehran RJ, Sepesi B, Walsh GL, Rice DC, Swisher SG, Roth JA, Vaporciyan AA, Hofstetter WL, Morris V, Antonoff MB. Primary Colorectal Cancer Laterality Predicts Survival After Pulmonary Metastasectomy. STSA 2019, 2019. e-Pub 2019.
52. Corsini EM, Mitchell KG, Mehran RJ, Sepesi B, Wlash GL, Antonoff MB, Rice DC, Swisher SG, Roth JA, Vaporciyan AA, Hofstetter WL. Endoscopic Biopsy Poorly Identifies Signet Ring Cell Histology in Untreated Esophageal Adenocarcinoma. STSA 2019, 2019. e-Pub 2019.
53. Skoulidis F, Montesion M, Schulz K, Bara I, Shen V, Hu S, Elamin Y, Le X, Goldberg ME, Wu CJ, Zhang J, Barreto DS, Rinsuongkawong W, Simon GR, Roth JA, Swisher S, Lee J, Tsao A, Papadimitrakopoulou VA, Gibbon DL, Glisson B, Miller VA, Alexander B, Frampton GM, Albacker LA, Shames DS, Zhang J, Heymach JV. BRAF Mutations Are Associated with Increased Benefit from PD1/PDL1 Blockade Compared with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. WCLC 2019, 2019. e-Pub 2019.
54. Corsini EM, Mitchell KG, Mehran RJ, Rice DC, Sepesi B, Antonoff MB, Walsh GL, Roth JA, Swisher SG, Vaporciyan AA, Hofstetter WL. Evaluation of Ketorolac Use with Occurrence of Esophageal Anastomotic Leak After Esophagectomy. 2019 AATS International Thoracic Surgical Oncology Summit, 2019. e-Pub 2019.
55. Corsini EM, Mitchell KG, Van Haren RM, Mehran RJ, Rice DC, Sepesi B, Antonoff MB, Walsh GL, Swisher SG, Vaporciyan AA, Roth JA, Hofstetter WL. Patient-Related Factors Are The Greatest Determinant Of Pulmonary Morbidity Following Lung Cancer Resection In Enhanced Recovery Setting. AATS International Thoracic Surgical Oncology Summit 2019, 2019. e-Pub 2019.
56. Simon GR, Williams LA, Shi Z, El Ferjani B, Hirschmann MS, Ponce D, Dibaj SS, Chandwani S, Roarty E, Rinsurongkawong W, Lewis J, Burke T, Cleeland CS, Lee J, Roth J, Swisher S, Heymach JV, Zhang J. Differences in Symptom Burden Between Responsive and Progressive Disease in Advanced Non-Small Cell Lung Cancer (aNSCLC). WCLC 2019, 2019. e-Pub 2019.
57. Lewis WE, Simon GR, Mott FE, Papadimitrakopoulou VA, Rinsurongkawong W, Lewis J, Lee J, Roth J, Swisher S, Heymach JV, Zhang J, Lam V. Clinical Outcomes in Metastatic Squamous Lung Cancer with Targetable Driver Alterations. WCLC 2019, 2019. e-Pub 2019.
58. Simon GR, Shi Q, Williams LA, El Ferjani B, Hirschmann MS, Ponce D, Dibaj SS, Chandwani S, Roarty E, Rinsurongkawong W, Lewis J, Burke T, Cleeland CS, Lee J, Roth J, Swisher S, Heymach JV, Zhang J. Body Mass Index Relating to Patient-Reported Symptoms in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer. WCLC 2019, 2019. e-Pub 2019.
59. Gay CM, Ciao L, Stewart CA, Xi Y, Cardnell RJ, Swisher S, Roth J, Glisson B, Wang J, Heymach JV, Byers LA. ASCL1, NEUROD1, and POU2F3 Drive Distinct Subtypes of Small Cell Lung Cancer with Unique Therapeutic Vulnerabilities. WCLC 2019, 2019. e-Pub 2019.
60. Corsini EM, Mitchell KG, Mehran RJ, Rice DC, Sepesi B, Walsh GL, Swisher SG, Roth JA, Hofstetter WL, Vaporciyan AA, Morris V, Antonoff MB. Primary Colorectal Cancer Laterality Predicts Survival After Pulmonary Metastasectomy. American Association of Thoracic Surgery International Thoracic Surgical Oncology Summit 2019, 2019. e-Pub 2019.
61. Skoulidis F, Arbour KC, Hellmann MD, Patil P, Marmarelis ME, Owen D, Awad MM, Murray J, Levy B, Hellyer J, Gainor JF, Stewart T, Goldberg S, Dimou A, Bestvina C, Cummings AL, Elamin YY, Lam VK, Zhang J, Shu CA, Riess JW, Blakely C, Pecot C, Mezquita L, Tabbò F, Sacher A, Scheffler M, Ricciuti B, Venkatraman D, Rizvi H, Liu C, Johnston RP, Ni Y, Azok J, Kier M, Katz S, Davies K, Segal J, Ritterhouse L, Shaish H, Laroix L, Memmott RM, Madrigal JR, Goldman JW, Lau S, Carter B, Woodcock M, Roth JA, Swisher SG, Leighl N, Wolf J, Scagliotti GV, Planchard D, Besse B, Bivona T, Gandara DR, Garon EB, Rizvi N, Camidge R, Schalper K, Herbst RS, Shaw A, Neal J, Wakelee HA, Brahmer J, Jänne P, Carbone DP, Aggarwal C, Pennell N, Rudin C, Papadimitrakopoulou V, Heymach JV. STK11/LKB1 genomic alterations are associated with inferior clinical outcomes with chemo-immunotherapy in non-squamous NSCLC. WCLC 2019, 2019. e-Pub 2019.
62. Sepesi B, Cascone T, William WN, Lin H, Leung CH, Weissferdt A, Walsh GL, Rice D, Roth J, Mehran R, Hofstetter W, Antonoff M, Heymach JV, Gibbons D, Papadimitrakopolou V, Fossella F, Mott F, Le X, Blumenschein G, Vaporciyan AA, Swisher SG. Surgical Outcomes Following Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab In Non-Small Cell Lung Cancer - NEOSTAR study. WCLC 2019, 2019. e-Pub 2019.
63. Woo X, Srivastava A, Zhao ZM, Lloyd M, Suh YS, Lee C, Bult C, Kim J, Yang HK, Welm BE, Welm AL, Scherer S, Klein MP, Cortes-Sanchez E, Bailey M, Lewis MT, Roth J, Fang B, Meric-Bernstam F, Davies M, Herlyn M, Rebecca V, Kossenkov A, Wickramasinghe P, Ding L, Govindan R, Mashl J, Sun H, Davies S, Evrard Y, Patidar R, Chen L, Medico E, Giordano J, Isella C, Rosains J, Frech C, Randjelovic J, Jeon R, Dean D, Chuang J. Large-scale DNA-based tracking of the evolution of copy number alterations during xenograft engraftment and passaging. SMBE 2019, 2019. e-Pub 2019.
64. Hong L, Dibaj S, Negrao MV, Reuben A, Roarty EB, Rinsurongkawong W, Lewis J, Gibbons DL, Sepesi B, Papadimitrakopoulou V, Glisson BS, Blumenschein GR, Futreal PA, Wistuba II, Roth JA, Swisher SG, Heymach JV, Simon G, Lee JJ, Zhang J. Spatial and Temporal Heterogeneity of PD-L1 and its Impact on Benefit from Immune Checkpoint Blockade in Non-Small Cell Lung Cancer (NSCLC). ASCO 2019, 2019. e-Pub 2019.
65. Van Haren RM, Rajaram R, MD, Correa AM, Mehran RJ, Antonoff MB, Hofstetter WL, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Rice DC, Roth JA. Preoperative Heparin for Lung Cancer Resection Increases Risk of Reoperation for Bleeding. American Association for Thoracic Surgery 99th Annual Meeting, 2019. e-Pub 2019.
66. Rajaram R, Mitchell K, Correa A, Antonoff M, Rice D, Mehran R, Roth J, Walsh G, Swisher S, Hofstetter W, Vaporciyan A, Gomez D, Liao Z, Sepesi B. Overall and Disease-Free Survival in Surgically Resectable and Unresectable IIIA (N2) Non-Small Cell Lung Cancer. AATS 2019, 2019. e-Pub 2019.
67. Van Haren R, Rajaram R, Correa A, Mehran R, Antonoff M, Hofstetter W, Sepesi B, Swisher S, Vaporciyan A, Walsh G, Rice D, Roth JA. Preoperative Heparin for Lung Cancer Resection Increases Risk of Reoperation for Bleeding. AATS 2019, 2019. e-Pub 2019.
68. Meraz IM, Majidi M, Meng F, Shao R, Ha MJ, Neri S, Fang B, Lin SH, Tinkey PT, Shpall EJ, Morris J, Roth JA. Development of an improved humanized patient-derived xenograft (Hu-PDX) mouse model for evaluation of antitumor immune response in lung cancer. AACR 2019, 2019. e-Pub 2019.
69. PDXNet Consortium TN, Evrard Y, Chuang JH. Systematic Establishment of Robustness and Standards in Xenograft Experiments and Analysis. AACR 2019, 2019. e-Pub 2019.
70. Le X, Negrao MV, Reuben A, Lee WC, Parra E, Li J, Karpinets T, Behrens C, Sepesi B, Vaporciyan A, Roth J, Haymaker C, Roarty E, Zhang J, Bernatchez C, Zhang J, Wistuba I, Gibbons D, Heymach JV. Characterization of the tumor immune microenvironment in treatment-naïve EGFR-mutant NSCLC uncovers a low IFN-gamma suppressed immune phenotype. AACR 2019, 2019. e-Pub 2019.
71. Gay CM, Diao L, Stewart CA, Xi Y, Cardnell RJ, Swisher SG, Roth JA, Glisson B, Wang J, Heymach JF, Byers LA. Inter- and intra-tumoral variations in ASCL1, NEUROD1, and POU2F3 transcriptional programs underlie the three distinct molecular subtypes of small cell lung cancers. AACR 2019, 2019. e-Pub 2019.
72. Stewart CA, Gay CM, Xi Y, Siva V Fujimoto J, Bolisetty M, Kalhor N, Hartsfield PM, Tran H, Zhang J, Swisher SG, Roth JA, Oliver TG, Heymach JV, Wistuba I, Glisson B, Robson P, Wang J, Byers LA. Single-cell analyses reveal increasing intratumoral heterogeneity as an essential component of treatment resistance in small cell lung cancer. AACR 2019, 2019. e-Pub 2019.
73. Corsini EM, Mitchell KG, Mehran RJ, Rice DC, Sepesi B, Walsh GL, Swisher SG, Roth JA, Hofstetter WL, Vaporciyan AA, Antonoff MB. Multidisciplinary Treatment of Thymic Neuroendocrine Tumors: Evaluation of Surgery, Chemotherapy, and Radiation. Multidisciplinary Thoracic Cancers Symposium 2019, 2019. e-Pub 2019.
74. Corsini EM, Mitchell KG, Mehran RJ, Sepesi B, Walsh GL, Swisher SG, Roth JA, Vaporciyan AA, Hofstetter WL, Antonoff MB Rice DC. Outcomes After Resection of Thymic Neoplasms with Pleural Metastases. GTSC 2019, 2019. e-Pub 2019.
75. Mitchell KG, Parra ER, Nelson DB, Corsini EM, Zhang J, Vaporciyan AA, Hofstetter WL, Mehran RJ, Swisher SG, Rice DC, Sepesi B, Walsh GL, Behrens C, Kalhor N, Weissferdt A, Moran CA, Skoulidis F, Wistuba II, Fujimoto J, Roth JA, Antonoff MB. Intratumoral LKB1/STK11 Expression Correlates with Immune Cell Infiltration and Oncologic Outcomes Following Resection of Lung Adenocarcinoma. STS 2019, 2019. e-Pub 2019.
76. Mitchell KG, Negrao M, Parra ER, Reuben A, Vaporciyan AA, Swisher SG, Roth JA, Alvarez de Lacerda Landry LC, Wistuba II, Bernatchez C, Haymaker C, Weissferdt A, Roarty E, Cascone T, Gibbons DL, Heymach JV, Zhang J, Sepesi B, Team I. Clinicopathological and Immune Microenvironment Features Associated with High Tumor Mutational Burden and PD-L1 Expression in Resected Non-Small Cell Lung Cancer. STS 2019, 2019. e-Pub 2019.
77. Corsini EM, Mitchell KG, Mehran RJ, Rice DC, Sepesi B, Walsh GL, Swisher SG, Roth JA, Hofstetter WL, Vaporciyan AA, Morris VK, Antonoff MB. Primary Colorectal Cancer Mutations Predict Survival and Recurrence After Pulmonary Metastasectomy. STS 2019, 2019. e-Pub 2019.
78. Nelson DB, Niu J, Mitchell KG, Sepesi B, Vaporciyan AA, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Antonoff MB, Mehran RJ, Rice DC. Persistent Opioid Use Among The Elderly After Lung Resection: A SEER-Medicare Study. STS 2019, 2019. e-Pub 2019.
79. Nelson DB, Mitchell KG, Wang J, Fujimoto J, Behrans C, Zheng X, Zhang J, Sepesi B, Vaporciyan AA, Hofstetter WL, Mehran RJ, Rice DC, Walsh GL, Swisher SG, Moran CA, Kalhor N, Weissferdt A, Wistuba II, Roth JA, Antonoff MB. Immune Regulatory Markers of Lepidic-Pattern Adenocarcinomas Presenting as Ground Glass Opacities. STS 2019, 2019. e-Pub 2019.
80. Mitchell KG, Parra ER, Zhang J, Nelson DB, Corsini EM, Villalobos P, Moran CA, Skoulidis F, Wistuba II, Fujimoto J, Roth JA, MD Anderson Lung Cancer Immune Microenvironment Working Group, Antonoff MB. LKB1/STK11 Expression in Lung Adenocarcinoma and Associations With Patterns of Recurrence. Annual Meeting of The Society of Thoracic Surgeons, 2019. e-Pub 2019.
81. Federico L, Ravelli A, Haymaker C, Forget MA, Karpinets T, Roszik J, Sakellariou-Thompson D, Kim YU, Bhatta A, Celestino M, Reuben A, Weissferdt A Vaporciyan AA, Antonoff MB Walsh G, Futreal A, Wistuba I, Roth J, Jianjun Z, Roarty E, de Lacerda-Landry LA, Swisher SG, Cascone T, Lizer GA, Heymach JV, Sepesi B, Gibbons D, Bernatchez C. Poster: CD8+ tumor-infiltrating lymphocytes expanded from a NSCLC immunosuppressive environment display neoantigen-specific recognition. The Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting, 2018. e-Pub 2018.
82. Mitchell KG, Ikoma N, Nelson DB, Maru DM, Erasmus JJ, Vaporciyan AA, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Swisher SG, Sepesi B, Walsh GL, Correa AM, Badgwell BD, Hofstetter WL. Predictors Of Mediastinal Involvement After Neoadjuvant Chemoradiation In Adenocarcinoma Of The Gastroesophageal Junction. STSA 2018, 2018. e-Pub 2018.
83. Mitchell KG, Nelson DB, Hofstetter WL, Mehran RJ, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Rice DC, Antonoff MB. Surveillance Patterns after Treatment of NSCLC with Lobectomy and Stereotactic Body Radiotherapy. STSA 2018, 2018. e-Pub 2018.
84. Nelson DB, Rice DC, Mitchell KG, Tsao AS, Vaporciyan AA, Antonoff MB, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Gomez DR, Mehran RJ, Sepesi B. Defining the Role of Adjuvant Radiotherapy for Malignant Pleural Mesothelioma: A Propensity Matched Landmark Analysis of the national Cancer Data Base. AATS International Thoracic Surgical Oncology Summit 2018, 2018. e-Pub 2018.
85. Nelson DB, Mehran RJ, Mitchell KG, Van Haren RM, Mena GE, Woodard T, Correa AM, Hofstetter WL, Sepesi B, Walsh GL, Vaporciyan AA, Swisher SG, Antonoff MB, Roth JA, Heymach JV, Rice DC. Adjuvant Chemotherapy is Facilitated by Enhanced Recovery After Thoracic Surgery. 2018 AATS International Thoracic Surgical Oncology Summit, 2018. e-Pub 2018.
86. Mohammad ZB, Nelson DB, Lapid D, Correa AM, Mitchell KG, Hofstetter WL, Mehran RJ, Sepesi B, Walsh GL, Vaporciyan AA, Swisher SG, Roth JA, Rice DC, Antonoff MB. Sex-Related Outcomes after Lobectomy for Stage I Non-Small Cell Lung Cancer: A Single Institution Experience. 2018 AATS International Thoracic Surgical Oncology Summit, 2018. e-Pub 2018.
87. Nelson DB, Rice DC, Mitchell KG, Hofstetter WL, Walsh GL, Vaporciyan AA, Swisher SG, Antonoff MB, Roth JA, Tsao AS, Gomez DR, Sepesi B, Mehran RJ. Poster: Return to Intended Oncologic Treatment (RIOT) After Extrapleural Pneumonectomy or Pleurectomy / Decortication for Malignant Pleural Mesothelioma. AATS International Thoracic Surgical Oncology Summit 2018, 2018. e-Pub 2018.
88. Mitchell KG, Parra ER, Nelson DB, Vaporciyan AA, Hofstetter WL, Mehran RJ, Swisher SG, Rice DC, Sepesi B, Walsh GL, Zhang J, Behrens C, Kalhor N, Weissferdt A, Moran CA, Wistuba II, Fujimoto J, Roth JA, Antonoff MB. Tumor cellular proliferation correlates with immune checkpoint expression and lymphocyte infiltration in resected non-small cell lung cancer. AATS International Thoracic Surgical Oncology Summit 2018, 2018. e-Pub 2018.
89. Shi Q, Williams LA, Vaghani VB, Hirschmann M, Landry LL, Roarty E, Zhang J, Rinsurnogkawong W, Lewis J, Cleeland C, Lee J, Roth JA, Swisher S, Heymach JV, Simon GR. Profiling the Symptom Burden of Patients with Metastatic NSCLC Receiving Either Chemotherapy or Targeted Therapy: Real-World Data. WCLC 2018, 2018. e-Pub 2018.
90. Sepesi B, Federico L, Mitchell KG, Parra E, Cruz AF, Ravelli A, Haymaker C, Karpinets T, Cascone T, Weissferdt A, Antonoff MB, Walsh GL, Bernatchez C, Roth JA, Zhang J, Roarty E, Landry LC, Vaporciyan AA, Swisher S, Heymach JV, Wistuba II, Gibbons DL. PD-L1 Expression is Predominant in CD68+ Tumor-Associated Macrophages in Stage I-III Non-Small Cell Lung Cancers. WCLC 2018, 2018. e-Pub 2018.
91. Simon GR, Vaghani VB, Chandwani S, Hirschmann M, Dibaj S, Landry LL, Roarty E, Zhang J, Rinsurongkawong W, Lewis J, Lee J, Roth JA, Swisher S, Heymach JV, Burke T. Computing the Impact of Immunotherapy on the Non-Small Cell Lung Cancer (NSCLC) Therapeutic Landscape. WCLC 2018, 2018. e-Pub 2018.
92. Pu X, Zhang R, Wang L, Pataer A, Meraz IM, Zhang X, Wu S, Chen Y, Wu L, Su D, Mao W, Heymach JV, JA <, Swisher SG, Fang B. Co-Residence of Patient-Derived Immune Cells in Patient-Derived Xenografts from Lung Cancer Patients. WCLC 2018, 2018. e-Pub 2018.
93. Lam VK, Tran HT, Vasquez ME, Li K, Yuen K, Vang F, Jaimovich A, Kennedy D, Odegaard J, Mortimer S, Olsen SR, Raymond VM, Vaporciyan AA, Antonoff MB, Walsh GL, Roarty E, Lacerda L, Roth JA, Swisher S, Bernatchez C, Sepesi B, Gibbons DL, Zhang J, Heymach JV. Circulating Tumor DNA Analysis with a Novel Variant Classifier for Recurrence Detection in Resected, Early-Stage Lung Cancer. WCLC 2018, 2018. e-Pub 2018.
94. Skoulidis F, Elamin YY, Lam VK, Zhang J, Lewis J, Rinsurongkawong W, Lee JJ, Roth JA, Swisher S, Papadimitrakopoulou VA, Heymach JV. Impact of STK11/LKB1 genomic alterations on clinical outcomes with chemo-immunotherapy in non-squamous NSCLC. WCLC 2018, 2018. e-Pub 2018.
95. Weissferdt A, Cascone T, Pataer A, Kalhor N, Moran C, Antonoff MB, Walsh GL, Bernatchez C, Gibbons DL, Wistuba II, Roth JA, Zhang J, Roarty E, Landry L, Vaporciyan AA, Heymach JV, Swisher S, Sepesi B. Histopathologic parameters define features of treatment response to neoadjuvant chemotherapy in non-small cell lung cancer. WCLC 2018, 2018. e-Pub 2018.
96. Negrao MV, Reuben A, Chen R, Sepesi B, Karpinets T, Parra E, Federico L, Quek K, Vence L, Weissferdt A, Tran H, Vaporciyan A, Celestiano M, Yee C, Haymaker C, Forget MA, Lizee G, Talukder A, Roszik J, Vasquez M, Prado E, Wu C, Zhang J, Li J, Behrens C, Rodriguez-Canales J, Fujimoto J, Roth J, Meraz I, Roarty E, Landry L, Byers L, William Jr W, Sharma P, Allison J, Fang B, Wagner H, Bogatenkova E, Bernatchez C, Futreal A, Wistuba I, Swisher S, Heymach J, Gibbons D, Zhang J. Prospective immunogenomic profiling of non-small cell lung cancer: genomic and immune profiling updates from Project ICON. WCLC 2018, 2018. e-Pub 2018.
97. Williams LA, Dibaj SS, Chandwani S, Vaghani V, Shi Q, Hirschmann M, Landry LL, Roarty E, Zhang J, Rinsurongkawong W, Lewis J, Burke T, Cleeland C, Lee J, Roth JA, Swisher S, Heymach JV, Simon GR. Real-World Patient-Reported Outcome Assessment of Patients with Metastatic Non-Small Cell Lung Cancer. WCLC 2018, 2018. e-Pub 2018.
98. Yan X, Zhang X, Wang L, Zhang R, Pu X, Wu S, Li L, Pan T, Wang J, Meng Q, Girard L, Minna J, Roth JA, Swisher SG, Heymach JV, Fang B. Synthetic lethality therapy for lung cancers with compromised glutathione homeostasis. UT Lung SPORE Workhop 2018, 2018. e-Pub 2018.
99. Zhang R, Zhang X, Wang L, Ren C, Zhang J, Xi Y, Wang J, Chen H, Liu S, Baladandayuthapani V, Heymach JV, Gibbons D, Roth JA, Swisher SG, Fang B. Lung Cancer PDX Models: Molecular annotation and translational application. UT Lung SPORE Workshop 2018, 2018. e-Pub 2018.
100. Meraz IM, Majidi M, Fang B, Lin SH, Shpall E, Roth JA. Development of a humanized PDX (Hu-PDX) mouse model for evaluation of immunotherapy. 2018 Lung SPORE Workshop, 2018. e-Pub 2018.
101. Lam VK, Blumenschein GR, Li L, Wang J, Sanchez CA, Oguhebe RC, Roarty E, Rinsurongkawong W, Lewis J, Roth JA, Swisher S, Lee JJ, Zhang J, Brophy F, Hyland N, Kurtis C, Holdich T, Amando RG, Heymach J. HLA, tumor antigen expression, and genomic subtypes of an NY-ESO-1c259 / MAGE-A10c796 TCR screening cohort. ASCO 2018, 2018. e-Pub 2018.
102. Nelson DB, Tayob N, Mitchell KG, Correa AM, Hofstetter WL, Sepesi B, Walsh GL, Vaporciyan AA, Swisher SG, Antonoff MB, Roth JA, Rice DC, Mehran RJ. Close Surgical Margins and Risks of Local Treatment Failure after Wedge Resection of Colorectal Pulmonary Metastases. AATS 2018, 2018. e-Pub 2018.
103. Nelson DB, Nguyen QN, Tayob N, Hofstetter WL, Sepesi B, Walsh GL, Vaporciyan AA, Swisher SG, Antonoff M, Roth JA, Rice DC, Mehran RJ. Local Failure after Stereotactic Body Radiation Therapy (SBRT) or Wedge Resection for Colorectal Pulmonary Metastases. AATS 2018, 2018. e-Pub 2018.
104. Stewart CA, Gay CM, Xi Y, Siva V, Fujimoto J, Tong P, Diao L, Li L, Bolisetty M, Kalhor N, Lawson P, Vasquez M, Tran H, Wistuba II, Glisson B, Zhang J, Swisher SG, Roth JA, Heymach JV, Robson P, Wang J, Byers LA. Single-cell profiling of small cell lung cancer circulating tumor cell-derived xenograft models reveals intratumoral heterogeneity among mediators of chemoresistance. AACR 2018, 2018. e-Pub 2018.
105. Vaghani V, Chandwani S, Hirschmann M, Lacerda L, Roarty E, Zhang J, Rinsurongkawong W, Lewis J, Burke T, Lee J, Roth J, Swisher S, Heymach J, Simon G. PDL1 testing patterns in stage IV NSCLC: Interim analysis of a prospective study. 2018 NCCN Annual Conference, 2018. e-Pub 2018.
106. Van Haren RM, Mehran R, Correa AM, Antonoff MB, Baker CM, Hofstetter WL, Mena GE, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Rice DC. J. Maxwell Chamberlain Memorial Paper for General Thoracic Surgery: Enhanced Recovery Protocol Decreases Pulmonary and Cardiac Complications Following Thoracotomy for Primary Lung Cancer. STS 2018, 2018. e-Pub 2018.
107. Atay SM, Van Haren R, Niu J, Giordano S, Antonoff AM, Hofstetter WL, Mehran R, Rice DC, Vaporciyan AA, Walsh GL, Roth JA, Swisher SG, Sepesi B. Pathologic Treatment Response is Associated with Increased Overall Survival in Patients Undergoing Neoadjuvant Chemotherapy Followed by Pneumonectomy. STS 2018, 2018. e-Pub 2018.
108. Pu X, Zhang R, Wang L, Meraz IM, Cao X, Zhang X, Wu S, Wu L, Su D, Mao W, Heymach JV, Roth JA, Swisher SG, Fang B. Co-residence of patient-derived immune cells in patient-derived xenografts from lung cancer patients. 2018 MD Anderson Cancer Center GAP Conference, 2018. e-Pub 2018.
109. Vaghani V, Chandwani S, Hirschmann M, Seyedeh D, Lacerda L, Roarty E, Zhang J, Shi Q, Rinsurongkawong W, Lewis J, Burke T, Lee J, Roth J, Swisher S, Heymach J, Williams L, Cleeland C, Simon G. Prospective Advanced Non-small Cell lung cancer Holistic Registry (ANCHoR Project). MDACC GAP Conference 2018, 2018. e-Pub 2018.
110. Vaghani V, Chandwani S, Hirschmann M, Lacerda L, Roarty E, Zhang J, Rinsurongkawong W, Lewis J, Burke T, Lee J, Roth J, Swisher S, Heymach J, Simon G. PDL-1 Testing Patterns in Stage IV Non-Small Cell Lung Cancer (NSCLC): Interim Analysis of a Prospective Study. National Comprehensive Cancer Network Conference 2018, 2018. e-Pub 2018.
111. Lam VK, Li L, Wang J, Tran HT, Rinsurongkawong W, Lanman RB, Lewis J, Roth J, Swisher S, Papadimitrakopoulou VA, Lee J, Zhang J, Heymach JV. Characteristics of Lung Cancer Cell-Free Tumor DNA (CfDNA) Shedding and Correlation with Tumor Burden as Measured by RECIST. WCLC 2017, 2017. e-Pub 2017.
112. Altan M, Fossella F, Zhang J, Landry L, Roarty E, Roth J, Swisher S, Heymach JV. Single Institutional Experience of the Use of PD-1 Inhibitors to Non-Small Cell Lung Cancer Patients with Preexisting Autoimmune Diseases. WCLC 2017, 2017. e-Pub 2017.
113. Chandwani S, Vaghani V, Hirschmann M, Lacerda L, Roarty E, Zhang J, Shi Q, Rinsurongkawong W, Lewis J, Williams L, Cleeland C, Burke T, Lee J, Roth J, Swisher S, Heymach J, Simon G. Computing the Impact of Immunotherapy on NSCLC landscape: The Advanced Non-Small Cell Lung Cancer Holistic Registry (ANCHoR). IASLC 2017, 2017. e-Pub 2017.
114. Sun B, Brooks ED, Komaki RU, Liao Z, Heter MD, McAleer MF, Allen PK, Balter P, Welsh JW, O'Reilly MS, Gomez DR, Hahn SM, Roth J, Mehran R, Heymach J, Chang JY. 7-year Follow-Up Outcomes After Stereotactic Ablation Radiation Therapy for Stage I NSCLC: Results of a Phase 2 Clinical Trial. ASTRO 2017, 2017. e-Pub 2017.
115. Xie Y, Lu W, Wang S, Tang X, Tang H, Zhou Y, Moran C, Behrens C, Roth J, Johnson D, Swisher S, Heymach J, Papadimitrakopoulou V, Xiao G, Minna J, Wistuba I. Validation of the 12-Gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer. 2017 Lung Cancer SPORE Workshop, 2017. e-Pub 2017.
116. Meraz IM, Majidi M, Cao X, Lin H, Li L, Wang J, Baladandayuthapani, Rice D, Sepesi B, Ji L, Roth J. TUSC2 Enhances Sensitivity to Anti-PD1 in Kras Mutant Syngeneic Mouse Lung Cancer Through NK Cells. 2017 Lung Cancer SPORE Workshop, 2017. e-Pub 2017.
117. Rice D, Mehran R, Correa A, Antonoff M, Hofstetter W, Roth J, Sepesi B, Swisher S, Walsh G, Vaporciyan A. Is There Any Value To Robotic Assisted Lobectomy for Lung Cancer?. 2017 ISMICS Annual Scientific Meeting, 2017. e-Pub 2017.
118. Nelson DB, Godoy M, Shewale J, Correa A, Spicer J, Hofstetter WL, Mehran RJ, Rice DC, Sepesi B, Walsh GL, Vaporciyan AA, Swisher SG, Roth JA, Antonoff M. Clinicoradiographic Predictors of Aggressive Behavior in Resected Malignant Ground Glass Opacity Lesions. WTSA 2017, 2017. e-Pub 2017.
119. Xie Y, Lu W, Tang H, Wang S, Tang X, Zhou Y, Moran C, Behrens C, Roth J, Johnson D, Minna J, Xiao G, Wistuba I. Validation of the 12-gene predictive signature for Adjuvant Chemotherapy Response in Lung Cancer. 2017 Lung Cancer SPORE Workshop, 2017. e-Pub 2017.
120. Schvartsman G, Peng SA, Bis G, Lee JJ, Benveniste MFK, Zhang J, Rinsurongkawong W, Lewis J, Roarty EB, Lacerda L, Roth JA, Swisher S, Heymach JV, Fossella FV, William Jr WM. Response to single-agent (SA) chemotherapy (CTx) after immunotherapy exposure in non-small cell lung cancer (NSCLC). 2017 ASCO, 2017. e-Pub 2017.
121. Elamin Y, Gomez D, Papadimitrakopoulou V, Tran H, Rinsurogkawong W, Lewis J, Landry L, Roarty E, Lee J, Roth J, Swisher S, Zhang J, Heymach J. Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non-small cell lung cancer (NSCLC). ASCO 2017, 2017. e-Pub 2017.
122. Nelson DB, Lapid DJ, Mitchell KG, Correa AM, Hofstetter WL, Mehran RJ, Rice DC, Sepesi B, Walsh GL, Vaporciyan AA, Swisher SG, Roth JA, Antonoff MB. Perioperative Outcomes for Stage I Non-Small Cell Lung Cancer: Differences Between Men and Women. AATS 2017, 2017. e-Pub 2017.
123. Antonoff MB, Shewale J, Nelson DB, Rice D, Sepesi B, Hofstetter W, Mehran RJ, Vaporciyan AA, Walsh G, Swisher S, Roth J. Natural History of Ground Glass Lesions Among Patients with Previous Lung Cancer: Predictors of Progression. AATS Centennial 2017, 2017. e-Pub 2017.
124. Sepesi B, Ye Y, Zhang L, Gu J, Ji L, Antonoff M, Hofstetter WL, Rice D, Mehran R, Walsh GL, Vaporciyan AA, Swisher SG, Roth JA, Wu X. Genetic Variants in Cytokine Signaling Pathways Are Associated With. AATS Centennial 2017, 2017. e-Pub 2017.
125. Nelson DB, Rice DC, Niu J, Atay SM, Vaporciyan AA, Antonoff MB, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Tsao AS, Gomez DR, Giordano SH, Mehran RJ, Sepesi B. Predictors of Trimodality Therapy and Trends in Therapy for Malignant Pleural Mesothelioma. European Society of Thoracic Surgeons Annual Meeting 2017, 2017. e-Pub 2017.
126. Antonoff M, Ragalie W, Sepesi B, Roth J, Walsh G, Hofstetter W, Swisher SG, Rice DC, Vaporciyan AA, Mehran R. Patient-Reported Symptoms: Differences Between Men and Women Following Pulmonary Resection. Int J Radiat Oncol Biol Phys 98(1):240, 2017. e-Pub 2017. PMID: 28587019.
127. Sepesi B, Cuentes EP, Canales JR, Behrens C, Correa A, Antonoff M, Gibbons DL, Heymach J, Hofstetter W, Mehran R, Rice DC, Roth J, Vaporciyan AA, Walsh G, Weissferdt A, Kalhor N, Moran C, Swisher SG, Wistuba I. Tumor-Infiltrating Lymphocytes and Overall Survival in Surgically Resected Stage II and III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 98(1):223, 2017. e-Pub 2017. PMID: 28586974.
128. Meraz IM, Majidi M, Cao X, Rice D, Sepesi B, Ji L, Roth JA. Tumor suppressor TUSC2 immunogene therapy is synergistic with anti-PD1 in syngeneic mouse models of lung cancer. AACR 2017, 2017. e-Pub 2017.
129. Nelson DB, Correa A, Dhupar R, Goltsov A, Maru D, Sepesi B, Antonoff M, Mehran RJ, Rice DC, Walsh GL, Vaporciyan AA, Swisher SG, Roth JA, Davila R, Betancourt S, Ajani J, Hofstetter W. Endoscopic Mucosal Resection for Submucosal Esophageal Cancer. AATS 2017, 2017. e-Pub 2017.
130. Bassuner J, Rice DC, Antonoff MB, Correa A, Walsh GL, Vaporciyan AA, Garg N, Sepesi B, Swisher SG, Hofstetter WL, Roth JA, Mehran RJ. Polytetrauoroethylene or Collagen Matrix for Diaphragmatic Reconstruction?. STS 2017, 2017. e-Pub 2017.
131. Chang J, Sun B, Liao Z, Jeter M, Welsh J, Balter P, Mehran R, Heymach J, Komaki R, Roth J. Long-Term Outcomes of Prospective Phase II Clinical Trial for Stereotactic Ablation Radiotherapy in Recurrent NSCLC. IASLC WCLC 2016, 2016. e-Pub 2016.
132. Sepesi B, Team I, Heymach J, Sharma P, Allison J, Fang B, Zhang J, Wagner H, Bogatenkova E, Wistuba I, Swisher S, Bernatchez C, Gibbons DL. Prospective Immunogenomic Profiling of Non-Small Cell Lung Cancer - the ICON Project. IASLC WCLC 2016, 2016. e-Pub 2016.
133. Atay SM, Niu J, Giordano SH, Antonoff M, Heymach J, Hofstetter WL, Mehran R, Rice D, Roth JA, Vaporciyan A, Walsh G, William W, Swisher S, Sepesi B. Perioperative Outcomes and Downstaging Following Neoadjuvant Therapy For Lung Cancer - Analysis of the National Cancer Database. IASLC 2016, 2016. e-Pub 2016.
134. Haymaker C, Federico L, Forget MA, Vence LM, Sharma P, Allison JP, Fang B, Zhang J, Wagner H, Bogatenkova E, Wistuba I, Sepesi B, Heymach J, Gibbons D, Bernatchez C, Weissferdt A, Vaporciyan AA, Futreal A, Karpinets T, Yee C, Lizee G, Talukder A, Roszik J, Tran H, Vasquez M, Prado E, Behrens C, Parra E, Rodriguez-Canales J, Fujimoto J, Roth J, Meraz I, Roarty E, Landry L, Byers L, Kalhor N, Swisher SG, William Jr W. Phenotypic and functional profiling of tumor-infiltrating lymphocytes (TIL) in early stage non-small cell lung cancer (NSCLC). IASLC WCLC, 2016. e-Pub 2016.
135. Atay SM, Correa A, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan A, Walsh G, Antonoff M. Perioperative Outcomes of Patients Undergoing Lobectomy on Clopidogrel. STSA 2016, 2016. e-Pub 2016.
136. Sceusi E, Atay S, Correa A, Swisher S, Vaporciyan A, Roth J, Walsh G, Hofstetter W, Mehran R, Rice D, Sepesi B, Antonoff M. Outcomes for Patients with Surgically Resected Thymic Neuroendocrine Tumors. NANETS Symposium, 2016. e-Pub 2016.
137. Sepesi B, Parra Cuentas E, Rodriguez Canales J, Behrens C, Correa A, Antonoff M, Gibbons M, Heymach J, Hofstetter W, Mehran R, Rice D, Roth J, Vaporciyan A, Walsh G, Weissferdt A, Kalhor N, Moran C, Swisher S, Wistuba W. The Expression of Programmed Death 1 Ligand (PD-L1) in the Tumor and Tumor Infiltrating Macrophages Predicts Overall and Disease Free Survival in Surgically Resected Pathologic Stage I Non-Small Cell Lung Cancer. WTSA 2016, 2016. e-Pub 2016.
138. Shimodaira Y, Slack RS, Chen HC, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Harada K, Amlashi FG, Mizrak D, Blum MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Komaki R, Walsh G, Ajani JA. Influence of Induction chemotherapy (IC) in Trimodality-Eligible Esophageal Cancer Patients: Secondary Analysis of a Randomized trial. ASCO 2016, 2016. e-Pub 2016.
139. Sceusi E, Miguel LJ, Mehran RJ, Kalhor N, Shaw K, Futreal A, Correa A, Moran C, Wistuba I, Junya I, Rao X, Swisher S, Vaporciyan A, Wang J, Antonoff M, Hofstetter W, Rice D, Sepesi B, Walsh G, Roth J. Well Differentiated Neuroendocrine Carcinoma (Typical Carcinoid) with Mediastinal Lymph Node Metastases: Surgical Outcomes and Whole Exome Sequencing (WES). AATS 2016, 2016. e-Pub 2016.
140. Pataer A, Chengcheng H, Correa AM, Fang B, Roth JA, Wistuba II, Swisher SG. PKR and Jagged1 associated with lymph node metastasis in lung cancer. Proc Am Assoc Cancer Res, 2016. e-Pub 2016.
141. Zhang L, Roth JA, Lian J, Ye Y, Gu J, Wu X. Serum microRNA signatures predict recurrence and survival in Caucasian patients with early stage non-small cell lung cancer. AACR 2015, 2016. e-Pub 2016.
142. Zhang L, Ye Y, Tu H, Hildebrandt MAT, Heymach JV, Roth JA, Gu J, Wu X. Dietary iron intake, genetic variants in microRNA related iron regulatory pathway genes, and the risk of non-small cell lung cancer. AACR 2016, 2016. e-Pub 2016.
143. Tu H, Heymach JV, Weng CP, Ye Y, Pierzynski JA, Roth JA, Wu X. Different dietary patterns and reduction of lung cancer risk: a large case-control study in the U.S. AACR 2016, 2016. e-Pub 2016.
144. Gentile E, Oba T, Lin J, Shao R, Meng F, Cao X, Roth JA, Lin Ji L. A novel cationic liquid crystalline nanoparticle for the delivery of synthetic RNAi-based therapeutics. AACR 2016, 2016. e-Pub 2016.
145. Lin J, Ye Y, Zhang L, Oba T, Gentile E, Wang J, Zhao Y, Gu J, Wistuba I, Roth JA, Wu X, Ji L. Circulating biomarker miRNA-150 promotes tumor cell proliferation and progression by targeting SRC kinase signaling inhibitor 1 (SRCIN1) in non-small cell lung cancer. AACR 2016, 2016. e-Pub 2016.
146. Oba T, Ye Y, Lin J, Gentile E, Wang J, Zhao Y, Wistuba I, Roth JA, Wu X, Ji L. Serum miR152 as a novel prognostic biomarker and potential tumor suppressor for early stage non-small cell lung cancer. AACR 2016, 2016. e-Pub 2016.
147. Sanchez N, Shewale JB, Baker C, Wilks SA, Correa AM, Sepesi B, Mehran R, Rice DC, Roth JA, Walsh GL, Swisher SG, Vaporciyan A, Hofstetter W. Implications of Early Foley Removal in Thoracic Surgical Oncology Patients Utilizing Epidural Analgesia. STSA 2015, 2015. e-Pub 2015.
148. Spicer JD, Shewale JB, Antonoff MB, Correa AM, Hofstetter W, Rice DC, Vaporciyan A, Mehran R, Walsh GL, Roth JA, Swisher SG, Sepesi B. The Influence of Reconstructive Technique on Perioperative Outcomes Following Chest Wall Resection. STSA 2015, 2015. e-Pub 2015.
149. Chang JY, Mehran R, Balter P, McRae S, Feng L, Berry DA, Komaki R, Roth JA. Phase II Clinical Trial of Stereotactic Ablative Radiotherapy (SABR) in Surgically Operable Stage I Non-Small Cell Lung Cancer (STARS). IASLC WCLC 2015, 2015. e-Pub 2015.
150. Spicer J, Shewale J, Sepesi B, Antonoff M, Correa A, Hofstetter W, Rice D, Vaporciyan A, Mehran R, Walsh G, Roth J, Swisher S. The Role of Pneumonectomy After Neoadjuvant Chemotherapy for N2 Non-Small Cell Lung Cancer. Canadian Surgery Forum 2015, 2015. e-Pub 2015.
151. Spicer JD, Shewale J, Correa AM, Heymach JV, Antonoff MB, Hofstetter W, Mehran R, Roth J, Rice D, Sepesi B, Vaporciyan AA, William W, Walsh G, Swisher S. Pre-Operative Chemotherapy Followed by Surgery for N2 Non-Small Cell Lung Cancer: A 15-Year Experience. IASLC 2015, 2015. e-Pub 2015.
152. Antonoff MB, Ragalie W, Correa AM, Spicer JD, Sepesi B, Roth JA, Walsh GL, WlL H, Swisher SG, Rice DC, Vaporciyan AA, Mehran RJ. Results of Postdischarge Nursing Telephone Assessments: Persistent Symptoms Common Among Pulmonary Resection Patients. Western Thoracic Surgical Association Annual Meeting 2015, 2015. e-Pub 2015.
153. Lin J, Zandi R, Gu J, Ye Y, Pertsemlidis A, Wu X, Roth J, Ji L. A SNP in the 3′-untranslated region of FZD4 linked to lung cancer survival modulates a miRNA-mediated FZD4 transcript binding, cleavage, expression, and Wnt-signaling in NSCLC cells. AACR 2015, 2015. e-Pub 2015.
154. Pataer A, Shao R, Correa AM, Behrens C, Roth JA, Wistuba II, Swisher SG. Evaulate biomarkers in NSCLC tumors receiving neoadjuvant chemotherapy. AACR 2015, 2015. e-Pub 2015.
155. Song K, Zheng G, Girard L, Wistuba II, Roth JA, Behrens C, Suraokar MB, Minna JD, Gazdar AF. Copy number variations distinguish lung adenocarcinomas from squamous cell carcinomas. AACR 2015, 2015. e-Pub 2015.
156. Pierzynski JA, Hildebrandt MA, Ye Y, Roth JA, Wu X. Baseline Quality of Life and Genetic Determinants and the Impact on Five-Year Lung Cancer Survival. AACR 2015, 2015. e-Pub 2015.
157. Sepesi B, Schmidt HE, Lada M, Correa A, Walsh GL, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Ajani JA, Watson TJ, Swisher SG, Low DE, Hofstetter WL. Surgical Therapy Is An Important Multimodality Component in Patient with Distal Esophageal Adenocarcinoma Independent of Regional Lymph Node Location. STSA 2014, 2014. e-Pub 2014.
158. Sepesi B, Correa AM, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Ajani JA, Walsh GL, Swisher SG, Hofstetter WL. Trends and Improving Outcomes of 882 Surgical Patients With Gastro-Esophageal Junction Adenocarcinoma – A Single Institution Experience. The International Society for Diseases of the Esophagus 2014, 2014. e-Pub 2014.
159. Ye Y, Wang Y, Roth J, Wu X. Serum MicroRNAs as biomarkers in early stage non-small cell lung cancer. AACR 2014, 2014. e-Pub 2014.
160. Pataer A, Guo C, Shao R, Correa AM, Behrens C, Fang B, Roth JA, Wistuba II, Swisher SG. Nutrient depletion caused by PKR induces phosphorylation of AMPK in lung cancer. American Association for Cancer Research 2014, 2014. e-Pub 2014.
161. Sepesi B, Hofstetter W, Rice DC, Mehran RJ, Vaporciyan AA, Walsh G, Roth JA, Swisher SG. Experience with Primary and Metastatic Adenoid Cystic Carcinoma. 2014 Society of Surgical Oncology Annual Cancer Symposium, 2014. e-Pub 2014.
162. Francis AM, Correa AM, Betancourt-Cuellar SL, Kim JY, Sepesi B, Ajani JA, Komaki R, Erasmus J, Maru D, Munden RF, Mehran R, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Hofstetter WL, Swisher SG. Esophageal Tumor Thickness on Computed Tomography as a Predictor of Residual Tumor in Esophageal Adenocarcinoma Following Preoperative Chemoradiation. Academic Surgical Congress 2014, 2014. e-Pub 2014.
163. Minna JD, Gazdar A, Augustyn A, Britt R, Carstens R, Dospoy P, Gao B, Girard L, Hight S, Huffman K, Larsen J, Peyton M, Shao CL, Mangelsdorf D, Brekken R, Deberardinis R, Chen PH, Behrens C, Byers L, Heymach J, Roth J, Wistuba I, Xie Y, Davis C, Wheeler D, Gibbs R, Marcotte E, Ready J, Nijhawan D, Williams N, McKnight S, Posner B, MacMillan J, Roth M, White M. Developing a new functional classification of lung cancer based on tumor acquired vulnerabilities. 3rd AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, 2014. e-Pub 2014.
164. Pataer A, Chengcheng G, Ruping S, Correa AM, Fang B, Roth JA, Wistuba II, Swisher SG. RNA-Dependent Protein Kinase (PKR) Depletes Nutrients, Inducing Phosphorylation of AMP-Activated Kinase in Lung Cancer. Proc Am Assoc Cancer Res, 2014. e-Pub 2014.
165. Wu Q, Liu Q, Sakai R, Hangauer D, Roth J, Ji L. The PDGFR/Src signaling pathway-targeted therapy with novel TUSC2-nanoparticles and tyrosine kinase inhibitors for human lung cancer. IASLC 2013, 2013. e-Pub 2013.
166. Chang JY, Zhang YL, Zhu Z, Welsh JW, Gomez DR, Komak R, Roth JA, Swisher SG. Stereotactic Ablative Radiotherapy: A Potentially Curable Approach to Multiple Primary Lung Cancer. IASLC 2013, 2013. e-Pub 2013.
167. Kim MP, Correa AM, Blackmon SH, Erasmus J, Hofstetter WL, Macapinlac H, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Swisher SG. Preoperative Flourodeoxyglucose-Positron Emission Tomography Scan with Positive N1 Disease Does Not Predict Worse Survival in Pathologic Stage II Patients. IASLC 2013, 2013. e-Pub 2013.
168. Chang JY, Xu Q, Li Q, Rebueno N, Balter P, Gomez DR, Komaki R, Mehran RJ, Swisher SG, Roth JA. Stereotactic ablative radiotherapy (SABR) for centrally located early-stage or isolated parenchymal recurrences of non-small cell lung cancer (NSCLC): How to fly in a “no fly zone”. IASLC 2013, 2013. e-Pub 2013.
169. Roth JA. Debate: Surgery or SABR in Borderline or Operable Stage I NSCLC. 2013 MDACC: International Stereotactic Radiotherapy Symposium, 2013. e-Pub 2013.
170. Chang JY, Komaki R, Welsh J, Gomez D, Roth JA, Swisher SG. Clinical Outcome and Toxicity in Central Located State I or Isolated Recurrent Non-Small Cell Lung Cancer Treated with Stereotatic Ablative Radiotherapy. Int J Rad Oncology Biol Phys 87(2):S654, 2013. e-Pub 2013.
171. Kim E, Ye Y, Vaporciyan AA, Xing J, Huang M, Gu J, Roth JA, Lippman SM, Wu X. Telomere length and recurrence risk after curative resection in women with adenocarcinoma of the lung: A prospective cohort study. Proc Am Soc Clin Oncol, 2013. e-Pub 2013.
172. Stephens A, Rice D, Swisher S, Vaporciyan A, Hofstetter W, Walsh G, Mehran R, Roth J. VATS lobectomy is Associated with Improved Short-Term and Long-Term Outcomes Compared to Open Lobectomy for C-Stage I NSCLC: A Propensity-Matched Analysis of 963 Cases. 21st European Conference on General Thoracic Surgery, 2013. e-Pub 2013.
173. Shu X, Lu C, Chang JY, Roth JA, Wu X. Genetic variations in apoptosis pathway are associated with survival in late stage non-small cell lung cancer. AACR 2013, 2013. e-Pub 2013.
174. Chowdhuri SR, Zaidi TM, Khanna A, Jiang F, Spitz MR, Vaporciyan AA, Roth JA, Ensor J, Katz RL. Deletion of 3p22.1 by FISH in non-small cell lung cancer (NSCLC) is significantly correlated with loss of ß-catenin membrane expression and dysregulated cell adhesion. Proc Am Assoc Cancer Res, 2013. e-Pub 2013.
175. Pu X, Skinner HD, Ye Y, Hildebrandt MAT, Chang JY, Lu C, Komaki R, Minna JD, Roth JA, Wu X. Genome-wide association study of toxicity following definitive radiotherapy in non-small cell lung cancer patients. Proc Am Assoc Cancer Res, 2013. e-Pub 2013.
176. Pu X, Wang L, Hildebrandt MAT, Ye Y, Chang JY, Lu C, Skinner HD, Niu N, Jenkins GD, Komaki R, Minna JD, Roth JA, Weinshilboum RM, Wu X. Inflammation-related genetic variants predict radiation-induced toxicity following definitive radiotherapy for non-small cell lung cancer. Proc Am Assoc Cancer Res, 2013. e-Pub 2013.
177. Sanchez-Espiridion B, Gu J, Chang DW, Chang JY, Lu C, Roth JA, Wu X. Constitutive short telomere length and lung cancer risk: a large case- control study. Proc Am Assoc Cancer Res, 2013. e-Pub 2013.
178. Francis AM, Sepesi B, Correa A, Mehran R, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Welsh J, Swisher SG, Hofstetter WL. Long-Term Survival and Recurrence Rates Following Trimodality Therapy of Esophageal Adenocarcinoma – The Influence of Histologic Tumor Viability. ASA 2013 Annual Meeting, 2013. e-Pub 2013.
179. Sepesi B, Correa AM, Pataer A, Kalhor N, Bekele NB, Erasmus JJ, Heymach J, Hofstetter WL, Komaki R, Mehran RJ, Moran CA, Gold K, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, William W, Wistuba I, Swisher SG. The Impact of Histopathologic Tumor Viability on AJCC 7th Lung Cancer Staging Following Neoadjuvant Chemotherapy. STS 2013, 2013. e-Pub 2013.
180. David EA, Wai C, Correa AM, Hofstetter WL, Rice DC, Roth JA, Swisher SG, Walsh GW, Vaporciyan AA, Thall P, Mehran R. Visceral Pleural Invasion is not predictive of survival In NSCLC patients with small tumors in a North American patient population. STS Annual Meeting 2013, 2013. e-Pub 2013.
181. Roth J, Chang J, Komaki R, Carpenter L, Kresl J. Challenges in design and accrual for a randomized clinical trial comparing surgery and SABR for early stage lung cancer (STARS). Advancing Radiation Oncology: A Collaborative Forum 2012, 2012. e-Pub 2012.
182. Ganeshan DM, Correa A, Bhosale P, Vaporciyan AA, Rice D, Mehran RJ, Walsh GL, Iyer R, Roth JA, Swisher SG, Hofstetter WL. Diaphragmatic Hernia After Esophagectomy in 440 Patients with Long-term Follow-up. STSA 2012, 2012. e-Pub 2012.
183. Norman P, Baker T, David EA, Roth JA. Thoracotomy With an Unstable Neck. American Society of Anesthesiologist 2012, 2012. e-Pub 2012.
184. Lin SH, Amini A, Lou F, Correa A, Roth JA, Swisher SG, Huang J, Rimner A, Vaporciyan AA. Predictors for locoregional recurrence for clinical stage III-N2 non-small cell lung cancer with nodal downstaging after induction chemotherapy and surgery. Proc Am Soc Clin Oncol, 2012. e-Pub 2012.
185. Sepesi B, Swisher SG, Walsh G, Correa A, Mehran R, Rice D, Roth J, Vaporciyan A, Hofstetter WL. Omental Reinforcement of the Thoracic Esophagogastric Anastomosis – An Analysis of Leak and Reintervention Rates in Planned and Salvage Esophagectomy Patients. Proc Am Assoc Thorac Surg, 2012. e-Pub 2012.
186. Yan S, Xu K, Lin J, Jayachandran G, Wang B, Watanabe Y, Ge Q, Wu Y, Guo D, Chen Y, Roth JA, Ji L. Synergistic inhibition of tumor growth and overcoming chemo-resistance by simultaneously targeting key components in DNA damage/repair, epigenetic, and putative cancer stem cell signaling pathways using novel dual-functional DNA-alkylating/HDAC inhibitor. Proc Am Assoc Cancer Res, 2012. e-Pub 2012.
187. Guo C, Shao R, Correa AM, Behrens C, Fang B, Roth JA, Wistuba II, Swisher SG, Lin T, Pataer A. Prognostic significance of combinations of RNA-dependent protein kinase and EphA2 biomarkers for NSCLC. Proc Am Assoc Cancer Res, 2012. e-Pub 2012.
188. Pu X, Ye Y, Spitz MR, Wang L, Gu J, Lippman SM, Hildebrandt MAT, Hong WK, Minna JD, Roth JA Yang P, Wu X. Predictors of survival in never-smokers with non-small cell lung cancer: A large-scale, two-phase genetic study. Proc Am Assoc Cancer Res, 2012. e-Pub 2012.
189. Wang Y, Lippman SM, Minna JD, Roth JA, Wu X. Pathway-based serum microRNA profiling and late-stage non-small cell lung cancer survival. Proc Am Assoc Cancer Res, 2012. e-Pub 2012.
190. Kim ES, Ye Y, Vaporciyan AA, Xing J, Huang M, Gu J, Roth JA, Lippman SM, Wu X. Genetic variations in epidermal growth factor receptor pathway predict recurrence and response to chemotherapy in early stage non-small cell lung cancer. Proc Am Assoc Cancer Res, 2012. e-Pub 2012.
191. He Y, Gong Y, Gu J, Lin J, Chang D, Lippman SM, Roth J, Wu X. A novel objective, image-based phenotypic assay reveals higher γ-radiation-induced γ-H2AX level in peripheral blood lymphocytes as a risk predictor for lung cancer. Proc Am Assoc Cancer Res, 2012. e-Pub 2012.
192. Meng J, Lara-Guerra H, Ji L, Roth JA. Synergistic antitumor activity of AKT inhibitor MK2206 and FUS1-nanoparticles in LKB1 mutant NSCLC. Proc Am Assoc Cancer Res, 2012. e-Pub 2012.
193. Blackmon SH, Correa AM, Skoracki R, Chevray P, Kim M, Mehran R, Rice DC, Roth J, Swisher SG, Vaporciyan AA Walsh GL, Hofstetter W. Super-Charged Pedicled Jejunal Interposition for Esophageal Replacement: A 10 Year Experience. STS 48th Annual Meeting, 2012. e-Pub 2012.
194. Blackmon SH, Stephens E, Correa AM, Hofstetter W, Kim MP, Mehran R, Rice DC, Roth JA, Swisher SG, Walsh GL, Vaporciyan AA. Predictors of Recurrence in the Lung and Survival in Pulmonary Metastasectomy for Colorectal Carcinoma Patients. STS 48th Annual Meeting, 2012. e-Pub 2012.
195. Kim JY, Hildebrandt MAT, Ye Y, Pu X, Correa AM, Vaporciyan AA, Wu X, Roth JA. Genetic Variations in the VEGF Pathway are Associated with Postoperative Pulmonary Complications After Lung Resection. STS 48th Annual Meeting, 2012. e-Pub 2012.
196. Marks JL, Hofstetter W, Correa A, Mehran RJ, Rice D, Roth J, Walsh G, Vaporciyan A, Erasmus J, Chang J, Maru D, Lee JH, Lee J, Ajani JA, Swisher SG. Salvage Esophagectomy After Failed Definitive Chemoradiation For Esophageal Adenocarcinoma. STS 48th Annual Meeting, 2012. e-Pub 2012.
197. Amini A, Lin SH, Correa AM, Swisher SG, Roth JA, Vaporciyan AA. Locoregional Recurrence Rate in Resected Stage III-N2 Non-Small Cell Lung Cancers (NSCLC) with Nodal Downstaging following Induction Chemotherapy. Int J Radiat Oncol Biol Phys 81(2):S134, 2011. e-Pub 2011.
198. Chang JY, Liu H, Xu Z, Balter P, Liao Z, Jeter M, Swisher R Mehran J, Roth J, Komaki R. Four-dimensional CT- and On-board Volumetric Image-guided Stereotactic Ablative Radiotherapy (SABR) for Stage I Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys - Proceedings of the 53rd Annual ASTRO Meeting 81(2):S623, 2011. e-Pub 2011.
199. He Y, Zhou Z, Hofstetter WL, Zhou Y, Hu W, Pataer A, Correa AM, Lu Y, Wang J, Diao L, Byers LA, Wistuba I, Roth JA, Swisher SG, Heymach JV, Fang B. Aberrant Signal Transduction and DNA Damage Response pathways in Primary Lung Cancer. ISLAC 2011 6(6, Supp 2):S972, 2011. e-Pub 2011.
200. Roth JA, Marks J. Local Recurrence After Definitive Chemoradiation: Is Salvage Surgery Indicated?. J Thor Onc 6(6, Supp 2):S247-S249, 2011. e-Pub 2011.
201. Ji L, Lin J, Xu K, Yan S, Chen Y, Roth JA. An Effective DNA Damage/Repair Signaling Pathway-Targeted Therapy for Lung Cancer Combining a Novel Dual-Funcation DNA-Alkylating/HDAC Inhibitor with Tumor Suppressor Gene Nanoparticles. J Thor Onc 6(6, Supp 2):S591-S592, 2011. e-Pub 2011.
202. Harvin JA, Lahat G, Correa A, Lee J, Maru D, Ajani J, Marom E, Welsh J, Bhutani MS, Walsh G, Roth J, Mehran R, Vaporciyan A, Rice D, Swisher S, Hofstetter W. Neoadjuvant Chemoradiation followed by Surgery for Esophageal Adenocarcinoma: Significance of Microscopically Positive Circumferential Margins. Proc Am Assoc Thorac Surg, 2011. e-Pub 2011.
203. Pataer A, He Y, Correa AM, Fang B, Roth JA, Wistuba II, Swisher SG. PKR signaling pathway plays an important role in prognosis for non-small cell lung cancer. Proc Am Assoc Cancer Res, 2011. e-Pub 2011.
204. Dai B, Meng J, Peyton M, Girard L, Bornmann WG, Ji L, Minna JD, Fang B, Roth JA. STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Proc Am Assoc Cancer Res, 2011. e-Pub 2011.
205. Hildebrandt MA, Roth JA, Vaporciyan AA, Pu X, Ye Y, Correa AM, Kim JY, Swisher SG, Wu X. Genetic variation in the p38 signaling pathway as markers for postoperative pulmonary complications in lung cancer patients. Proc Am Assoc Cancer Res, 2011. e-Pub 2011.
206. Pu X, Spitz MR, Amos C, Ye Y, Hildebrandt MA, Chang D, Lu C, Stewart D, Roth JA, Lippman SM, Christiani D, Wu X. Genetic predictors of clinical outcomes for patients with non-small cell lung cancer. Proc Am Assoc Cancer Res, 2011. e-Pub 2011.
207. Kim ES, Vaporciyan AA, Xing J, Huang M, Gu J, Roth J, Lippman SM, Wu X. Use of telomere length and genetic variations in maintenance genes to predict risk of recurrence and survival in patients with early-stage non-small cell lung cancer. Proc Am Assoc Cancer Res, 2011. e-Pub 2011.
208. Lu C, Stewart DJ, Ji L, Ramesh R, Jayachandran G, Nunez MI, Wistuba II, Erasmus JJ, Lee JJ, Templeton NS, McMannis JD, Roth JA. Systemic gene therapy with tumor suppressor TUSC2/FUS1 nanoparticles for recurrent/metastatic lung cancer. Proc Am Assoc Cancer Res, 2011. e-Pub 2011.
209. Kim JY, Correa AM, Swisher SG, Rice DC, Walsh GL, Vaporciyan AA, Mehran RJ, Roth JA, Bhutani M, Maru D, Welsh J, Ajani J, Rohren E, Hofstetter WL. Does the Timing of Esophagectomy After Neoadjuvant Chemoradiation Affect Outcome?. The Society of Thoracic Surgeons, 2011. e-Pub 2011.
210. Stewart DJ, Behrans C, Swisher S, Roth J, Wistuba II. Factors associated with membrane carbonic anhydrase IX (mCAIX) expression in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 29, 2011. e-Pub 2011.
211. Blackmon SH, Stephens EH, Correa AM, Roth JA, Hofstetter W, Benjamin R, Mehran R, Swisher SG, Walsh GL, Vaporciyan AA. Progression following chemotherapy is a novel predictor of poor outcome following pulmonary metastasectomy in sarcoma patients. J Am Coll Surg Supp 211(3):S35, 2010. e-Pub 2010.
212. Lu C, Stewart DJ, Ji L, Ramesh R, Jayachandran G, Erasmus JJ, Lee J, Templeton NS, McMannis JD, Roth JA. Systemic gene therapy with tumor suppressor FUS1-nanoparticles for recurrent/metastatic lung cancer. J Clin Oncol 28(Supplement):558s, 2010. e-Pub 2010.
213. Wagner KW, Ye Y, Lin J, Vaporciyan AA, Roth JA, Spitz MR, Wu X. Association of genetic variations in DNA-methyltransferases, histone-methyltransferases, and methylated DNA-binding proteins with recurrence and survival in early-stage non-small cell lung cancer treated with surgery alone or surgery and chemotherapy. J Clin Oncol 28(Supplement):517s, 2010. e-Pub 2010.
214. Komaki R, Wei X, Allen P, Roth JA, Swisher S, Rice DC, Walsh GL, Fossella FV, Erasmus JJ, Cox JD. Treatment for superior sulcus tumors (SST): Effect of surgery first followed by adjunct concurrent chemoradiotherapy on survival of patients with marginally resectable SST. J Clin Oncol 28(Supplement):521s, 2010. e-Pub 2010.
215. Kim ES, Vaporciyan AA, Xing J, Huang M, Spitz MR, Lippman SM, Gu J, Roth JA, Wu X. Use of telomere length in peripheral leukocytes to predict risk of recurrence in patients with early-stage non-small cell lung cancer after curative resection. J Clin Oncol 28(Supplement):522s, 2010. e-Pub 2010.
216. Kim MP, Chen Y, Lopez A, Wistuba I, Ji L, Roth JA, Katz RL. AP2 Nucleolar Localization Predicts Poor Survival After Lung Cancer Resection in Stage I Patients. Proc Am Assoc Thorac Surg, 2010. e-Pub 2010.
217. Pataer A, Lu X, Roth JA, Swisher SG. Inhibition of RNA-dependent protein kinase (PKR) enhances radiation sensitivity in lung cancer cells. Proc Am Assoc Cancer Res, 2010. e-Pub 2010.
218. Tan W, Gu J, Hildebrandt M, Huang M, Wistuba II, Roth JA, Spitz MR, Wu X. Aberrant miRNA methylation in tumors from surgically resected lung cancer patients and association with survival. Proc Am Assoc Cancer Res, 2010. e-Pub 2010.
219. Watanabe Y, Jayachandran G, Xu K, Chen Y, Katz RL, Roth JA, Ji L. Genomic abnormality and genetic alterations of a novel ZMIZ1 gene at human chromosome 10q22.3 in lung cancer oncogenesis and prognosis. Proc Am Assoc Cancer Res, 2010. e-Pub 2010.
220. Liu Q, Wu G, Xu K, Roth JA, Ji L. FUS1-mediated tumor suppression by inhibiting PDGF/ PDGFR signaling pathway in human lung cancer. Proc Am Assoc Cancer Res, 2010. e-Pub 2010.
221. Behrens C, Lin H, Nunez M, Yuan P, Solis L, Raso NG, Prudkin L, Sun M, Li X, Tang X, Roth JA, Minna JD, Stewart D, Hong WK, Lee JJ, Wistuba II. Differences in protein expression patters in lung adenocarcinomas arising in never versus ever Smokers. Proc Am Assoc Cancer Res, 2010. e-Pub 2010.
222. Kuroda S, Yokoyama T, Tam J, Scott AW, Shanker M, Correa A, Roth JA, Sokolov K, Ramesh R. EGFR-targeted hybrid plasmonic magnetic nanoparticles induce autophagy and apoptosis through DNA damage in non-small cell lung cancer cells. Proc Am Assoc Cancer Res, 2010. e-Pub 2010.
223. Wismach M, Xu K, Chen Y, Katz R, Roth JA, Ji L. Amplification and Up-regulation of Transcription Factor AP-2 β Gene and Gene Products Promote Human Lung Bronchial Epithelial Cell Transformation and Carcinogenesis. Proc Am Assoc Cancer Res, 2010. e-Pub 2010.
224. Lin J, Xu K, Roth JA, Ji L. Regulation of Novel Tumor Suppressor Gene FUS1 Expression through 5’- and 3’-UTRs and in Response to DNA Damage in Human Lung Cancer Cells. Proc Am Assoc Cancer Res, 2010. e-Pub 2010.
225. Jayachandran G, Wu X, Coombes KR, Wistuba I, Roth JA, Ji L. Identification and Characterization of Phospho-ORM-1 as a Novel Nicotinic Acetylcholine Receptor (NAChR) -associated protein and a Potential Serum Marker for Lung Cancer Detection. Proc Am Assoc Cancer Res, 2010. e-Pub 2010.
226. Sakai R, Xu K, Fang B, Roth JA, Ji L. Overcoming drug resistance to EGFR-tyrosine kinase Inhibitors by FUS1 or FHIT-gene therapy in human lung cancer. Proc Am Assoc Cancer Res, 2010. e-Pub 2010.
227. Gaur P, Sepesi B, Hofstetter WL, Correa AM, Bhutani MS, Ajani JA, Erasmus J, Komaki R, Lee JHL, Maru D, Mehran R, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Peters JH, Watson TJ, Swisher SG. A Clinical Nomogram Predicting Pathologic Lymph Node Involvement in Esophageal Cancer Patients. American Surgical Association 130th Annual Meeting 77, 2010. e-Pub 2010.
228. Kim MP, Correa A, Moran C, Erasmus J, Hofstetter WL, Mehran RJ, Rice DC, Walsh GL, Vaporciyan AA, Swisher SG, Roth JA. Resection of lung cancer in lymphoma survivors. 46th Annual Meeting Program, The Society of Thoracic Surgeons:204, 2010. e-Pub 2010.
229. Kim MP, Hofstetter WL, Correa A, Rice DC, Roth JA, Walsh GL, Mehran RJ, Vaporciyan AA, Ajani JA, Maru DM, Chang JY, Marom EM, Macapinlac HA, Lee JH, Swisher SG. Pathologic T0N1 after neoadjuvant therapy and surgery for esophageal cancer: an orphan status. 46th Annual Meeting Program, The Society of Thoracic Surgeons:p174-175, 2010. e-Pub 2010.
230. Katz RLI, He W, Khanna A, Fernandez RL, Zaidi TM, Krebs M, Caraway NP, Zhang HZ, Jiang F, Spitz MR, Blowers DP, Jimenez CA, Mehran RJ, Swisher SG, Roth JA, Morris JS, Etzel CJ, El-Zein R. Genetically Abnormal CirculatingCells in Lung Cancer Patients: An Antigen-Independent Fluorescebce In situ Hybridization-Based Case-Control Study. AACR 2010, 2010. e-Pub 2010.
231. Swisher SG, Hofstetter WL Komaki R, Correa AM, Erasmus J, Liao Z, Lee JH, Maru DM, Mehran RJ, Patel S, Phan A, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Ajani JA. Improved Long-term Outcome With Chemoradiotherapy Strategies in Locoregionally Advanced Esophageal Cancer. Southern Thoracic Surgical Association 2009, 2009. e-Pub 2009.
232. Gaur P, Hofstetter WL, Bekele NB, Correa AM, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Rice TW, Swisher SG. Staging of Gastroesophageal Adenocarcinomas: A Comparison Between Esophageal Staging, Gastric Staging, and a Novel Worldwide Esophageal Cancer Collaboration Staging System. STSA 56th Annual Meeting 2009, 2009. e-Pub 2009.
233. Roth JA, Johnson B. Gene therapy for lung cancer. J Thorac Oncol 4(9):S265, 2009. e-Pub 2009.
234. Ji L, Wu G, Sakai R, Roth JA. The Src-P13K-Akt and apoptosis signaling pathway-targeted therapy with novel pro-apoptotic FUS1-nanoparticles and Src kinase inhibitors for lung cancer. J Thorac Oncol 4(9):S601, 2009. e-Pub 2009.
235. Ivanova AV, Ivanov SV, Prudkin L, Nonaka D, Liu Z, Tsao A, Roth J, Wistuba I, Pass HI. J Thorac Oncol, IASLC, 13th World Conference on lung Cancer. Mechanisms of FUS1 deficiency in mesothelioma and its tumorigenic transcriptional effects 4(9):S764, 2009. e-Pub 2009.
236. Christensen CL, Gjetting T, Poulsen TT, Ramesh R, Roth JA, Poulsen HS. The suicide fusion gene YCD-YUPRT induces high and specific cytotoxicity in small cell lung cancer cell lines and tumor growth delay in xenografts when regulated from a cancer-specific promoter. J Thorac Oncol 4(9):S797, 2009. e-Pub 2009.
237. Pataer A, Swisher SG, Roth JA, Logothetis CJ, Corn P. Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity. Proc Am Assoc Cancer Res, 2009. e-Pub 2009.
238. Shanker M, Gopalan B, Scott AW, Miranda D, Jones L, Roth JA, Ramesh R. Proteasome and drug resistance: identification of a novel mechanism for the β5 subunit of the 20S proteasome in regulating cisplatin resistance. Proc Am Assoc Cancer Res, 2009. e-Pub 2009.
239. Meng J, Peng H, Guo W, Wang L, Ji L, Minna J, Chresta CM, Smith PD, Fang B, Roth JA. High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). Proc Am Assoc Cancer Res, 2009. e-Pub 2009.
240. Sobol RE, Nemunaitis J, Clayman G, Roth JA, Olivier M, Hainaut P, Agarwala S, Hrushesky W, Wells JR, Moore C, Hamm J, Yoo G, Baselga J, Murphy BA, Menander KA, Chada S, Licato LL, Gibbons R, Goodwin WJ. Biomarkers predict p53 gene therapy efficacy in recurrent squamous cell carcinoma of the head and neck (SCCHN). Proc Am Assoc Cancer Res, 2009. e-Pub 2009.
241. Gaur R, Correa AM, Huang JL, Hofstetter W, Maru D, Mehran R, Roth JA, Vaporciyan AC, Walsh GL, Swisher SG. Correlation of endoscopic tumor length with lymph node involvement and poor long-term survival in esophageal cancer patients. 2009 Gastrointestinal Cancers Symposium, 2009. e-Pub 2009.
242. Dawood O, Chang JY, Balter P, Komaki R, Roth JA. Complexities of lung stereotactic radiotherapy planning target volumes. J Thorac Oncol 4(9):S491, 2009. e-Pub 2009.
243. Shanker M, Began G, Scott AW, Miranda D, Jones L, Roth JA, Ramesh R. Proteasome and drug resistance: identification of a novel mechanism for the β5 subunit of the 20S proteasome in regulating cisplatin resistance. Proc Am Assoc Cancer Res, 2009. e-Pub 2009.
244. Wu G, Sakai R, Xu K, Hangauer D, Roth J, Ji L. The Src-PI3K-Akt and apoptosis signaling pathway-targeted therapy with novel pro-apoptotic FUS1-nanoparticles and Src kinase inhibitors for lung cancer. Proc Am Assoc Cancer Res, 2009. e-Pub 2009.
245. Sakai R, Jayachandran G, Fang B, Roth J, Ji L. Enhanced sensitivity of tumor cells to the EGFR/VEGFR Inhibitor ZD6474 by FUS1 and FHIT-nanoparticle-mediated gene therapy in human lung cancer. Proc Am Assoc Cancer Res 50, 2009. e-Pub 2009.
246. Lu C, Stewart DJ, Ji L, Ramesh R, Jayachandran G, Erasmus J, Lee JJ, Templeton NS, McMannis JD, Roth JA. A phase I trial of intravenous therapy with tumor suppressor FUS1-nanoparticles for recurrent/metastatic lung cancer. Proc Am Soc Clin Oncol 27:15S, e19065, 2009. e-Pub 2009.
247. Katz RL, He W, Khanna A, Fernandez RL, Caraway NP, H-Z Z, Spitz MR, Blowers DP, Mehran R, Swisher SG, Roth J, Etzel C, El Zein R. Levels of genetically abnormal circulating cells in patients with non small cell lung cancer correlate with stage and genetic phenotype of tumor, recurrence and survival: a FISH based case and control study. IASLC 13th World Conference on Lung Cancer:D8.3, 2009. e-Pub 2009.
248. Blackmon S, Shah N, Correa AM, Benjamin R, Hofstetter W, Lev D, Pollock R, Rice DC, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Mehran R. Complete resection of extra-pulmonary sarcomatous metastases in addition to pulmonary metastasectomy is associated with long-term survival. The Society of Thoracic Surgeons 45th Annual Meeting, 2009. e-Pub 2009.
249. Kim MP, Chen Y, Khanna A, Chen JQ, Bekele BN, Spitz MR, Ji L, Roth JA, Katz RL. AP2β nucleolar localization predicts poor survival after lung cancer resection in stage I patients. J Thorac Oncol:PD7.3.3, 2009. e-Pub 2009.
250. Chen Y, Kim MP, Khanna A, Chen JQ, Fernandez RL, Zaidi TM, Chan B, H-Z Z, Caraway NP, Ji L, Roth J, Katz RL. Colocalization of AP-2β with hTERT suggests AP-2β is a novel tumor marker in NSCLC. J Thorac Oncol:P3.117, 2009. e-Pub 2009.
251. Shanker M, Kumar M, Scott AW, Branch CD, Roth JA, Ramesh R. RNA-Binding Protein is a Novel Target for Cancer Therapy: SiRNA-Mediated One Hit on the Target Produces a Global Inhibitory Effect against Lung Cancer Cells. ASGT, 2009. e-Pub 2009.
252. Began G, Branch CD, Roth JA, Ramesh R. Systematic Examination and Molecular Analysis of DNA-Nanoparticles-Mediated Toxicity Leads to Organ Site Identification and Methods to Overcome Toxicity In Vivo: Translation from Laboratory to the Clinic. ASGT, 2009. e-Pub 2009.
253. Deus HF, Stanislaus R, Behrens C, Wistuba II, Minna JD, Garner HR, Swisher SG, Roth JA, Correa AM, Broom B, Coombes K, Almeida JS. Data driven semantic integration of translational lung cancer research at MD Anderson Cancer Center. AMIA Ann Symp Proc 6:927, 2008. e-Pub 2008.
254. Roth JA, Lu C, Sepulveda CA, Ji L, Ramesh R, O’Connor S, Jayachandran G, Hicks M, Munden R, Bekele BN, Prudkin L, Wistuba II, Minna J, Lee JJ, Templeton N, McMannis JD. Systemic Therapy with Tumor Suppressor FUS1-nanoparticles for Stage IV Lung Cancer. NCI Translates (#513), 2008. e-Pub 2008.
255. Minna JD, Heymach J, Girard L, Xie Y, Peyton M, Lee W, Fang B, Coombes, Byers L, Greer R, Frink R, Sullivan J, Gao B, Weber S, Spinola M, Larsen J, Story M, Nirodi C, Pertsemlidis A, Wang YZ, Lam S, Mills G, Shay J, Schiller J, Kaufman J, Gazdar, A, Roth J, Carbone D, Behrens C, Wistuba I. Molecular Signatures Predicting Response to Therapy in Lung Cancer. NCI Translational Science Meeting, 2008. e-Pub 2008.
256. Stewart DJ, Behrens C, Roth J, Wistuba II. Prognostic/predictive factors (PPFs): Implications of exponential decay nonlinear regression analysis (EDNRA) of patient survival curves (PSCs). Second Annual Meeting on Molecular Markers Highlights in Advances in Personalized Cancer Medicine (ASCO), 2008. e-Pub 2008.
257. Nemunaitis J, Senzer N, Roth JA, Menander KB, Kharkevitch D, Paradiso L, Zumstein LA, Chada S, Sobol RE. Abnormal p53 is associated with efficacy of adenoviral p53 gene therapy in tumors of diverse histologies. Proc Am Assoc Cancer Res, 2008. e-Pub 2008.
258. Yokoyama T, Tam J, Larson T, Scott A, Kondo S, Roth J, Sokolov K, Ramesh R. EGFR-targeted multifunctional nanoparticles induce autophagic cell death and enhance the antitumor effect of Cisplatin and –irradiation in non-small cell lung cancer cells. Proc Am Assoc Cancer Res, 2008. e-Pub 2008.
259. Shivapurkar N, Stastny V, Okumura N, Girard L, Xie Y, Prinsen C, Thunnissen F, Wistuba I, Czerniak B, Frenkel E, Roth J, Liloglou T, Xinarianos G, Field J, Minna J, Gazdar A. Cytoglobin, the newest member of the globin family, functions as a tumor suppressor gene. Proc Am Assoc Cancer Res, 2008. e-Pub 2008.
260. Jayachandran G, Deng W, Roth JA, Ji L. Bystander Effects in FUS1-nanoparticle-mediated human lung cancer gene therapy. Proc Am Assoc Cancer Res, 2008. e-Pub 2008.
261. Shanker M, Kumar M, Garcia A, Scott AW, Bekele NB, Roth JA, Ramesh R. HuR: A mRNA-binding protein as target for cancer therapy. Proc Am Assoc Cancer Res, 2008. e-Pub 2008.
262. Mehran R, Shah N, Correa A, Vaporciyan A, Rice D, Hofstetter W, Walsh G, Benjamin R, Swisher S, Pollock R, Roth J. Pulmonary Metastatectomy In Sarcoma Patients With Extra-Thoracic Metastases. 18th World Congress of the World Society of Cardio-Thoracic Surgeons, 2008. e-Pub 2008.
263. Byers LA, Nanjundan M, Girard L, Coombes KR, Xie Y, Peyton M, Zachariah S, Weber S, Siwak D, Nikolinakos P, Wistuba I, Roth J, Mills G, Minna JD, Heymach JV. Reverse-phase protein array (RPPA) profiling of response to taxanes and epidermal growth factor (EGFR) inhibitors identifies an inverse correlation between markers of sensitivity to docetaxel and erlotinib in non-small cell lung cancer lines. Proc Am Assoc Cancer Res, 2008. e-Pub 2008.
264. Pataer A, Chada S, Roth JA, Hunt KK, Swisher SG. Development of Ad-mda7/IL-24-resistant lung cancer cells lines. Proc Am Assoc Cancer Res, 2008. e-Pub 2008.
265. Roth JA, Chang JY, Komaki R. Stereotactic Radiosurgery (SRS)– An Alternative to Surgery for Small Tumor. AATS/STS, 2008. e-Pub 2008.
266. Kassis ES, Vaporciyan AA, Swisher SG, Correa AM, Bekele N, Erasmus JJ, Hofstetter WL, Komaki R, Mehran RJ, Moran CA, Pisters KM, Rice DC, Walsh GL, Roth JA. Application of the Revised Lung Cancer Staging System (IASLC Staging Project) to a Cancer Center Population. Proc Am Assoc Thorac Surg, 2008. e-Pub 2008.
267. Bolton W, Rice D, Goodyear A, Correa A, Erasmus J, Hofstetter W, Komaki R, Mehran R, Pisters K, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Weaver J, Rhines L. Long-Term Survival with Surgical Management For Superior Sulcus Tumors with Vertebral Resection. Proc Am Assoc Thorac Surg, 2008. e-Pub 2008.
268. Bolton WD, Hofstetter W, Francis A, Correa AM, Ajani JA, Bhutani B, Erasmus J, Komaki R, Maru D, Mehran R, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Swisher SG. Impact of Tumor Length and Submucosal Involvement on the Long-Term Survival of pT1 Early Stage Esophageal Adenocarcinoma. Proc Am Assoc Thorac Surg, 2008. e-Pub 2008.
269. Pataer A, Hu W, Lu X, Chada S, Roth J, Hunt K, Swisher S. Adenoviral ER-targeted mda-7/IL-24 vector enhances cell killing and overcomes MDA-7/IL-24 resistance. Proc Am Assoc Cancer Res, 2008. e-Pub 2008.
270. Deng W, Kawashima H, Roth J, Ji L. Overcoming gefitinib/erlotinib-induced resistance by tumor suppressor fus1-mediated downregulation of met/akt3 signaling pathway in human lung cancer. Proc Am Assoc Cancer Res, 2008. e-Pub 2008.
271. Sobol R, Nemunaitis J, Clayman G, Hamm J Licato L, Chada S, Menander K, Roth J, Goodwin J. Tumor p53 biomarkers personalize selection of adenoviral p53 gene therapy or methotrexate as potentially efficacious treatments in different and complementary groups of recurrent squamous cell carcinoma of the head and neck (SCCHN). Proc Am Assoc Cancer Res, 2008. e-Pub 2008.
272. Deng W, Uno F, Kawashima H, Ueda K, Wu G, Lu C, Ohtani S, Jayachandran G, Coombes K, Wistuba I, Minna JD, Roth JA, Ji L. Molecular Therapeutic Prospects of Novel 3p21.3 Tumor Suppressor Cluster. Proc World Cancer Congress, 2008. e-Pub 2008.
273. Yendamuri S, Vaporciyan AA, Zaidi T, Fernandez R, Rice DC, Walsh GL, Swisher SG, Spitz M, Roth JA, Katz RL. Deletion of chromosome 10q detected by luorescent in situ hybridization (FISH) is a potential new tool for early detection of non small cell lung cancer (NSCLC). 12th World Conference on Lung Cancer 2(8):S357-S357, 2007. e-Pub 2007.
274. Komaki R, Roth JA. Stereotactic Radiation Therapy Workshop Introduction. J Thorac Oncol 2(Suppl 3):S93, 2007. e-Pub 2007.
275. Rice D, Correa A, Hofstetter W, Mehran R, Swisher S, Walsh G, Vaporciyan A, Roth J. Recent Survival Trends for Clinically Staged Stage I Lung Cancer. The Society of Thoracic Surgeons 43rd Annual Meeting, 2007. e-Pub 2007.
276. Blackmon SH, Rice DC, Correa AM, Hofstetter W, Swisher SG, Mehran R, Vaporciyan AA, Walsh GL, Roth JA. Does A Gastrostomy Tube Versus Jejunostomy Tube Prior To Esophagectomy For Primary Esophageal Cancer Patients Have Additional Risk?. Society of Thoracic Surgeons 43rd Annual Meeting, 2007. e-Pub 2007.
277. Sepulveda CA, Roth JA, Lu C, Ji L, Ramesh R, O’Connor S, Sadeghi T, Flagge F, Baez O, Shen AC, Mondesir E, Jenkins J, Shpall E, Champlin RE, McMannis JD. Establishing a GMP manufacturing site for nanoparticles. 10th Annual NSTI Nanotechnology 2007, Santa Clara, CA. Technical Proceedings 2:413-6, 2007. e-Pub 2007.
278. Chang JY, Balter P, Liao Z, Bucci KM, McAleer MF, Yang Q, Dong L, Roth JA, Cox JD, Komaki R. Hypofractionated stereotactic body radiotherapy in patients with peripherally or centrally located medically inoperable stage I or isolated recurrent non-small cell lung cancer. J Thorac Oncol 2(8, Supplemental 4):S477, 2007. e-Pub 2007.
279. Yendamuri S, Walsh G, Vaporciyan A, Hofstetter W, Rice DC, Mehran RJ, Roth JA. Comparison of limited surgery and 3D conformal radiation in high risk patients with stage IA non small cell lung cancer: A propensity score matched analysis. J Thorac Oncol 2(8):S388, 2007. e-Pub 2007.
280. Menander K, Licato LL, Sobol RE, Zumstein LA, French M, Bocangel D, Ball G, Clayman G, Roth JA, Chada S. Identification of a predictive molecular biomarker of p53 therapy (Advexin; adenoviral p53) in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN). Proc Am Assoc Cancer Res, 2007. e-Pub 2007.
281. Jayachandran G, Roth JA, Li J. Identification of RasGTPase activating protein as a potential cellular target of the novel tumor suppressor FUS1 in lung cancer by tandem affinity purification and mass spectrometry. Proc Am Assoc Cancer Res, 2007. e-Pub 2007.
282. Pataer A, Chada S, Roth JA, Hunt KK, Swisher SG. Geldanamycin and its 17-Allyl-amino-a7-demethoxy analogue overcome Ad-mda7 resistance in lung cancer. Proc Am Assoc Cancer Res, 2007. e-Pub 2007.
283. Iwamaru A, Deng W, Kawashima H, Roth JA, Li J. Interaction of tumor suppressor FUS1 with nuclear receptor tyrosine kinase RAR-α proteins enhances the sensitivity of non-small cell lung cancer (NSCLC) to retinoid-mediated therapy. Proc Am Assoc Cancer Res, 2007. e-Pub 2007.
284. Deng W, Uno F, Wu G, Kawashima H, Roth JA, Ji L. Nanoparticle-mediated delivery of therapeutic peptide derived from novel tumor suppressor FUS1 protein for human lung cancer treatment. Proc Am Assoc Cancer Res, 2007. e-Pub 2007.
285. Yamamoto H, Nomura M, Shigematsu H, Majmudar K, Liu H, Suzuki M, Wistuba II, Toyooka S, Date H, Fujisawa T, Roth JA, Minna JD, Gazdar AF. Function of PIK3CA mutations and gene copy number in human lung cancers. Proc Am Assoc Cancer Res, 2007. e-Pub 2007.
286. Prudkin L, Liu DD, Massarelli E, Ozburn N, Brown KC, Tsao AS, Minna JD, Bekele B, Roth JA, Moran C, Wistuba II. Epithelial mesenchymal transition phenotype correlates with lung cancer histology and EGFR abnormalities in non-small cell lung carcinoma. Proc Am Assoc Cancer Res, 2007. e-Pub 2007.
287. Byers LA, Nanjundan M, Girard L, Coombes KR, Xie Y, Peyton M, Zachariah S, Weber S, Siwak D, Nikolinakos P, Wistuba I, Roth J, Mills G, Minna JD, Heymach JV. Reverse-phase protein array (RPPA) profiling of response to taxanes and epidermal growth factor (EGFR) inhibitors identifies an inverse correlation between markers of sensitivity to docetaxel and erlotinib in non-small cell lung cancer lines. AACR-NCI-EORTC Molecular Targets and Therapeutics, 2007. e-Pub 2007.
288. Lu C, Sepulveda CA, Ji L, Ramesh R, O’Connor S, Jayachandran G, Hicks ME, Munden RF, Lee JJ, Templeton NS, McMannis JD, Roth JA. Systemic therapy with tumor suppressor FUS1-nanoparticles for stage IV lung cancer. Proc Am Assoc Cancer Res, 2007. e-Pub 2007.
289. Yendamuri S, Vaporciyan AA, Zaidi T, Fernandez R, Rice DC, Spitz M, Swisher S, Walsh GL, Roth JA, Katz RL. 3p and 10q deletions detected by fluorescence in situ hybridization (FISH): A potential new tool for early detection of non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 25:18S, 2007. e-Pub 2007.
290. Ramesh R, Lu C, Sepulveda CA, Ji L, O’Connor S, Jayachandran G, Hicks M, Munden R, Bekele N, Prudkin L, Wistuba II, Minna J, Lee JJ, Tempelton N, McMannis JD, Roth JA. Nanoparticle-based systemic gene delivery for lung cancer: translation from the laboratory to the clinic. 15th International Conference on Gene Therapy of Cancer, 2007. e-Pub 2007.
291. Deng W, Kawashima H, Iwamaru A, Wu G, Minna JD, Roth JA, Ji L. Apoptosis and EGFR signaling pathway-targeted molecular therapy with FUS1-nanoparticles and EGFR inhibitors for non-small cell lung cancer. Proc Cancer Gene Ther, 2007. e-Pub 2007.
292. Roth JA. Targeting the lung cancer genome. Int J Molecular Medicine S5(101), 2007. e-Pub 2007.
293. Ohtani S, Ueda K, Jayachandran G, Xu K, Minna JD, Roth JA, Ji L. Synergistic and selective inhibition of NSCLC cell growth via a caspase-independent cell death pathway by tumor suppressor 101F6 nanoparticles plus vitamin C in vitro and in vivo. Proc Am Assoc Cancer Res 24(18S), 2006. e-Pub 2006.
294. Tanaka F, Ogawa E, Wada H, Shanker M, Garcia-Soto AE, Branch CD, Wistuba I, Roth JA, Ramesh R. Clinical significance of HuR expression, an mRNA-binding protein in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 24(18S), 2006. e-Pub 2006.
295. Bakaeen F, Chu D, Correa AM, Rice D, McAllister R, Vaporciyan AA, Walsh G, Putnam JB, Swisher SG, Roth JA, Huh J, Smythe, WR. The Use of Aprotinin in Extrapleural Pneumonectomy: Effect on Hemostasis And Blood Product Utilization. Association of VA Surgeons Meeting, 2006. e-Pub 2006.
296. Herrera LJ, Correa AM, Vaporciyan AA, Hofstetter WL, Rice DC, Swisher SG, Walsh GL, Roth JA, Mehran RJ. Increased Risk of Aspiration and Pulmonary Complications after Lung Resection in Head and Neck Cancer Patients. STS 42nd Annual Meeting:214, 2006. e-Pub 2006.
297. Chang JY, Balter P, Liao Z, Jeter MD, Guerero T, Borghero Y, Tutt TE, Roth JA, Cox JD, Komaki R. Preliminary report of image-guided hypofractionated stereotactic body radiotherapy to treat patients with medically inoperable stage I or isolated peripheral lung recurrent non-small cell lung cancer. Int J Radiat Oncol Biol Phys 66:S480, 2006. e-Pub 2006.
298. Kawashima H, Jayachandran G, Deng W, Xu K, Minna JD, Roth JA, Ji L. Overcoming gefitnib resistance in NSCLC via inactivation of the P13K/AKT signaling pathway by a combination of FUS1 nanoparticles and EGFR inhibitors. Proc Am Assoc Cancer Res 47:5426, 2006. e-Pub 2006.
299. Gu J, Spitz MR, Roth JA, Wu X. Aberrant promoter methylation profile associated with survival in patients with non-small cell lung cancer. Proc Am Assoc Cancer Res 47:28, 2006. e-Pub 2006.
300. Pataer A, Holzen UV, Bocangel D, Chada S, Roth JA, Hunt KK, Swisher SG. RNA-dependent protein kinase (PKR) indirectly regulates AKT in human lung cancer cells. Proc Am Assoc Cancer Res 47:712, 2006. e-Pub 2006.
301. Wu G, Deng W, Jayachandran G, Minna JD, Roth JA, Ji L. Interaction of the tumor suppressor FUS1 with PDGFRβ inhibits PDGFR-mediated proliferation of human lung cancer cells. Proc Am Assoc Cancer Res 47:1460, 2006. e-Pub 2006.
302. Ueda K, Ohtani S, Minna JD, Roth JA, Ji L. Activation of tumor suppressor NPRL2 facilitates cisplatin-mediated cell cycle arrest and apoptosis in DNA-damage checkpoint pathways in lung cancer. Proc Am Assoc Cancer Res 47:2340, 2006. e-Pub 2006.
303. Deng W, Jayachandran G, Xu K, Roth JA, Ji L. Tumor-specific activation of hTERT promoter activity by the AP-2β transcription factor in human lung cancer cells. Proc Am Assoc Cancer Res 47:3948, 2006. e-Pub 2006.
304. Massarelli E, Zhou X, Ozburn NC, Wislez M, Bekele BN, Roth JA, O’Reilly M, Hong WK, Kurie JM, Herbst RS, Wistuba II. TGF-α and phosphorylated EGFR protein levels impact the survival of patients with stage I-IIIA non small cell lung cancer. Proc Am Assoc Cancer Res 47:5729, 2006. e-Pub 2006.
305. Licato LL, Menander K, Sobol RE, Zumstein LA, French M, Bocangel D, Roth JA, Chada S. Abnormal overexpression of p53 is a predictive molecular biomarker of Advexin (adenoviral p53) efficacy in recurrent squamous cell carcinoma of the head and neck (SCCHN). Proc Am Assoc Cancer Res 47, 2006. e-Pub 2006.
306. Hofstetter W, Correa AM, Ajani JA, Phan A, Komaki R, Liao Z, Wu TT, Blackmon S, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Swisher SG. Proposed Modifications of Nodal Status in AJCC Esophageal Cancer Staging System. 53rd Annual Meeting Southern Thoracic Surgeon’s Association, 2006. e-Pub 2006.
307. Rice DC, Stevens C, Forster K, Vaporciyan AA, Walsh GL, Swisher SG, Hofstetter W, Mehran RJ, Roth JA, Liao Z, Smythe WR. Survival and recurrence patterns following extrapleural pneumonectomy and intensity modulated radiation therapy for malignant pleural mesothelioma. Southern Thoracic Surgical Association 53rd Annual Meeting, 2006. e-Pub 2006.
308. Blackmon SH, Martin LW, Correa AM, Wynn B, Hofstetter W, Mehran R, Rice D, Swisher S, Walsh GL, Roth JA, Vaporciyan AA. Propensity matched analysis of three techniques for intrathoracic esophagogastric anastomosis. Southern Thoracic Surgical Association 53rd Annual Meeting, 2006. e-Pub 2006.
309. Wu X, Stewart DJ, Gu J, Lin J, Lu C, Dong Q, Roth JA, Hong WK, Spitz MR. Genetic variations in Platinum action pathways modulate Therapeutic response in non-small cell lung cancer. 14th SPORE Workshop, 2006. e-Pub 2006.
310. Kawashima H, Uno F, Kurie J, Minna JD, Roth JA, Ji L. Synergistic inhibition of EGFR tyrosine kinase activity and NSCLC cell growth by combination treatment with FUS1-nanoparticle and gefitinib. Proc Am Assoc Cancer Res 23(16S), 2005. e-Pub 2005.
311. Martin LW, Swisher SG, Hofstetter W, Correa AM, Rice DC, Vaporciyan AA, Walsh GL, Roth JA. Outcomes for resected stage IIIA non-small cell lung cancer over 15 years at a single institution. Proc Am Assoc Cancer Res:72, 2005. e-Pub 2005.
312. Ascioti AA, Hofstetter, WL, Miller MJ, Rice DC, Swisher SG, Vaporciyan AA, Roth JA, Jr PJ, Smythe WR, Walsh GL. Long segment supercharged predicled jejunal flap for total esophageal reconstruction. Proc Am Assoc Thorac Surg:98, 2005. e-Pub 2005.
313. Malaisrie SC, Hofstetter WL, Correa AM, Ajani JA, Komaki RR, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Lahoti S, Lee JH, Bresalier R, Roth JA, Swisher SG. Endoscopic ultrasonography-identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinoma. STS 2005, 2005. e-Pub 2005.
314. Malaisrie SC, Correa AM, Ajani JA, Komaki RR, Hofstetter WL, Rice DC, Vaporciyan AA, Walsh GL, Lahoti S, Lee JH, Bresalier R, Roth JA, Swisher SG. EUS-identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in patients with adenocarcinoma of the distal esophagus. Proc Am Assoc Thorac Surg:102, 2005. e-Pub 2005.
315. Roth JA. Therapeutic gene transfer for lung cancer. Proc Am Assoc Cancer Res, 2005. e-Pub 2005.
316. Ueda K, Kawashima H, Deng W, Minna JD, Roth JA, Ji L. Inactivation of the potential 3p21.3 tumor suppressor NPRL2 significantly correlates with the cisplatin-induced resistance in human NSCLC cells. Proc Am Assoc Cancer Res 46, 2005. e-Pub 2005.
317. Lin J, Sun T, Ji L, Roth J, Minna J, Arlinghaus RB. Activated c-Abl in FUS1 haplo insufficient non-small cell lung carcinoma. Proc Am Assoc Cancer Res:46, 2005. e-Pub 2005.
318. Roth JA. Therapeutic gene transfer for lung cancer. Proc Am Assoc Cancer Res, 2005. e-Pub 2005.
319. Wu G, Uno F, Arlinghaus R, Kundra V, Minna JD, Roth JA, Ji L. Inactivation of c-Abl and c-Kit activities and inhibition of SCLC cell growth by a combination treatment with FUS1-nanop article and Gleevec in vitro and in vivo. Proc Am Assoc Cancer Res 46, 2005. e-Pub 2005.
320. Deng W, Uno F, Minna JD, Roth JA, Ji L. Synergistic tumor suppression by coexpression of FUS1 and p53 concurrences with FUS1-mediated down regulation of MDM2, accumulation of p53 and activation of Apaf-1-dependent apoptotic pathway in human NSCLC cells. Proc Am Assoc Cancer Res 46, 2005. e-Pub 2005.
321. Wu G, Deng W, Kundra V, Fang B, Roth JA, Ji L. A novel synthetic hTERT-Mini-CMV chimera promoter-driven tumor-selective and high-efficiency expression of transgene for systemic gene therapy. Proc Am Assoc Cancer Res 46, 2005. e-Pub 2005.
322. Gopalan B, Branch CD, Stephens CL, Roth JA, Ramesh R. A novel strategy for suppressing toxicity-mediated by systemic deliver of DNA-nanoparticles. Proc Am Assoc Cancer Res 46, 2005. e-Pub 2005.
323. Malaisrie SC, Hofstetter WL, Correa AM, Ajani JA, Komaki RR, Rice DC, Vaporciyan AA, Walsh GL, Roth JA, Swisher SG. The Addition of Induction Chemotherapy to Preoperative Concurrent Chemoradiotherapy Improves Tumor Response in Patients with Esophageal Adenocarcinoma. Western Thoracic Surgical Association, 2005. e-Pub 2005.
324. von Holzen UW, Pataer A, Bocangel D, Lu X, Barber GN, Roth JA, Hunt KK, Swisher SG. Role for double-stranded RNA activated kinase PKR in Ad-TNFalpha gene therapy. Proc Soc Univ Surg, 2005. e-Pub 2005.
325. Pataer A, Bocangel D, Chada S, Roth JA, Hunt KK, Swisher SG. Enhancement of Adenoviral mda-7 mediated cell killing in human lung cancer cells by geldanamycin and its 17-allylamino-17-demethoxy analogue. Proc Am Assoc Cancer Res 46, 2005. e-Pub 2005.
326. Rohatgi P, Swisher S, Correa A, Wu TT, Liao X, Komaki R, Walsh G, Vaporciyan A, Rice DC, Roth JA, Ajani JA. Degree of pathologic response after preoperative chemoradiotherapy correlates with failure patterns and outcome of patients with carcinoma of the esophagus. Proc Am Assoc Cancer Res 46, 2005. e-Pub 2005.
327. Tang X, Shigematsu H, Roth JA, Minna JD, Hong WK, Gazdar AF, Wistuba II. EGFT tyrosine kinase domain mutations are also found in histologically normal lung epithelium of patients containing lung adenocarcinomas with EGFR mutations indicating a field effect. Proc Am Assoc Cancer 46, 2005. e-Pub 2005.
328. Martin LW, Swisher SG, Hofstetter W, Correa AM, Rice DC, Vaporciyan AA, Walsh GL, Roth JA. Intrathoracic leaks following esophagectomy are no longer associated with increased mortality. American Surgical Assoc 64, 2005. e-Pub 2005.
329. Ji L, Kawashima H, Lu C, Kurie J, Chada S, Minna JD, Roth JA. Synergistic inhibition of EGFR tyrosine kinase and tumor cell growth in non-small cell lung cancer (NSCLC) by combination treatment with FUS1-nanoparticles and gefitnib. J Clin Oncol 23:640S, 2005. e-Pub 2005.
330. Wu TT, Chireac LR, Swisher SG, Komaki R, Correa AM, Roth J, Rashid A, Hamilton SR, Ajani JA. Post-chemoradiation surgical pathologic stage accurately predicts outcome of patients with esophageal or gastroesophageal junction carcinoma. Proc Am Soc Clin Oncol 22(14S), 2004. e-Pub 2004.
331. Liao Z, Liu H, Swisher SG, Wang L, Wu TT, Correa AM, Roth J, Cox JD, Komaki R, Ajani JA, Wei Q. Polymorphisms of Thymidylate Synthase Gene Predict Local Or Distant Recurrence After Preoperative Chemoradiation In Esophageal Cancer. Proc Semin Oncol, 2004. e-Pub 2004.
332. Swisher SG, Maish M, Erasmus J, Correa AM, Rice D, Putnam JB, Smythe WR, Walsh G, Vaporciyan A, Roth J. Utility of PET, CT, and EUS to Identify Pathologic Responders In Esophageal Cancer. Proc Soc Thorac Surg:170-171, 2004. e-Pub 2004.
333. Gopalan B, Litwak A, Sharma S, Mhashilkar AM, Roth JA, Chada S, Ramesh R. MDA-7/IL-24 mediated killing of human ovarian cancer cells involves the Fas/FasL signaling pathway. Proc Am Assoc Cancer Res 45:1196, 2004. e-Pub 2004.
334. Ji L, Jayachandran G, Sazaki J, Xu K, Girard L, Minna JD, Roth JA. Fhit-mediated tumor suppression by targeting multiple key cellular components in Ras/Rho GTPase molecular switches in lung cancer. Proc Am Assoc Cancer Res 45, 2004. e-Pub 2004.
335. Miyahara R, Banerjee S, Mhashilkar AM, Roth JA, Chada S, Ramesh R. Involvement of PERK in human MDA-7/IL-24 mediated inhibition of murine tumor cell growth. Proc Am Assoc Cancer Res 45, 2004. e-Pub 2004.
336. Oida Y, Gopalan B, Inoue S, Miyahara R, Mhashilkar AM, Bekele BN, Roth JA, Chada S, Ramesh R. Mda-7/IL-24 in combination with sulindac induces a synergistic therapeutic effect in human lung cancer cells. Proc Am Assoc Cancer Res 45, 2004. e-Pub 2004.
337. Saito Y, Swanson X, Gopalan B, Branch CD, Roth JA, Zumstein L, Ramesh, R. Combined treatment with adenovirus-mediated PTEN and caffeine produces synergistic effect in colorectal cancer cells. Proc Am Assoc Cancer Res 45, 2004. e-Pub 2004.
338. Sasaki J, Uno F, Minna JD, Roth JA, Ji L. Enhanced sensitivity of tumor cells to chemotherapeutic agents by activation of fus1 tumor suppressor gene in lung cancer cells. Proc Am Assoc Cancer Res 45, 2004. e-Pub 2004.
339. Uno F, Sasaki J, Jayachandran G, Xu K, Minna JD, Roth JA, Ji L. Activation of apoptotic signaling pathway by direct interaction between tumor suppressor Fus1 snf Apaf-1 proteins in lung cancer cells. Proc Am Assoc Cancer Res 45, 2004. e-Pub 2004.
340. Uno F, Sasaki J, Jayachandran G, Deng W, Wu G, Xu K, Minna JD, Roth JA, Ji L. 3p21.3 tumor suppressor FUS1 as a key apoptotic mediator and therapeutic agent for lung cancer. Proc Am Assoc Cancer Res:45, 2004. e-Pub 2004.
341. Pataer A, Vorgurger SA, Balachandran S, Barber GN, Chada S, Roth JA, Hunt KK, Swisher SG. Melanoma differentiation associated gene-7 protein physically associates with the double-stranded RNA activated protein kinase PKR in vitro. Proc Am Assoc Cancer Res 45, 2004. e-Pub 2004.
342. Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Roth J, Rashid A, Hamilton SR, Wu TT. Residual Tumor Status Predicts the Survival Of Patients with Treated Esophageal Carcinoma. Mod Pathol 17(1):112A, 2004. e-Pub 2004.
343. Vaporciyan AA, Lee H, Cox J, Swisher SG, Komaki R, Smythe WR, Walsh GL, Rice DC, Roth JA, Putnam JB, Jr. The impact of chemoradiotherapy on pulmonary morbidity after esophagectomy. Proc Am Assoc Thorac Surg, 2004. e-Pub 2004.
344. Swisher SG, Ajani JA, Chirieac L, Vaporciyan AA, Wu TT, Hunt KK, Correa AM, Komaki R, Rice DC, Walsh GL, Roth JA. Impact of pathologic response on pTNM esophageal cancer staging system following preoperative chemoradiation (CRT). Proc South Surg Assoc:55, 2004. e-Pub 2004.
345. Swisher SG, Erasmus J, Maish M, Correa AM, Ajani J, Cox J, Komaki R, Lee HK, Macapinlac H, Putnam JB, Rice D, Smythe WR, Vaporciyan A, Walsh G, Hong D, Wu TT, Pollock R, Roth J. PET predicts pathologic response and long-term survival following preoperative chemoradiation in esophageal cancer. Proc Am Soc Clin Oncol - GI Symposium, 2004. e-Pub 2004.
346. Ramesh R, Ito I, Miyahara R, Saito Y, Wu Z, Mhashilkar AM, Wilson DR, Branch CD, Chada S, Roth JA. Local and systemic inhibition of lung tumor growth after liposome mediated mda-7/IL-24 gene delivery. Mol Ther 9:190, 2004. e-Pub 2004.
347. Pataer A, Chada S, Hunt KK, Roth JA, Swisher SG. Adenoviral mda-7 induces apoptosis in p53 resistant lung cancer cells through PKR induction. Society of University Surgeons, 2004. e-Pub 2004.
348. Komaki R, Putnam JB, Roth JA, Allen P, Swisher S, Walsh G, Kies M, Fossella FV, Hong WK, Herbst R, Oh YW, Liao Z, Vaporciyan A, Rice D, Smythe R, Munden R, Cox JD. Does surgery and preoperative treatments improve the outcome of patients with locally advanced superior sulcus tumor?. Proc Amer Radium Soc, 2004. e-Pub 2004.
349. Gopalan B, Ji L, Ito I, Saito Y, Branch CD, Xu K, Stephens C, Minna JD, Roth JA, Ramesh R. Protection of mice from liposome-DNA complex induced toxicity by anti-inflammatory drugs. Annual Trainee Recognition Day, M. D. Anderson Cancer Center, 2003. e-Pub 2003.
350. Swisher SG, Ajani JA, Komaki RR, Nesbitt JC, Cox J, Lahoti S, Martin F, Jr PJ, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA. Final results of phase II trial evaluating chemotherapy, concurrent chemoradiation and surgery in locoregionally advanced esophageal cancer. American College of Surgeons South Texas Chapter Annual Meeting, 2003. e-Pub 2003.
351. Mhashilkar A, Ekmekcioglu S, Stewart A, Mumm J, Sieger K, Sutton B, Roth J, Ramesh R, Grimm E, Chada S. The mda-7 gene encodes both tumor suppressor and Th1 cytokine (IL-24) activities- prospects for systemic therapy. Mol Ther 7:S269, 2003. e-Pub 2003.
352. Mhashilkar AM, Stewart A, Sieger K, Yang HY, Ito I, Saito Y, Grimm EA, Roth JA, Ramesh R, Chada S. MDA-7 negatively regulates the beta-catenin and p13k signaling pathways in breast and lung tumor cells. J Intl Soc Cancer Gene Therapy 10:S6, 2003. e-Pub 2003.
353. Mhashilkar AM, Stewart AL, Sieger K, Yang H, Hunt KK, Roth JA, Ramesh R, Chada S. MDA-7 coordinately regulates the beta-catenin and p13k signaling pathways in breast and lung tumor cells to promote apoptosis and increase homotypic adhesion. Mol Ther 7:S17, 2003. e-Pub 2003.
354. Oida Y, Gopalan B, Banerjee S, Miyahara R, Mhashilkar AM, Chiao P, Roth JA, Chada S, Ramesh R. Suppression of adenovirus-mediated mda-7/IL-24 activation of NFκβ induces a synergistic therapeutic effect in human lung cancer cells. Mol Ther 7:S8, 2003. e-Pub 2003.
355. Ramesh R, Mhashilkar AM, Tanaka F, Saito Y, Branch CD, Sieger K, Mumm JB, Stewart AL, Boquio A, Dumoutier L, Grimm EA, J-C R, Kotenko S, Roth JA, Chada S. MDA-7/IL-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. J Intl Soc Cancer Gene Therapy 10:S3, 2003. e-Pub 2003.
356. Roth JA, Minna JD, Ji LX, Ramesh R. New gene targets for cancer therapy. Cancer Gene Therapy 10:S1, 2003. e-Pub 2003.
357. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, Roth J, Putnam JB, Moran C, Cox JD. SUV by FDG-PET predicts outcome of non-small cell lung cancer. Int J Rad Oncology Biol Phys 57:S166, 2003. e-Pub 2003.
358. Minna J, White M, Shivakumar L, Gao B, Burbee D, Zochbauer-Muller S, Fong K, Tooyoka S, Maruyama R, Harada K, Rathi A, Kuzmin I, Linhehan W, Lerman M, Agathanggelou A, Latif F, Roth J, Tomizawa Y, Yokota J, Gazdar A. The 3p21.3 tumor suppressor gene RASSF1A epigenetically inactivated in many tumor types controls G1/S cell cycle progression via regulation of cyclin D1 levels. Cancer Genetics & Tumor Suppressor Genes:313, 2003. e-Pub 2003.
359. Carboni GL, Shao J, Xu K, Gao B, Nishizaki M, Schmid RA, Minna JD, Roth JA, Ji L. Synergistic inhibition of tumor cell growth by CACNA2D2 and p53 via activation of DAPK pathway in lung cancer. Proc Am Assoc Cancer Res 44:241-242, 2003. e-Pub 2003.
360. Gopalan B, Ji L, Ito I, Saito Y, Branch CD, Xu K, Stephens C, Minna JD, Roth JA, Ramesh R. The anti-inflammatory drug naproxen protects mice from lipoplex-mediated toxicity. Proc Am Assoc Cancer Res 44:1064, 2003. e-Pub 2003.
361. Gopalan B, Saito Y, Sharma S, Branch CD, Mhashilkar AM, Roth JA, Chada S, Ramesh R. Gene therapeutic approach for treatment of human ovarian cancer using mda-7/il-24 gene. Proc Am Assoc Cancer Res 44:382-383, 2003. e-Pub 2003.
362. Ji L, Xu K, Nishizaki M, Sasaki J, Futoshi U, Girard L, Garner H, Minna JD, Roth JA. Discovery of specific cellular regulatory pathway mediated by the tumor suppressor gene FHIT in NSCLC cells by gene and protein expression profiling. Proc Am Assoc Cancer Res 44:281, 2003. e-Pub 2003.
363. Mhashilkar AM, Stewart A, Sieger K, H-Y Y, Grimm EA, Roth JA, Ramesh R, Chada S. MDA-7 negatively regulates the beta-catenin and P13K signaling pathways in breast and lung tumor cells. Proc Am Assoc Cancer Res 44:463, 2003. e-Pub 2003.
364. Nishizaki M, Sasaki J, Carboni G, Roth JA, Ji L. Overexpression of FHIT inhibits tumor cell invasion and metastases via inactivation of the Rho-PKC-Ezrin signaling pathway in human pancreatic cancer. Proc Am Assoc Cancer Res 44:1354, 2003. e-Pub 2003.
365. Ohtani S, Kagawa S, Tango Y, Umeoka T, Tokunaga N, Tsunemitsu Y, Roth JA, Tanaka N, Fujiwara T. Quantitative analysis of p53-targeted gene expression and visualization of p53 transcriptional activity following intratumoral administration of adenoviral p53 in vivo. Proc Am Assoc Cancer Res 44:1086, 2003. e-Pub 2003.
366. Ramesh R, Mhashilkar AM, Tanaka F, Saito Y, Branch CD, Sieger K, Mumm JB, Stewart A, Boquio A, Dumoutier L, Grimm EA, J-C R, Kotenko S, Roth JA, Chada S. MDA-7/IL-24 is a novel ligand that regulates angiogensis via the IL-22 receptor. Proc Am Assoc Cancer Res 44:1106, 2003. e-Pub 2003.
367. Saito Y, Mhashilkar AM, Roth JA, Chada S, Ramesh R. Selective induction of cell cycle arrest and apoptosis in human prostate cancer cells through adenoviral transfer of the melanoma differentiation associated-7(mda-7) gene. Proc Am Assoc Cancer Res 44:247, 2003. e-Pub 2003.
368. Tsunemitsu Y, Kagawa S, Tokunaga N, Otani S, Umeoka T, Fujiwara T, Tanaka N, Fang B, Roth JA. Antitumor effect of adenovirus-mediated Bax gene transfer on human gastric cells. Proc Am Assoc Cancer Res 44:1261, 2003. e-Pub 2003.
369. Uno F, Sasaki J, Nishizaki M, Carboni G, Xu K, Minna JD, Roth JA, Ji L. Myristoylation of Fus1 protein is required for Fus1-mediated tumor-suppressing activities in lung cancer. Proc Am Assoc Cancer Res 44:90-91, 2003. e-Pub 2003.
370. Vaporciyan AA, Correa AM, Rice DC, Roth JA, Smythe WR, Swisher SG, Walsh GL, Jr PJ. Identification of risk factors associated with atrial fibrillation after thoracic surgery: prospective analysis of 2,335 patients. Proc Am Assoc Thorac Surg 22:78, 2003. e-Pub 2003.
371. Swisher SG, Roth JA. Gene therapy for lung cancer. 2nd Kyoto Lung Cancer Forum, 2003. e-Pub 2003.
372. Gopalan B, Ji L, Ito I, Saito Y, Branch C, Xu K, Stephens C, Minna JD, Roth JA, Ramesh R. The anti-inflammatory drug naproxen protects mice from lipoplex-mediated toxicity. National Cancer Institute, Winter Lung Cancer SPORE, 2003. e-Pub 2003.
373. Swisher SG, Ajani J, Komaki R, Putnam J, Walsh G, Liao Z, Yao J, Faust J, Wu TT, Roth J, Study Group MER. CPT-11-Taxotere-5-FU regimen for induction; and concurrent chemoradiotherapy prior to surgery in patients with resectable esophageal or GEJ carcinoma. Proc Am Soc Clin Oncol 22:272, 2003. e-Pub 2003.
374. Agarwal B, Swisher S, Kelly K, Ajani J, Komaki R, Molke K, Lehman J, Walsh G, Correa A, Ho LN, Liao ZX, Lynch P, Rice D, Smythe R, Steven C, Vaporciyan AA, Yao J, Roth J. Pre-operative chemoradiation downstages esophageal adenocarcinoma and abolishes differences in post-operative survival between T3N0 and T3N1 esophageal cancers. Gastroenterology 124:A652, 2003. e-Pub 2003.
375. Ji L, Sasaki J, Nishizaki M, Uno F, Carboni G, Xu K, Minna JD, Roth JA. Myristoylation of FUS1 protein plays an important role in FUS1-mediated tumor suppression activities in human lung cancer cells. Cold Springs Harbor Laboratory Conference on Cancer Genetics and Tumor Suppressor Genes:103, 2003. e-Pub 2003.
376. Rice DC, Swisher SG, Correa AM, Ajani JA, Putnam JB, Smythe WR, Walsh GL, Vaporciyan AA, Roth JA. Induction chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. Ann Thor Surg:266-267, 2003. e-Pub 2003.
377. Jr PJ, Correa A, Swisher SG, Smythe WR, Rice DC, Roth JA, Vaporciyan AA, Walsh GL. A model for prospective quality improvement in thoracic surgical oncology. Texas Surg Soc, 2003. e-Pub 2003.
378. Lee HK, Vaporciyan AA, Cox JD, Putnam JB, Ajani JA, Liao Z, Swisher SG, Roth JA, Smythe RW, Walsh GL, Mohan R, Komaki R. Postoperative pulmonary complications following preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram. ASTRO 2002 Annual Meeting 54:132-133, 2002. e-Pub 2002.
379. Taylor NA, Liao Z, Stevens C, Walsh G, Roth J, Jr PJ, Fossella F, Cox JD, Komaki R. Postoperative radiotherapy increases local regional control of patients with stage IIIA non-small cell lung cancer treated with induction chemotherapy followed by surgery. Proc of the Eighty-fourth Annual Meeting of the American Radium Society, 2002. e-Pub 2002.
380. Agarwal B, Swisher S, Kelly K, Ajani J, Komaki RU, Putnam JB, Molke KL, Lehman J, Bismar MM, Walsh GL, Correa AM, Ho L, Liao Z, Lynch P, Rice DC, Smythe WR, Steven CW, Vaporciyan AA, Yao J, Roth JA. Determinants of response to chemoradiation in patients with esophageal cancer. Proc Am Gastroenterol Assoc 122:A351, 2002. e-Pub 2002.
381. Lazo G, Yao JC, Najam AA, Swisher SG, Putnam JB, Roth JA, Mansfield PF, Pisters PW, Ajani JA. Clinical risk factors for peritoneal metastases in esophagogastric junction carcinoma (GEJC). Proc Am Soc Clin Oncol 21:141a, 2002. e-Pub 2002.
382. Pataer A, Chada S, Hunt KK, Roth JA, Swisher SG. Adenoviral MDA-7 induces apoptosis in lung cancer cells through mitochondrial permeability transition independent cytochrome C release. Proc Am Assoc Thor Surg 82:40, 2002. e-Pub 2002.
383. Chada S, Mhashilkar A, Mumm J, Caudel E, Ekmekcioglu S, Sieger K, Stewart A, Sutton B, Roth JA, Ramesh R, Grimm EA. The mda-7 tumor suppressor is a novel cytokine (IL-24) in the IL-10 family. Molecular Therapy 5:S22, 2002. e-Pub 2002.
384. Huang X, Lin T, Gu J, Zhang L, Roth JA, Yu Y, Liu J, Fang B. Combined therapy of the TRAIL and BAX genes prolonged survival of animals with ovarian cancer xenograft. Molecular Therapy 5:S263, 2002. e-Pub 2002.
385. Tanaka F, Ito I, Branch CD, Roth JA, Ramesh R. Enhancement of liposome-mediated transgene expression using butyric acid. Molecular Therapy 5:S78, 2002. e-Pub 2002.
386. Yang H, Mhashilkar A, Stewart A, Ekmekcioglu S, Saito Y, Seiger K, Schrock R, Onishi E, Swanson X, Zumstein L, Snary D, Roth JA, Ramesh R, Grimm EA, Chada S. Ad-PTEN: a novel anti-melanoma agent in vitro. Molecular Therapy 5:S265, 2002. e-Pub 2002.
387. Agarwal B, Swisher S, Ajani, J, Kelly K, Fanning C, Komaki RR, Putnam JB, Abu-Hamda I, Molke KL, Walsh GL, Correa AM, Ho L, Liao ZX, Lynch PM, Rice DC, Smythe WR, Stevens CW, Vaporciyan AA, Yao J, Roth JA. Persistent malignant lymphadenopathy after preoperative chemoradiation identifies patients with poor postoperative survival. Gastroinest Endosc 56:S110, 2002. e-Pub 2002.
388. Carboni GL, Gao B, Nishizaki M, Minna JD, Roth JA, Ji L. Induction of apoptosis by CACBA2D2 overexpression via regulation of the intracellular calcium signaling and interruption of the mitochondrial membrane integrity in NSCLC cells. Proc Am Assoc Cancer Res 43:618-619, 2002. e-Pub 2002.
389. Gomyo Y, Sasaki J, Nishizaki M, Roth JA, Mukhopadhyay T. Role of p53 in cell cycle regulation and apoptosis following exposure to histone deacetylase inhibitor. Proc Am Assoc Cancer Res 43:253, 2002. e-Pub 2002.
390. Milas I, Komaki R, Hachiya T, Bubb RS, Ro JY, Langford L, Sawaya R, Putnam JB, Allen P, Cox JD, McDonnell TJ, Brock W, Hong WK, Roth JA, Milas L. Association of EGFR, Cox-2 and BAX expression of the primary non-small cell lung cancer lesion with brain metastatic lesion. Proc Am Soc Clin Oncol 21:312a, 2002. e-Pub 2002.
391. Hofstetter W, Swisher SG, Correa AM, Jr PJ, Ajani J A, Dolormente M, Francisco R, Komaki RR, Lara A, Martin F, Rice DC, Sarabia AJ, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA. Evolving treatment outcomes of resected esophageal cancer over three decades for 951 patients at a single institution. Proc Am Surg Assoc:100, 2002. e-Pub 2002.
392. Minna JD, Ji L, Gao B, Burbee D, Carboni GL, Xu K, Nishizaki M, Fang B, Rivera EC, Kondo M, Tomizawa Y, Gazdar AF, Atkinson EN, Sekido Y, White M, Lerman MI, Roth JA. Multiple genes in the 3p21.3 homozygous lung cancer deletion region can function to suppress tumor growth. Cold Spring Harbor Symposia on Cancer Genetics & Tumor Suppressor Genes:179, 2002. e-Pub 2002.
393. Nishizaki M, Fang B, Minna JD, Roth JA, Ji L. Induction of apoptosis by FHIT gene via activation of death receptor signaling pathway and caspase cascade in human lung cancer cells. Proc Am Assoc Cancer Res 43:997, 2002. e-Pub 2002.
394. Pataer A, Vorburger SA, Barber GN, Chada S, Balachandran S, Mhashilkar AM, Helena YX, Roth JA, Hunt KK, Swisher SG. MDA-7 induces apoptosis via upregulation of the double stranded-RNA dependent protein kinase. Proc Am Assoc Cancer Res 43:1099, 2002. e-Pub 2002.
395. Ramesh R, Mhashilkar AM, Sieger K, Saeki T, Branch CD, Roth JA, Chada S. Ad-mda7 is a novel anti-angiogenic agent. Proc Am Assoc Cancer Res 43:597-598, 2002. e-Pub 2002.
396. Pirocanac E, Nassirpour R, Yang M, Wang JW, Nardin SR, Shun JG, Fang B, Roth JA, Moossa AR, Hoffman RM, Bouvet M. Bax-induction gene therapy of pancreatic cancer. Proc Am Assoc Cancer Res 43:82, 2002. e-Pub 2002.
397. Roth JA, Ramesh R, Ji L, Ito I, Tanaka F, Branch CD, Xu K, Stephens LC, Atkinson EN, Templeton N, Minna JD. Intratumoral and intravenous treatment with liposomal-Fus1 complex inhibits the growth of primary and disseminated human lung tumors in a xenograft model. CHL Conference on Cancer Genetics & Tumor Suppressor Genes:218, 2002. e-Pub 2002.
398. Sah NK, Roth JA, Meyn RE. Adenoviral-mediated p53 gene expression enhances radiosensitivity of A431 human epidermoid carcinoma cells by modulating apoptotic genes. Proc Am Assoc Cancer Res 43:646, 2002. e-Pub 2002.
399. Saito Y, Swanson X, Zumstein L, Roth JA, Ramesh R. Adenovirus mediated PTEN expression (Ad-PTEN) in colorectal tumor cells induces G2/M cell cycle arrest and apoptosis. Proc Am Assoc Cancer Res 43:1100, 2002. e-Pub 2002.
400. Sasaki J, Gomyo Y, Chada S, Mhashilkar AM, Yang H, Stewart A, Roth JA, Mukhopadhyay T. A novel microtubule inhibitor with antitumor activity in vitro and in vivo. Proc Am Assoc Cancer Res 43:265, 2002. e-Pub 2002.
401. Yang H, Mhashikar A, Stewart A, Ekmekcioglu S, Saito Y, Sieger K, Schrock R, Onishi E, Swanson X, Zumstein L, Snary D, Roth JA, Grimm EA, Ramesh R. Ad-PTEN: a novel anti-melanoma agent in vitro. . Proc Am Assoc Cancer Res 43:1100, 2002. e-Pub 2002.
402. Zhang L, Gu J, Lin T, Huang X, Roth JA, Fang B. Different mechanisms involved in development of resistance to adenovirus-mediated proapototic gene therapy in DLD1 human colon cancer cells. Proc Am Assoc Cancer Res 43:1100-1101, 2002. e-Pub 2002.
403. Yao JC, Najam AA, Rashid A, Lynch P, Gagneja H, Agarwal B, Giacco G, Putnam J, Swisher SG, Roth J, Ajani JA. Clinical and pathologic features of patients with carcinoma associated with Barrett’s metaplasia: an analysis of 1,162 patients with esophageal or esophagogastric junction cancer. Proc Am Soc Clin Oncol 21:137a, 2002. e-Pub 2002.
404. Gu J, Zhang L, Huang X, Lin T, Yin M, Xu K, Ji L, Roth JA, Fang B. A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo. 10th SPORE Investigators Workshop NIH/NCI, 2002. e-Pub 2002.
405. Rice DC, Kim HW, Putnam JB, Smythe WR, Swisher SG, Vaporciyan AA, Walsh GL, Lee JJ, Sabichi A, Lippman SM, Roth JA. The risk of second primary lung cancer after resection of stage I non-small-cell lung cancer. Proc Soc Thor Surg 29:108, 2002. e-Pub 2002.
406. Agarwal B, Swisher S, Kelly K, Lynch P, Ajani J, Komaki RR, Putanm JB, Molke KL, Lehmann J, Bismar MM, Walsh GL, Correa AM, Ho L, Kelly J, Liao ZX, Rice DC, Smythe WR, Stevens CW, Vaporciyan AA, Yao J, Roth JA. Role of EUS lymph node assessment after preoperative chmoXRT in esophageal cancer patients. Gastrointestinal Endoscopy 55:AB229, 2002. e-Pub 2002.
407. Jr PJ, Robersonjan SL, Lewin S, Correa AM, Swisher SG, Walsh GL, Rice DC, Vaporciyan AA, Roth JA, Smythe WR. Risk analysis for pneumonia following esophagectomy. Proc Soc Thor Surg:258, 2002. e-Pub 2002.
408. Vaporciyan AA, Merriman KW, Ece F, Roth JA, Smythe WR, Swisher SG, Walsh GL, Putnam JB, Jr. Incidence of major pulmonary morbidity after pneumonectomy: association with timing of smoking cessation. Proc South Thorac Surg, 2002. e-Pub 2002.
409. Chada S, Mhashilkar AM, Mumm J, Caudell E, Sutton RB, Ekmekcioglu S, Sieger K, Zou-Yang H, Roth JA, Ramesh R, Grimm EA. The mda-7 tumor suppressor is a novel cytokine in the IL-10 family. Cancer Gene Ther 8:S5, 2001. e-Pub 2001.
410. Chada S, Nikitina EY, Muro-Cacho C, Fang B, Zhang R, Roth JA, Gabrilovich DI. Immunotherapy using activated dendritic cells transduced with full-length wild-type p53. Cancer Gene Ther 8:S25, 2001. e-Pub 2001.
411. Ito I, Saeki T, Saito Y, Branch C, Stephens LC, Bucana C, Roth JA, Ramesh R. Selective uptake of liposomal DOTAP: cholesterol-DNA complex by lung tumors following intravenous administration. Mol Ther 3:S192, 2001. e-Pub 2001.
412. Mhashilkar A, Zou-Yang H, Caudell E, Ekmekcioglu S, Sieger K, Ramesh R, Roth JA, Grimm E, Chada S. MDA-7 is a novel apokine in the IL-10 family. Mol Ther 3:S211, 2001. e-Pub 2001.
413. Mhashilkar AM, Seiger K, Zhou-Yang H, Stewart A, Roth JA, Ramesh R, Hunt K, Chada S. Herceptin augments Ad-mda7 mediated killing in Her-2 over-expressing breast cancer cells. Cancer Gene Ther 8:S20, 2001. e-Pub 2001.
414. Ramesh R, Mhashilkar A, Saeki T, Swanson X, Sieger K, Zumstein L, Yang H, Stewart A, Branch CD, Chada S, Roth JA. Anti-tumor and anti-angiogenic properties of the melanoma differentiation associated gene-7 (mda-7) in NSCLC. Cancer Gene Ther 8:S4, 2001. e-Pub 2001.
415. Yang XH, Mhashilkar A, Stewart A, Ekmekcioglu S, Saito Y, Sieger K, Schrock R, Onishi E, Swanson X, Zumstein L, Snary D, Roth J, Ramesh R, Grimm EA, Chada S. Ad-PTEN: a novel anti-melanoma agent in vitro. Cancer Gene Ther 8:S8-S9, 2001. e-Pub 2001.
416. Ajani JA, Komaki R, Walsh GL, Putnam JB, Swisher SG, Lahoti S, Ho L, Faust J, Ro J, Smythe WR, Vaporciyan AA, Pisters P, Kelly J, Stevens C, Roth JA. CPT-11 plus cisplatin as induction chemotherapy followed by chemoradiotherapy in resectable carcinoma of the esophagus and GE junction (EC-GEJC). Proc Am Soc Clin Oncol 20:131a, 2001. e-Pub 2001.
417. Honda T, Coppola S, Ghibelli L, Cho SH, Kagawa S, Spurgers KB, Brisbay S, Roth JA, Meyn RE, Fang B, McDonnell TJ. GSH depletion enhanced H322 to be induced to apoptosis through BAX translocation. Proc Am Assoc Cancer Res 42:29-30, 2001. e-Pub 2001.
418. Ito I, Saeki T, Mohiuddin I, Branch CD, Saito Y, Stephens LC, Vaporciyan A, Templeton N, Roth J, Ramesh R. Persistent gene expression in lung tumor bearing mice but not in non-tumor bearing mice after DOTAP: cholesterol-DNA:liposome complex treatment. Proc Am Assoc Cancer Res 42:31, 2001. e-Pub 2001.
419. Ji L, Nishizaki M, Fang B, Gao B, Burbee D, Kamibayashi G, Lerman MI, Roth JA, Minna JD. Functional characterization of potential tumor suppressor genes in human chromosome 3p21.3 critical region in vitro and in vivo. Proc Am Assoc Cancer Res 42:136, 2001. e-Pub 2001.
420. Kagawa S, Gu J, Chao H, Koch PE, Roth JA, Curley SA, Fang B. Bystander effects of the TRAIL gene in cancer cells. Proc Am Assoc Cancer Res 42:274, 2001. e-Pub 2001.
421. Kagawa S, Gu J, Koch P, Roth JA, Fang B. Proapoptotic activity and bystander effect of the TRAIL gene in cancer cells. Proc Am Assoc Cancer Res A-2, 2001. e-Pub 2001.
422. Sharma C, Roth J, Vaporciyan A. Perfluorocarbon improves adenoviral-mediated transfection of lung cancer cell lines via cell mediated effects. Clin Cancer Res 7:3781s-3782s, 2001. e-Pub 2001.
423. Nakamura S, Roth JA, Mukhopadhyay T. p53 requires intact C terminus for G2 delay. Proc Am Assoc Cancer Res 42:734, 2001. e-Pub 2001.
424. Mukhopadhyay T, Sasaki J, Ramesh R, Roth JA. Mebendazole: A novel microtubule agent having potent antitumor activity. Proc Am Assoc Cancer Res 42:1197, 2001. e-Pub 2001.
425. Mohiuddin I, Cao X, Roth JA, Smythe WR. PTEN over-expression in mesothelioma engenders cellular death via AKT hypophosphorylation. Soc Surg Oncol 54th Annual Symposium:17, 2001. e-Pub 2001.
426. Xiong Q, Yao JC, Phan A, Giacco G, Hess K, Roth JA, Putnam JB, Jr, Walsh GL, Swisher SG, Mansfield PF, Pisters PW, Feig BW, Ajani JA. Frequency of esophagogastric junction involvement among upper gastrointestinal cancers. Proc Am Soc Clin Oncol 20:430a, 2001. e-Pub 2001.
427. Nishizaki M, Ji L, Roth JA. Synergistic inhibition of tumor cell growth by adenoviral vector-mediated FHIT and p53 gene transfer in human non-small cell lung cancer. Proc Am Assoc Cancer Res 42:656, 2001. e-Pub 2001.
428. Saeki T, Ito I, Ji L, Roth JA, Ramesh R. Systemic injection of cationic liposome deliver FHIT gene and suppress lung tumor in vivo. . Surg Forum L1:135-136, 2001. e-Pub 2001.
429. Swisher SG, Roth JA, Komaki R, Hicks M, Ro J, Hong WKM, Ahrar K, Atkinson N, Correa A, Dolormente M, Dreiling L, Fang B, Fossela F, Francisco R, Glisson B, Herbst R, Huaringa A, Gu J, Kelly J, Kemp B, Khuri FR, Kurie JM, Lee JJ, Lee JS, Liao Z, McDonnell TJ, Merritt JA, Morice R, Morello F, Mosheim M, Munden R, Papadimitrakopouolou V, Pisters KMW, Jr PJ, Sarabia AJ, Shelton T, Stevens C, Shin D, Smythe WR, Vaporciyan A, Walsh GL, Yin M, Yver A. Induction of pro-apoptotic mediators and tumor regression following intratumoral delivery of adenoviral p53 (RPR/INGN 201) and radiation therapy in patients with non-small cell lung cancer (NSCLS). Proc Am Soc Clin Oncol 20:257a, 2001. e-Pub 2001.
430. Mukhopadhyay T, Roth, JA. Inhibition of Akt kinase after p53 transgene expression and its implication for p53-induced apoptosis. Proc Am Assoc Cancer Res 42:223, 2001. e-Pub 2001.
431. Kawabe S, Nishikawa T, Roth JA, Chada S, Meyn RE. Adenovirus-mediated MDA7 gene expression radiosensitizes non-small cell lung cancer cells, but not normal lung fibroblasts. Proc Am Assoc Cancer Res 42:452, 2001. e-Pub 2001.
432. Swisher SG, Wynn P, Mosheim MB, Putnam JB, Komaki RR, Ajani JA, Smythe WR, Vaporciyan AA, Roth JA, Walsh GL. Is surgical salvage indicated for recurrent esophageal tumors following definitive chemoradiation?. Proc Am Assoc Thorac Surg 146:46, 2001. e-Pub 2001.
433. Swisher SG, Ajani JA, Komaki RR, Walsh GL, Nesbitt J, Martin J, Lahoti S, Smythe WR, Vaporciyan AA, Putnam JB, Roth JA. Improved long-term survival in esophageal cancer following the novel strategy of induction chemotherapy, concurrent chemoradiation and surgery. Proc Western Thorac Surg Assoc:146, 2001. e-Pub 2001.
434. Ramesh R, Saeki T, Mhashilkar A, Swanson X, Zumstein L, Branch C, Roth JA, Chada S. Inhibition of lung tumor growth following adenovirus mediated MDA-7 gene expression in vivo. Proc Am Assoc Cancer Res 42:657, 2001. e-Pub 2001.
435. Pataer A, Nutt L, Yu R, Mhashilkar A, Chada S, McConkey DJ, Hunt KK, Roth JA, Swisher SG. MDA-7 induces apoptosis by caspase activation through mitochondrial cytochrome C release. Proc Am Assoc Cancer Res 42:449, 2001. e-Pub 2001.
436. Lee HY, Wiehle S, Cristiano R, Fang B, Ji L, Roth J, Hong WK, Kurie JM. The effects of insulin-like growth factor binding protein-3 on lung cancer. Proc Am Assoc Cancer Res 42:159, 2001. e-Pub 2001.
437. Vaporciyan AA, Rice DC, Correa AM, Walsh GL, Swisher SG, Smythe WR, Putnam JB, Roth JA. Resection of advanced thoracic malignancies requiring cardiopulmonary bypass (CPB). Proc Eur Assoc Cardiothorac Surg, 2001. e-Pub 2001.
438. Saeki T, Mhashikar A, Chada S, Roth JA, Ramesh R. The MDA-7 gene activates caspase cascade and induces apoptosis in human lung cancer cells. Proc Am Assoc Cancer Res 41:157, 2000. e-Pub 2000.
439. Kataoka M, Schumacher G, Cristiano RJ, Atkinson NE, Fujiwara T, Tanaka N, Roth JA, Mukhopadhyay T. Systemic delivery of adenovirus-p53 with 2-methoxyestradiol inhibits lung metastasis in nude mice. Lung Cancer 29:121, 2000. e-Pub 2000.
440. Gu J, Kagawa S, Takakura M, Kyo XS, Inoue M, Roth JA, Fang B. Tumor-specific transgene expression from the hTERT promoter enables targeting of the therapeutic effects of the bax gene to cancers. Mol Ther 1:S319-S320, 2000. e-Pub 2000.
441. Mhashilkar A, Saeki T, Ramesh R, Roth JA, Chada S. Ad-mda7 is a broad-spectrum antitumor agent, which activates the caspase cascade. Mol Ther 1:S321, 2000. e-Pub 2000.
442. Roth JA, Swisher SG, Mukhopadhyay T, Fang B, Ramesh R, Ji L. Local and system gene replacement for cancer: p53 and beyond. Lung Cancer 29:S20-21, 2000. e-Pub 2000.
443. Swisher SG, Pataer A, Yu R, Nishizaki M, Fang B, Hunt KK, Roth JA. Enhancement of adenoviral mediated p3 (Adp53) tumor killing with amifostine induced CDC2 kinase activation. J Am Coll Surg 191:S88-S89, 2000. e-Pub 2000.
444. Honda T, Kagawa S, Higuchi M, Spurgers K, Gjertsen B, Bruckheimer E, Brisbay S, Roth JA, Fang B, McDonnell TA. A recombinant adenovirus expressing wild type bax induces apoptosis in prostate cancer cells. Proc Am Assoc Cancer Res 41:50, 2000. e-Pub 2000.
445. Komaki R, Roth JA, Walsh GL, Jr PJ, Swisher SG, Vaporciyan AA, Lee JS, Fossella F, Chasen M, Cox JD. Multidisciplinary approach for 143 patients with superior sulcus tumors treated at the University of Texas M. D. Anderson Cancer Center. J JASTRO 12:110, 2000. e-Pub 2000.
446. Nakamura S, Roth JA, Mukhopadhyay T. Roles of p53 C-terminal domain in distribution and ubiquitination. Proc Am Assoc Cancer Res 41:716, 2000. e-Pub 2000.
447. Li X, Marani M, Fang B, Roth JA, He Z, Denner L, Marcelli M. Intracellular trafficking of apoptotic molecules during treatment with straurosporine of Incap and pc-3 prostate cancer cells. Proc Am Assoc Cancer Res 41:48, 2000. e-Pub 2000.
448. Nishizaki M, Ji L, Meyn R, White RA, Roth JA. Synergistic inhibition of tumor cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation in human lung cancer. Proc Am Assoc Cancer Res 41:671, 2000. e-Pub 2000.
449. Pataer A, Fang B, Yu R, Kagawa S, Hunt KK, McDonnell T, Roth JA, Swisher SG. Adenoviral bak overexpression mediates caspase-dependent tumor killing. Proc Am Assoc Cancer Res 41:731, 2000. e-Pub 2000.
450. Ramesh R, Saeki T, Templeton N, Wu Z, Wilson D, Pardes A, Chu W, Branch C, Roth JA. Inhibition of primary and disseminated human lung cancers by systemic delivery of p53 tumor suppressor gene using an improved liposome. Proc Am Assoc Cancer Res 41:603, 2000. e-Pub 2000.
451. Ramesh R, Saeki T, Templeton NS, Wu Z, Wilson DR, Branch C, Roth JA. Inhibition of primary and disseminated human lung cancers by systemic delivery of p53 tumor suppressor gene using DOTAP: Cholesterol liposome. Mol Ther 1:324, 2000. e-Pub 2000.
452. Roth JA, Swisher SG, Fang B, Ji LX, Mukhopadhyay T, Ramesh R, Templeton N. Local and systemic pro-apoptotic gene replacement for non-small cell lung cancer. Lung Cancer 29:136-137, 2000. e-Pub 2000.
453. Schnirer I, Komaki R, Yao JC, Swisher SG, Jr PJ, Pisters PW, Roth JA, Yan M, Janjan N, Mansfield PF, Feig BW, Ajani JA. A study of concurrent 5FU/paclitaxel and radiotherapy in patients with carcinoma of the upper gastrointestinal tract. Proc Am Assoc Cancer Res:72a, 2000. e-Pub 2000.
454. Sueoka N, Lee HY, Walsh G, Fang B, Ji L, Roth JA, LaPushin R, Hong W, Kurie J. Role of insulin-like growth factor binding protein-6 in the proliferation of human bronchial epithelial cells and non-small cell lung cancer cell lines. Proc Am Assoc Cancer Res 41:500, 2000. e-Pub 2000.
455. Swisher S, Roth JA, Komaki R, Hicks M, Ro J, Dreiling L, Yver AB, Stevens C, Putnam JB, Smythe WR, Vaporciyan AA, Walsh GL. A phase II trial of adenoviral mediated p53 gene transfer (RPR/INGN 201) in conjunction with radiation therapy in patients with localized non-small cell lung cancer (NSCLC). Am Soc Clin Oncol 19:461a, 2000. e-Pub 2000.
456. Siegenthaler MP, Pisters KM, Merriman KW, Swisher SG, Roth JA, Walsh GL, Vaporciyan AA, Smythe WR, Putnam JB, Jr. Preoperative chemotherapy for lung cancer does not increase surgical morbidity. Proc Soc Thorac Surg, 2000. e-Pub 2000.
457. Putnam JB, Jr, Benjamin RS, Rha SJ, Walsh GL, Swisher SG, Vaporciyan AA, Smythe WR, Roth JA. Early results of isolated single lung perfusion for treatment of unresectable sarcomatous metastases. Proc Am Assoc Thorac Surg 21:78-79, 2000. e-Pub 2000.
458. Munden RF, Truong M, Swisher SG, Roth JA. CT evaluation of non-small cell lung cancer undergoing gene therapy with adenoviral p53. Proc Radiol Soc N Am 323:173, 2000. e-Pub 2000.
459. Pataer A, Smythe WR, McDonnell T, Roth JA, Fang BL, Swisher SG. Adenovirus-mediated bak gene transfer induces apoptosis in mesothelioma cell lines. Proc Am Assoc Thorac Surg 3:184-185, 2000. e-Pub 2000.
460. Walsh GL, Davis BM, Swisher SG, Vaporciyan AA, Smythe WR, Roth JA, Putnam JB, Jr. A single-institution, multidisciplinary approach to primary sarcomas involving the chest wall requiring full thickness resections. Proc Am Assoc Thorac Surg 23:82-83, 2000. e-Pub 2000.
461. Fukazawa T, Fujiwara T, Nishizaki M, Kadowaki Y, Shao J, Waku T, Roth JA, Tanaka N. TRAIL (Apo2-L) is not an essential mediator of p53-mediated apoptosis in human cancer cells. Proc Am Assoc Cancer Res 40:169, 1999. e-Pub 1999.
462. Schumacher G, Bruckheimer EM, Beham A, Honda T, Roth JA, McDonnell TJ. Gene therapy for human prostate cancer using an adenovirus expressing wild-type p53 when bcl-2 is overexpressed. Proc Am Assoc Cancer Res 40:482, 1999. e-Pub 1999.
463. Fujiwara T, Shao J, Kadowaki Y, Fukazawa T, Waku T, Nishizaki M, Roth JA, Tanaka N. Inhibition of NF-kB activity by adenovirus-mediated wild-type p53 gene transfer in human colon cancer cells: synergy with aspirin to induce apoptosis. Proc Am Assoc Cancer Res 40:482, 1999. e-Pub 1999.
464. Waku T, Fujiwara T, Nishizanki M, Hizuta A Nishimori H, Tokino T, Nakamura Y, Roth JA, Tanaka N. A Proposed Mechanism for the Bystander Effect of the p53 Gene Therapy: p53-Mediated Antiangiogenic Effect. Proc Am Assoc Cancer Res 40:730, 1999. e-Pub 1999.
465. Pearson S, Wilson D, Bouvet M, Ramesh R, Lee J, Mhashilkar A, Evans D, Janicot M, Chada S, Roth JA. In vivo growth suppression of pancreatic cancer by gene transfer of a single chain antibody to RAS. 52 Annual Cancer Symposium 55:22, 1999. e-Pub 1999.
466. Zhao J, Komminoth P, Multetta-Feurer S, Rütimann K, Saremaslani P, Roth JA, Heitz PU, Speel EJM. Genomic alterations in adrenocortical lesions detected by comparative genomic hybridization. Proc Am Assoc Cancer Res 40:537, 1999. e-Pub 1999.
467. Ramesh R, Pearson S, Wilson D, Janicot M, Roth JA. Treatment of pancreatic cancer using single chain antibody (AV1Y28) to Ras. Proc Am Assoc Cancer Res 40:485, 1999. e-Pub 1999.
468. Pamarthi M, Lakka S, Mohanam S, Chintala SK, Fang B, Roth JA, Kyritsis AP, Sawaya R, Rao JS. Adenovirus mediated delivery of antisense message to urokinase type plasminogen activator receptor (uPAR) inhibits invasiveness of human glioma cell lines. Proc Am Assoc Cancer Res 40:521, 1999. e-Pub 1999.
469. Munshi A, Roth JA, Meyn RE. Adenoviral-mediated p53 does not radiosensitize normal human lung epithelial cells. Proc Am Assoc Cancer Res 40:594, 1999. e-Pub 1999.
470. Mukhopadhyay T, Roth JA. Induction of p21 protein expression following 5-aza-2'-deoxycytidine treatment protects human lung cancer cells from p53-mediated apoptosis. Proc Am Assoc Cancer Res 40:102, 1999. e-Pub 1999.
471. Lakka S, Pamarthi M, Mohanam S, Chintala SK, Fang B, Roth JA, Kyritsis AP, Sawaya R, Rao JS. Adenovirus-mediated delivery of antisense message to downregulate urokinase type plasminogen activator receptor (uPAR) inhibits invasiveness of human non-small-cell lung cancer cell line H1299. Proc Am Assoc Cancer Res 40:595, 1999. e-Pub 1999.
472. Kataoka M, Spitz FR, Schumacher G, Liu TJ, Fujiwara T, Tanaka T, Roth JA, Cristiano RJ. Induction of apoptosis in non-small cell lung cancer cells by p16INK4 is related to down-regulation of bcl-2 and Rb. Proc Am Assoc Cancer Res 40:729, 1999. e-Pub 1999.
473. Kadowaki Y, Fujiwara T, Nishizaki M, Fukazawa T, Shao J, Waku T, Roth JA. Up-regulation of RAR a and induction of RA sensitivity of human cancer cells by adenovirus-mediated p21 gene transfer. Proc Am Assoc Cancer Res 40:527, 1999. e-Pub 1999.
474. Huober J, Nakamura S, Roth JA, Mukhopadhyay T. Radiation and 2-methoxyestradiol can cooperate in wild-type p53 human lung cancer cells and induce apoptosis. Proc Am Assoc Cancer Res 40:144, 1999. e-Pub 1999.
475. Gabrilovich DI, Ishida T, Chada S, Nadaf S, Ciernik FI, Roth JA, Fang B, Zhang R, Carbone DP. Dendritic cells transduced with wild type p53 gene elicit potent antitumor immune responses. Proc Am Assoc Cancer Res 40:85, 1999. e-Pub 1999.
476. Kagawa S, Ji L, Xu K, McDonnell T, Swisher SG, Roth JA, Fang B. Induction of bax gene expression by adenoviral mediated gene codelivery. Proc Am Assoc Cancer Res 40:218, 1999. e-Pub 1999.
477. Timmons T, Burt K, Chema D, Tigelaar B, Hanvy P, Wilson J, Swisher SG, Nemunaitis J, Roth JA, Merritt J, Wilson D. Biodistribution of Ad-p53 (INGN 201) in a phase I/II trial of gene therapy for non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17:431a, 1999. e-Pub 1999.
478. Nakamura S, Roth JA, Mukhopadhyay T. p53 requires intact C-terminus for G2 delay. MD Anderson Symposium, 1999. e-Pub 1999.
479. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, El-Naggar AK, Hong WK, Mack M, Weill D, Merritt JA, Jr PJ, Walsh G. Outcome of intralesional adenoviral p53 gene replacement with or without cisplatinum in patients with advanced non-small cell lung cancer. Proc Am Assoc Thorac Surg 79, 1999. e-Pub 1999.
480. Ramesh R, Saeki T, Templeton NS, Wilson D, Pardes A, Chu W, Branch C, Roth JA. Inhibition of solid and disseminated lung tumors following DOTAP-cholesterol lipsome-mediated p53 gene delivery. Texas Medical Center Gene Therapy Symp, 1999. e-Pub 1999.
481. Ramesh R, Saeki T, Wu Z, Smythe-Templeton N, Zhang S, Wilson DR, Branch C, Roth JA. Inhibition of tumor growth following liposome-mediated p53 delivery. American Society of Gene Therapy 2:30a, 1999. e-Pub 1999.
482. Schumacher G, Ramesh R, Fan Z, Mendelsohn J, Roth JA. A combination of wild-type p53 and the anti EGF-receptor antibody C225 up-regulates P27KIP1 and induces enhanced apoptosis. The International Society of Cancer Gene Therapy 14:14, 1999. e-Pub 1999.
483. Eton O, East M, Ross MI, Savary CA, Cohen L, Lee JE, Mansfield PE, Walsh GL, Roth JA, Callender DL, Eicher SA, Curley SA, Myers J, Ellerhorst JA, Papdopoulos NE, Plager C, Bedikian AY, Tomasovic SP, Reitsma D, Srivastava PK. Preliminary Clinical Results of an Active Specific Immunotherapy Induction Trial of Autologous Tumor-Derived Heat-Shock Protein Peptide Complex-96 in Patients with Metastatic Melanoma. Cancer Immunosurveillance, Cancer Res Inst 1:11, 1999. e-Pub 1999.
484. Ramesh R, Saeki T, Templeton NS, Wilson D, Pardes A, Chu W, Branch C, Roth JA. Inhibition of SOLID and disseminated lung tumors following DOTAP-cholesterol lipsome-mediated p53 gene delivery. Texas Medical Center Gene Therapy Symposium, 1999. e-Pub 1999.
485. Kagawa S, Gu J, Swisher SG, Ji L, McDonnell TJ, Roth JA, Fang B. Induction of bax gene expression by adenoviral mediated gene co-transfer elicited apoptosis in cancer cells and suppressed tumor growth in animals. Texas Medical Center Gene Therapy Symposium, 1999. e-Pub 1999.
486. Alspaugh E, Antelman D, Barber J, Csaky KG, Fang B, Frederik P, Honda H, Johnson D, Litvak F, Machemer T, Ramesh R, Robbins J, Roth JA, Sebastian M, Tritz R, Wen SF, Wu Z, Smyth-Templeton N. Non-viral vectors for the treatment of disease. Molecular and Cellular Biology of Gene Therapy A4:37, 1999. e-Pub 1999.
487. Schumacher G, Fan Z, Mendelsohn J, Roth JA. An adenoviral vector expressing wild-type p53 enhances the expression of the EGF receptor and P27KIP1, which results in additional growth inhibition in combination with the anti EGF receptor antibody C225. Langenbecks Arch Surg, 1999. e-Pub 1999.
488. Swisher SG, Deford L, Merriman K, Hunt KK, Walsh G, Vaporciyan A, Smythe WR, Morris M, Roth J, Putnam JB, Jr. Impact of operative volume on morbidity, mortality and hospital usage following esophagectomy for esophageal cancer. Proc West Thorac Surg Assoc, 1999. e-Pub 1999.
489. Gandhi S, Walsh GL, Komaki R, Gokaslan Z, Putnam JB, Jr, Roth J, Merriman K, Vaporciyan AA, Swisher SG. An aggressive multidisciplinary surgical approach to superior sulcus tumors with vertebral invasion can lead to long-term. Proc Soc Thorac Surg 35:90-91, 1999. e-Pub 1999.
490. Bouvet M, Bold RJ, Evans DB, Abbruzzese JL, Chiao JL, McConkey DJ, Chandra J, Fang B, Roth JA. Adenoviral-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer in vitro and in vivo. Proc Am Assoc Cancer Res 39:515, 1998. e-Pub 1998.
491. Shin DM, Walsh GL, Putnam J, Komaki R, Cox JD, Roth JA, Hong WK. Recent advances in the management of malignant thymoma. New Frontier in Research and Treatment of Aerodigestive Tract Cancers 41:53-54, 1998. e-Pub 1998.
492. Clayman GL, El-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA, Zumstein LA, Timmon TM, Liu TJ, Ginsberg L, Roth JA, Hong WK, Bruso P, Goepfert H. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. New Frontiers in Research and Treatment of Aerodigestive Tract Cancers 41:109-110, 1998. e-Pub 1998.
493. Schumacher G, Fan Z, Mendelsohn J, Roth JA. An adenovirus vector expressing wild-type p53 (Ad-p53) upregulates the EGF receptor and enhances growth inhibition of human breast cancer cell line when combined with anti-EGF receptor mAB C225. Proc Am Assoc Cancer Res 39:419, 1998. e-Pub 1998.
494. Schumacher G, Kataoka M, Roth JA, Mukhopadhyay T. 2-methoxyestradiol induces apoptosis in human pancreatic cancer cell lines and inhibits tumorigenicity in vivo. Proc Am Assoc Cancer Res 39:602, 1998. e-Pub 1998.
495. Schneider PM, Roth JA, Holscher AH, Mizumoto S, Wegerer S, Fink U, Siewert JR. p53 mutational status defines low- and high-risk groups for treatment failure in patients with curatively resected Barrett’s cancer. Proc Am Assoc Cancer Res 39:464, 1998. e-Pub 1998.
496. Pearson AS, Koch PE, Lee JJ, Finberg RW, Roth JA, Fang B. Adenovirus transduction efficiency is determined by combined cellular presence of receptor for attachment and integrins for internalization. Proc Am Assoc Cancer Res 39:513, 1998. e-Pub 1998.
497. Owen-Schaub LB, Cusack JC, Kruzel E, Bucana CD, Roth JA. Induction of FAS expression and sensitivity by adenoviral-mediated p53 gene transfer in a non-small cell lung carcinoma: implications for gene therapy for lung cancer. Proc Am Assoc Cancer Res 39:78, 1998. e-Pub 1998.
498. Nishizaki M, Fujiwara T, Kagawa S, Hizuta A, Nishimori H, Tokino T, Nakamura Y, Roth JA, Tanaka, N. Modulation of VEGF and BAI1 gene expression by the wild-type p53 gene transfer is a potent strategy for antiangiogenesis. Proc Am Assoc Cancer Res 39:39-40, 1998. e-Pub 1998.
499. Mukhopadhyay T, Multani AS, Roth JA, Pathak S. Reduced telomeric signals and increased telomeric associations in human lung cancer cell lines undergoing p53-mediated apoptosis. Proc Am Assoc Cancer Res 39:549, 1998. e-Pub 1998.
500. Mukhopadhay T, Roth JA, Acosta SA, Maxwell SA. Two-dimensional gel analysis of apoptosis-specific p53 isoforms induced by 2-methoxyestradiol in human lung cancer cells. Proc Am Assoc Cancer Res 39:556-557, 1998. e-Pub 1998.
501. Kataoka M, Schumacher G, Roth JA, Mukhopadhyay T. 2-Methoxyestradiol inhibits multiple metastases of human non-small lung cancer in nude mice with combination of systemic adenovirus-p53. Proc Am Assoc Cancer Res 39:419, 1998. e-Pub 1998.
502. Kadowaki Y, Fujiwara T, Kagawa S, Nishizaki M, Fukazawa T, Hizuta A, Roth JA, Tanaka N. Senescence-directed molecular therapy for human cancer cells by a recombinant adenovirus expressing the p21/sdi1 gene. Proc Am Assoc Cancer Res 39:256, 1998. e-Pub 1998.
503. Fukazawa T, Fujiwara T, Kagawa S, Nishizaki M, Kadowaki Y, Hizuta A, Roth JA, Tanaka N. The FAS/APO-1 (CD95) receptor/ligand system is differentially involved in apoptosis induced by the wild-type p53 gene transfer. Proc Am Assoc Cancer Res 39:462, 1998. e-Pub 1998.
504. Fujiwara T, Ogawa N, Kagawa S, Nishizaki M, Hizuta A, Tanaka N, Roth JA. Regional molecular surgery for human colorectal cancer with a recombinant adenovirus expressing the wild-type p53 gene. Proc Am Assoc Cancer Res 39:59, 1998. e-Pub 1998.
505. Swisher S, Hu M, Holmes EC, Hunt K, Ajani J, McFadden D, Nelson S, Nesbitt J, Putnam JB, Vaporciyan A, Walsh G, Zinner M, Roth JA. Impact of number of involved lymph nodes on long-term survival in esophageal cancer. Cancer Symp 51:64, 1998. e-Pub 1998.
506. Spitz FR, Kataoka M, Sarkiss MG, Meyn RE, McDonnell TJ, Swisher SG, Cristiano RJ, Roth JA. Apoptotic mechanisms following adenovirus-mediated p53 replacement gene therapy. Cancer Symp 51:21, 1998. e-Pub 1998.
507. Schumacher G, Kataoka M, Roth JA, Mukhopadhyay, T. Induction of p53 independent apoptosis in human pancreatic cancer cells after treatment with 2-methoxyestradiol. Cancer Symp 51:59, 1998. e-Pub 1998.
508. Kataoka M, Schumacher G, Johnson M, Roth JA, Mukhopadhyay T. 2-Methoxyestradiol and systemic adenovirus-p53 co-operate to inhibit human non-small cell lung cancer metastases in nude mice. Cancer Symp 51:15, 1998. e-Pub 1998.
509. Bouvet M, Bold R, Evans D, Chandra J, McConkey D, Abbruzzese J, Chiao P, Fang B, Roth JA. Adenoviral mediated p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Cancer Symp 15:10, 1998. e-Pub 1998.
510. Pearson AS, Fang B, Hunt KK, Yu R, Wilson-Heiner M, McDonnell TJ, Sarkiss M, Bruckheimer E, Roth JA, Swisher SG. Adenoviral mediated overexpression of Bax induces apoptosis in breast cancer: correlation with BCL-2 status. Proc Am Assoc Cancer Res 51:9, 1998. e-Pub 1998.
511. Owen-Schaub L, Cusack JC, Kruzel E, Bucana CD, Roth JA. Induction of Fas expression and sensitivity by adenoviral-mediated p53. Proc Am Assoc Cancer Res 39:78, 1998. e-Pub 1998.
512. Mukhopadhyay T, Roth JA, Acosta SA, Maxwell SA. Two-dimensional gel analysis of apoptosis-specific p53 isoforms induced by 2-methoxyestradiol in human lung cancer cells. Proc Am Assoc Cancer Res 39:556-557, 1998. e-Pub 1998.
513. Nesbitt JC, Ajani A, Komaki R, Walsh G, Jr P, JB, Swisher SG, Pisters P, Lynch P, Raijman I, Pazdur R, Delclos M, Martin F, JA <. Preoperative taxol-based chemotherapy (CT) followed by chemoradiation therapy (CTRT) in patients (PTS) with potentially resectable esophageal carcinoma (EC). Proc Am Soc Clin Oncol 17:282a, 1998. e-Pub 1998.
514. Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA. Induction of apoptosis, inhibition of tumorigenicity, and suppression of tumor growth by adenoviral vector-mediated FHIT gene overexpression in vitro and in vivo. Mol Cell Biol Gene Ther A4(413):65, 1998. e-Pub 1998.
515. Schumacher G, Bruckheimer EM, Beham A, Honda T, Roth JA, McDonnell TJ. Adenoviral transfer of wild-type p53 leads to growth inhibition and apoptosis in human prostate cancer cell lines, which is inhibited by bcl-2 overexpression. Proc 17th Intl Cancer Congress:1087-1090, 1998. e-Pub 1998.
516. Swisher SG, Roth JA, Neumanitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors C, El-Nagger AK, Fossela FV, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Merritt JA, Nesbitt JC, Nguyen D, Pisters KMW, Jr PJ, Schrump DS, Shin DM, Perez-Soler R, Walsh GL. Adenoviral mediated p53 gene transfer in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17:431a, 1998. e-Pub 1998.
517. Schumacher G, Kataoka M, Roth JA, Mukhopadhyay T. Induction of p53 independent apoptosis in human pancreatic cancer cells after treatment with 2-methoxyestradiol. Ann Surg Oncol:500B, 1998. e-Pub 1998.
518. Pearson S, Fang B, Hunt K, Yu R, Wilson-Heiner M, McDonnell T, Sarkiss M, Bruckheimer E, Roth JA, Swisher S. Induction of apoptosis in human breast cancer by adenoviral mediated overexpression of the proapoptotic gene bax. Cancer Symp 51:9, 1998. e-Pub 1998.
519. Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner S, Goodman GE, Kardinal C, Winn RJ, Roth JA, Hong WK. Phase-III intergroup trial of 13-cis-retinoic acid to prevent second primary tumors in stage-I non-small cell lung cancer (NSCLC): interim report of NCI#191-0001. Proc Am Soc Clin Oncol 17:456a, 1998. e-Pub 1998.
520. Kataoka M, Schumacher G, Johnson M, Roth JA, Mukhopadhyay T. 2-Methoxyestradiol and systemic adenovirus-p53 co-operate to inhibit human non-small cell lung cancer metastases in nude mice. Ann Surg Oncol:500T, 1998. e-Pub 1998.
521. Clayman GL, El-Naggar AK, Merritt J, Bruso P, Roth JA, Lippman S, Hong WK, Goepfert H. Adenovirus-mediated p53 gene transfer in a phase I trial of patients with advanced recurrent head and neck squamous carcinoma. Proc Am Soc Clin Oncol 16:383a, 1998. e-Pub 1998.
522. Nemunaitis J, Swisher SG, Roth JA, Merritt J. Adenoviral mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small cell lung cancer (NSCLC). Proc of the First American Society for Gene Therapy Meeting, 1998. e-Pub 1998.
523. Fang B, Koch P, Ji L, Bouvet M, Roth JA. Evaluation of GAL4/TATA in vivo: induction of transgene expression by adenovirally mediated gene codelivery. Keystone Symposia on Molecular and Cellular Biology, 1998. e-Pub 1998.
524. Clayman GL, El-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA, Zumstein LA, Timmon TM, Liu TJ, Ginsberg L, Roth JA, Hong WK, Bruso P, Goepfert H. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. New Frontiers in Research and Treatment of Aerodigestive Tract Cancers 41:109-110, 1998. e-Pub 1998.
525. Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE, Kardina C, Winn RJ, Roth JA, Hong WK. Phase-III Intergroup Trial of 13-CIS-Retonic Acid to Prevent Second Primary Tumors in Stage-I Non-Small Cell Lung Cancer (NSCLC): Interim Report of NCI #I91-0001. Proc Am Soc Clin Oncol 17:456a, 1998. e-Pub 1998.
526. Ajani JA, Nesbitt J, Komaki R, Walsh GL, Putnam JB, Jr, Swisher SG, Pisters P, Lynch P, Pazdur RR, Delclos M, Martin F, Roth JA. Three-step paclitaxel-based therapy in patients with resectable esophageal carcinoma. Proc Invest Taxol Workshop, 1998. e-Pub 1998.
527. Nesbitt JC, Whitehead WE, Darwish AA, Walsh GL, Schrump DS, Swisher SG, Willis KD, Roth JA, Jr PJ. Survival and operative risk following pneumonectomy. American College of Chest Physician:8S-9S, 1997. e-Pub 1997.
528. Merritt JA, Clayman G, Swisher SG, Nemunaitis J, El-Naggar A, Timmons T, Laurence D, Kemp B, Frederick M, Connors D, Bruso P, Geopfert H, Hong WK, Roth JA. Clinical gene therapy strategies: Phase 1/II results with adenoviral p53 (INGN 201) gene transfer in advanced head and neck and non-small cell lung cancers. 3rd European Conference on Gene Therapy of Cancer:4, 1997. e-Pub 1997.
529. Roth JA, Swisher SG, Lawrence DD, Kemp BL, Carrasco CH, El-Naggar AK, Fossela FV, Glisson BS, Hong WK, Khuri FR, Kurie JM, Nesbitt JC, Pisters K, Jr PJ, Schrump DS, Shin DM, Walsh GL. Gene replacement for lung cancer. Lung Cancer 18:76, 1997. e-Pub 1997.
530. Shin DM, Komaki R, Jr PJ, Walsh GL, Nesbitt J, Ro JY, Schea RA, Pisters KMW, Schrump D, Gregurich MA, Cox JD, Roth J, Hong WK. Multidisciplinary approach of therapy for advanced stages of unresectable invasive thymoma. First International Meeting on Advances in the Knowledge of Cancer Management, UICC, 1997. e-Pub 1997.
531. Swisher SG, Roth JA, Lawrence D, Kemp B, Carrasco C, Fossella F, Glisson B, Hong WK, Khurie F, Kurie J, Nesbitt J, Pisters K, Putnam JB, Schrump D, Shin D, Walsh G. Persistent transgene expression following repeated injections of a recombinant adenovirus containing the p53 wild-type gene in patients with non-small cell lung cancer. Proc Am Assoc Cancer Res 38:342, 1997. e-Pub 1997.
532. Spitz FR, Kataoka M, Sarkiss M, Meyn R, McDonnell TJ, Swisher S, Cristiano RJ, Roth JA. An investigation of apoptotic responses following adenovirus-mediated p53 gene delivery. Proc Am Assoc Cancer Res 38:137, 1997. e-Pub 1997.
533. Schneider P, Stoeltzing O, Manning J, Wegerer S, Prauer HW, Fink U, Roth JA. Different prognostic impact of mutations in p53 and c Ki-ras and altered expression of C-ERBB-2 in curatively resected non-small cell lung cancer. Proc Am Assoc Cancer Res 38:329, 1997. e-Pub 1997.
534. Nishizaki M, Fujiwara T, Kagawa S, Ogawa N, Hizuta A, Roth JA, Tanaka N. Antianglogenic therapy for human lung cancer by wild-type p53-mediated downregulation of vascular endothelial growth factor (VEGF) expression. Proc Am Assoc Cancer Res 38:175, 1997. e-Pub 1997.
535. Kagawa S, Fujiwara T, Nishizaki M, Ogawa N, Inoue F, Hizuta A, Roth JA, Tanaka N. p53 overexpression converses p21-mediated G1 arrest into apoptosis in human lung cancer cells: clinical implication for p53 gene therapy. Proc Am Assoc Cancer Res 38:A631, 1997. e-Pub 1997.
536. Mukhopadhyay T, Roth JA. 2-Methoxyestradiol-induced accumulation of wild-type p53 protein in MCF-7 breast cancer cells undergoing apoptosis. Proc Am Assoc Cancer Res 38:274, 1997. e-Pub 1997.
537. Walsh GL, Gokaslan ZL, McCutcheon IE, Yasko AW, Mineo MT, Swisher SG, Schrump DS, Nesbitt JC, Jr PJ, Roth JA. Anterior approaches to the thoracic spine in patients with cancer: indications and results. Proc Soc Thorac Surg 33:221, 1997. e-Pub 1997.
538. Schrump DS, Chen A, Consuli U, Malkinson AM, Roth JA. Cyclin D1 ribozyme inhibits the proliferation of urethane induced lung cancer cells containing activated K-ras. Lung Cancer 18:142, 1997. e-Pub 1997.
539. Roth JA, Swisher SG, Lawrence DD, Kemp BL, Carrasco CH, El-Naggar AK, Fossela FV, Glisson BS, Hong WK, Khuri FR, Kurie JM, Nesbitt JC, Pisters K, Jr PJ, Schrump DS, Shin DM, Walsh GL. Gene therapy strategies for lung cancer. Lung Cancer 18:141, 1997. e-Pub 1997.
540. Swisher SG, Roth JA, Lawrence DD, Kemp BL, Carrasco CH, Fossella FV, Glisson BS, Hong WK, Khuri FR, Kurie JM, Nesbitt JC, Pisters KM, Putnam JB, Schrump DS, Shin DM, Walsh GL. Adenoviral-mediated p53 gene transfer in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 16:437a, 1997. e-Pub 1997.
541. Shin D, Komaki R, Putnam JB, Walsh G, Nesbitt JC, Ro Y, Schea R, Schrump D, Cox J, Roth JA, Hong WK. Induction chemotherapy (IC) followed by surgical resection (SR), radiotherapy (RT), and consolidative chemotherapy (CC) may cure the advanced stages of unresectable thymoma. Proc Am Soc Clin Oncol 16:456a, 1997. e-Pub 1997.
542. Morice RC, Walsh GL, Ali MK, Roth JA. Redefining the lowest exercise peak oxygen consumption acceptable for lung resection of high risk patients. American College of Chest Physician 110:161S, 1996. e-Pub 1996.
543. Walsh GL, Soysal O, Jr PJ, Nesbitt JC, Willis KM, Roth JA. Should pulmonary metastasectomies be performed in patients over 70 years of age?. Can J Surg 39(4):A3, 1996. e-Pub 1996.
544. Wolf JK, Bazelle L, Mills GB, Bast RC, Roth JA, Gershenson DM. Growth inhibition of human ovarian cancer cells by transfection with adenovirus-mediated p53 is independent of endogenous p53 status. Proc Am Assoc Cancer Res 37:205, 1996. e-Pub 1996.
545. Spitz FR, Nguyen D, Skibber J, Meyn R, Cristiano RJ, Roth JA. Adenoviral mediated p53 gene therapy enhances radiation sensitivity of colorectal cancer cell lines. Proc Am Assoc Cancer Res 37:347, 1996. e-Pub 1996.
546. Nguyen D, Wiehle S, Koch P, Roth JA, Cristiano R. Gene therapy for lung cancer: enhancement of tumor suppression by a combination of systemic cisplatin and adenovirus-mediated p53 gene transfer. Proc Am Assoc Cancer Res 37:347, 1996. e-Pub 1996.
547. Nguyen D, Spitz F, Kataoka M, Wiehle S, Roth JA, Cristiano, R. Enhancement of gene transduction in human carcinoma cells by DNA-damaging agents. Proc Am Assoc Cancer Res 37:347, 1996. e-Pub 1996.
548. Mukhopadhyay T, Roth JA, Maxwell SA. Differential regulation of the human and murine p53 promoters by NF-Kb. Proc Am Assoc Cancer Res 37:500, 1996. e-Pub 1996.
549. Kagawa S, Fujiwara T, Ogawa N, Hamada M, Hizuta A, Tanaka N, Orita K, Cai DW, Zhang WW, Roth JA. Recombinant virus-mediated transfer of the wild-type p53 gene is a potent therapeutic strategy against various types of human cancer. Proc Am Assoc Cancer Res 37:339, 1996. e-Pub 1996.
550. Hamada K, Horio Y, Alemany R, Zhang WW, Hittelman WN, Lotan R, Roth JA, Mitchell MF. Inhibition of in vitro and in vivo growth of human cervical cancer by adenovirus-antisense HPV 16. Proc Am Assoc Cancer Res 37:205, 1996. e-Pub 1996.
551. Gotoh A, Kao C, Ko SC, Hamada K, Roth JA, Chung WK. Gene therapy with p21WAF1/CIP1 adenovirus for human prostate cancers. Proc Am Assoc Cancer Res 37:205, 1996. e-Pub 1996.
552. Fumiyuki I, Katsuyuki H, Kataoka M, Yoshitsugu H, Kunzo O, Roth JA. Adenovirus-mediated transfer of wild-type p21 gene into the non-small cell lung cancer cells. Proc Am Assoc Cancer Res 37:590, 1996. e-Pub 1996.
553. Nguyen DM, Wiehle SA, Koch PE, Cristiano RJ, Roth JA. Gene therapy for lung cancer: Enhancement of tumor suppression by a combination of systemic cisplatin and adenovirus-mediated p53 gene transfer. Proc Am Assoc Thorac Surg 76:142-143, 1996. e-Pub 1996.
554. Roth JA. Gene replacement for cancer. International Congress on Anti-Cancer Treatments 6:54, 1996. e-Pub 1996.
555. Fang B, Koch P, Roth JA. Replacing adenoviral E4 promoter with GAL4/TATA dramatically reduces viral gene expression. Cancer Gene Ther 3:S25, 1996. e-Pub 1996.
556. Harper ME, Cristiano RJ, Spitz F, Nguyen D, Gjerset RA, Roth JA. Enhancement of antitumor effects of p53 gene therapy by combination with DNA-damaging agents. Cancer Gene Ther 3:S41, 1996. e-Pub 1996.
557. Kataoka M, Roth JA, Cristiano RJ. Induction of apoptosis in non-small cell lung cancer cells by p16INK4. Cancer Gene Ther 3:S40, 1996. e-Pub 1996.
558. Mukhopadhyay T, Roth JA. Selective induction of wild-type p53 protein by 2-methoxyestradiol as a biochemical tool for inducing programmed cell death. Cancer Gene Ther 3:S39, 1996. e-Pub 1996.
559. Schrump DS, Roth JA. Gene therapy of esophageal cancer. Thoracic and Oesophageal Surgery, 1996. e-Pub 1996.
560. Schrump DS, Chen GA, Jin X, Cristiano RJ, Roth JA. p53 gene replacement in esophageal adenocarcinomas. Polydisciplinary World Congress, 1996. e-Pub 1996.
561. Schrump DS, Chen GA, Jin X, Cristiano RJ, Roth JA. Strategies for gene therapy intervention in esophageal cancers. Polydisciplinary World Congress, 1996. e-Pub 1996.
562. Roth JA. Gene replacement strategies for lung cancer. Lung Cancer: Strategies for the 21st Century Biology, Prevention and Management:12, 1996. e-Pub 1996.
563. Roth JA. Biology and management of stage I lung cancer. Lung Cancer: Strategies for the 21st Century Biology, Prevention and Management:30, 1996. e-Pub 1996.
564. Roth JA. Does induction therapy alter stage and resectability for non-small cell lung cancer. International Workshop on Intrathoracic Staging, 1996. e-Pub 1996.
565. Nguyen D, Spitz F, Koch P, Wiehle S, Roth JA, Cristiano RJ. An improved gene therapy strategy for non-small cell lung cancer: a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. The Royal College of Physicians and Surgeons of Canada:39, 1996. e-Pub 1996.
566. Schrump DS, Chen GA, Consuli U, Jin X, Roth JA. Inhibition of esophageal cancer proliferation by adenoviral-mediated delivery of p16INK4. Exp Clin Oncol, 1996. e-Pub 1996.
567. Sastry KJ, Michell MF, Hamada K, Sarkar AK, Satterfield WC, Buchl S, Ortolero-Luna G, Keeling ME, Roth JA. Recombinant adenovirus-mediated gene delivery for cervical cancer gene therapy: feasibility studies in rhesus monkeys as non-human primate model. Gene Ther, 1996. e-Pub 1996.
568. Roth JA, Clayman G, Nguyen D, Cristiano RJ. Gene replacement for cancer. Proc Perspect Lung Cancer:27, 1996. e-Pub 1996.
569. Roth JA. Gene therapy and the new biology. Lung Cancer, 1996. e-Pub 1996.
570. Ferson DZ, Nesbitt JC, Kenfield-Nesbitt K, Walsh GL, Jr PJ, Schrump DS, Johansen MJ, Jones RL, Roth JA. The laryngeal mask airway: a new standard for airway evaluation in thoracic surgery. Southern Thorac Surg Assoc:66, 1996. e-Pub 1996.
571. Roth JA. Gene replacement strategies for prevention and treatment of aerodigestive tract cancers. American Society for Therapeutic Radiology and Oncology, 1995. e-Pub 1995.
572. Nguyen DM, Wiehle SA, Koch PE, Roth JA, Cristiano RJ. Modulation of in vivo tumor growth of p53 gene replacement therapy using a conjugated adenovirus/DNA complex as a novel delivery system. Genetic Mechanisms of Cancer 48:152-153, 1995. e-Pub 1995.
573. Jr PJ, Walsh GL, Nesbitt JC, McMurtrey MJ, Roth JA, Suell DA, Schrump DS, Ohnmacht GA, Willis KM. The technique of esophagectomy does not influence survival after resection of esophageal carcinoma. Proceedings of the 6th World Congress of the International Society for Diseases of the Esophagus 6:22, 1995. e-Pub 1995.
574. Jr PJ, Soysal J, Roth JA, Walsh GL, Nesbitt JC, Schrump DS. Results of esophagectomy for severe dysplasia in Barrett’s esophagus. Proceedings of the 6th World Congress of the International Society for Diseases of the Esophagus 6:168, 1995. e-Pub 1995.
575. Yung WK, Shi YX, Zhang WW, Roth JA, Steck PA. Growth suppression of human glioma cells by restoration of wild-type p53 gene utilizing an adenovirus vector. Proc Am Assoc Cancer Res 36:423, 1995. e-Pub 1995.
576. Clayman GL, El-Naggar AK, Roth JA, Zhang WW, Goepfert H, Taylor DL, Liu TJ. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Proc Am Assoc Cancer Res 36:423, 1995. e-Pub 1995.
577. Hamada K, Zhang W, Alemany R, Roth JA, Wolf J, Follen-Mitchell M. Growth inhibition of human cervical cancer cells by the recombinant adenovirus p53. Proc Am Assoc Cancer Res 36:437, 1995. e-Pub 1995.
578. Koura AN, Cusack J, Roth JA, Radinsky R, Ellis LM. Regulation of vascular endothelial growth factor (VEGF) by wild-type p53. Proc Am Assoc Cancer Res 36:88, 1995. e-Pub 1995.
579. Mukhopadhyay T, Roth JA. WAF1 gene expression does not correlate with the p53 status of the cell line. Proc Am Assoc Cancer Res 36:193, 1995. e-Pub 1995.
580. Srinivasan R, Maxwell SA, Roth JA. p53 conformational domain-binding proteins enhances p53 DNA-binding by interacting with consensus p53 binding sequences. Proc Am Assoc Cancer Res 36:193, 1995. e-Pub 1995.
581. Zhang WW, Alemany R, Wang J, Koch PE, Ordonez NG, Roth JA. Safety evaluation of Ad5CMV-p53 in vitro and in vivo. Proc J Cell Biochem 21A:430, 1995. e-Pub 1995.
582. Walsh GL, O'Conner M, Wong R, Milas M, Willis K, Nesbitt JC, Jr PJ, Roth JA. Is follow up of lung cancer patients following resection medically indicated and cost effective?. Ann Thorac Surg 48:134, 1995. e-Pub 1995.
583. Hamada K, Zhang WW, Alemany R, Roth JA, Wolf J, Follen-Mitchell M. Growth inhibition of human cervical cancer cells by the recombinant adenovirus-mediated transfer of a wild-type p53 gene. Soc Gynecol Oncologist:30, 1995. e-Pub 1995.
584. Jr PJ, Suell DA, Roth JA, McMurtrey MJ, Ryan MB, Walsh GL, Nesbitt JC, Schrump DS. A comparison of three techniques of esophagectomy for carcinoma of the intrathoracic oesophagus. International Conference on Biology 2:100, 1995. e-Pub 1995.
585. Roth JA. Gene replacement for cancer. Proc Am Assoc Cancer Res, 1995. e-Pub 1995.
586. Walsh GL, Morice RC, Putnam JB, Nesbitt JC, McMurtrey MJ, Ryan MB, Roth JA. Resection of lung cancer is justified in high-risk patients selected by exercise oxygen consumption. Lung Cancer 12:301, 1995. e-Pub 1995.
587. Spitz MR, Hsu TC, Wu X, Fueger JJ, Amos CI, Roth JA. Mutagen sensitivity as a biological marker of lung cancer risk in African Americans. Lung Cancer 13:81, 1995. e-Pub 1995.
588. Roth JA. Gene replacement strategies for lung cancer. Lung Cancer:12, 1995. e-Pub 1995.
589. Roth JA. Gene replacement strategies for prevention and treatment of aerodigestive tract cancers. General Motors Cancer Research Foundation Annual Conference, 1995. e-Pub 1995.
590. Roth JA, Nguyen D, Lawrence D, Kemp BL, Nesbitt JC, Putnam JB, Han J, Martin F, Hong WK, Komaki R, Yen N, Mukopadhyay T, Cai D, Carrasco CH, Dolormente M. Gene transfer of wild-type p53 in cancer patients with mutant p53 tumors. Cancer Gene Ther 2:335, 1995. e-Pub 1995.
591. Liu TJ, Taylor DL, Zhang WW, Roth JA, Goepfert H, Clayman GL. Developing a novel gene therapy for head and neck cancer. Proc J Cell Biochem 21A:425, 1995. e-Pub 1995.
592. Inoue F, Hamada K, Kataoka M, Akimaru Y, Horio Y, Oritz K, Roth JA. Growth inhibition of non-small cell lung cancer cells by a recombinant adenovirus-mediated transfer of p21 gene. Cancer Gene Ther 2(4):339, 1995. e-Pub 1995.
593. Hamada K, Zhang WW, Alemany R, Roth JA, Wolf J, Follen-Mitchell M. Gene therapy of cervical cancer by adenovirus-mediated p53 gene transfer. Proc J Cell Biochem 21A:421, 1995. e-Pub 1995.
594. Hamada K, Akimaru Y, Horio Y, Inoue F, Hittelman WN, Lotan R, Roth JA, Follen-Mitchell M. In vivo molecular therapy for human cervical cancer by a recombinant adenovirus containing a wild-type p53 gene. Cancer Gene Ther, 1995. e-Pub 1995.
595. Cusack JC, Zhang WW, Roth JA, Owen-Schaub LB. Reconstitution of Fas/APO-1 sensitivity following adenovirus-mediated transfer of wild-type p53. Proc J Cell Biochem 21A:390, 1995. e-Pub 1995.
596. Soysal O, Walsh GL, Nesbitt JC, McMurtrey MJ, Roth JA. Resection of sternal tumors: extent, reconstruction, and survival. Proc Ann Thorac Surg 11:42, 1994. e-Pub 1994.
597. Roth JA, Zhang WW, Fujiwara T, Grimm EA, Mukhopadhyay T. Gene replacement strategies for therapy and prevention of lung cancer. Japan Society for Cancer Therapy 32:2, 1994. e-Pub 1994.
598. Roth JA. Gene replacement strategies for therapy and prevention of lung cancer. 1994 Aspen Cancer Conference Workshop 9:66-67, 1994. e-Pub 1994.
599. Roth JA. Biology and management of stage I lung cancer. Lung Cancer:30, 1994. e-Pub 1994.
600. Roth JA. The biology of non-small cell lung cancer. Current Perspectives in the Treatment of Non-Small Cell Lung Cancer Symposium 11:243, 1994. e-Pub 1994.
601. Cai DW, Mukhopadhyay T, Roth JA. A novel ribozyme for modification of mutated p53 pre-mRNA in non-small cell lung cancer cell lines. Proc Am Assoc Cancer Res 35:610, 1994. e-Pub 1994.
602. Mukhopadhyay T, Cavender A, Branch C, Roth JA. Modulation of cytokeratin 8 and 18 gene expression in NSCLC cell lines after reduction of p53 protein by antisense RNA. Proc Am Assoc Cancer Res 36:610, 1994. e-Pub 1994.
603. Roth JA. Gene replacement strategies for therapy and prevention of lung cancer. Proc Am Assoc Cancer Res 35:692, 1994. e-Pub 1994.
604. Srinivasan R, Roth JA, Maxwell SA. Cellular proteins associate with the conformational domain of p53 and enhance its sequence-specific DNA-binding activity. Proc Am Assoc Cancer Res 35:180, 1994. e-Pub 1994.
605. Zhang WW, Maxwell SA, Koch PE, Johnson M, Roth JA. Adenovirus-mediated suppression of p53 in lytically infected cells. Proc Am Assoc Cancer Res 35:255, 1994. e-Pub 1994.
606. Roth JA, Fossella J, Komaki M, Ryan M, Putnam J, Lee J, Dhingra H, DeCaro L, Chassen M, McGavran M, Atkinson E, Hong W. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage III non-small cell lung cancer. Proc Am Soc Clin Oncol 35:692-693, 1994. e-Pub 1994.
607. Schneider PM, Casson AG, Garewal HS, Levin B, Hoelscher AH, Stewart JR, Roth JA. Mutation in the p53 tumor suppressor gene in Barrett’s esophagus is a marker for development of adenocarcinoma: results of an international multi-institutional prospective study. Proc Am Assoc Thorac Surg, 1994. e-Pub 1994.
608. Walsh G, Shin D, Komaki R, McMurtrey M, Hong W, Roth JA. An aggressive multimodality protocol does not improve survival in patients with malignant pleural mesothelioma (MPM). Proc Ann Surg Oncol 4:36, 1994. e-Pub 1994.
609. Ryan B, Glisson B, Putnam J, Roth JA. A prospective trial of neoadjuvant chemotherapy in superior sulcus carcinomas of the lung. Proc Ann Surg Oncol 68:182, 1994. e-Pub 1994.
610. Schrump DS, Zhang Y, Cai DW, Zhang WW, Roth JA. Viral delivery of gene constructs to lung cancer cells. 7th International Symposium on Cancer Research of the Foundation for Promotion of Cancer Research, 1994. e-Pub 1994.
611. Walsh GL, Morice R, Putnam JB, Nesbitt JC, McMurtrey MJ, Ryan MB, Reising JM, Natarjan G, Roth JA. An Aggressive Surgical Approach Is Justified in High-Risk Patients with Lung Cancer Identified by Exercise Oxygen Consumption Testing. Ann Thorac Surg 44:126, 1994. e-Pub 1994.
612. Cristiano RJ, Roth JA. Non-viral gene delivery systems for cancer treatment. Proc J Cell Biochem 21A:390, 1994. e-Pub 1994.
613. Roth JA, Johnson B. The biology of lung cancer. Lung Cancer 11:243, 1994. e-Pub 1994.
614. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB, Lee JS, Dhingra H, DeCaro L, Chasen M, McGavran M, Atkinson EN, Hong WK. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage III non-small cell lung cancer. Lung Cancer 7:180, 1994. e-Pub 1994.
615. Roth JA. Gene replacement strategies for the prevention and therapy of lung cancer. Lung Cancer 11:66-67, 1994. e-Pub 1994.
616. Roth JA. Modulation of oncogene and tumor suppressor gene expression for prevention and therapy of lung cancer. Lung Cancer 10:367-368, 1994. e-Pub 1994.
617. Maxwell SA, Roth JA. Binding of cellular proteins to the conformational domain of p53. Lung Cancer 10:364, 1994. e-Pub 1994.
618. Maxwell SA, Srinivasan, R, Roth JA. Cellular proteins modulate nonspecific and sequence-specific DNA binding of a conformational domain of p53. Proc J Cell Biochem, 1994. e-Pub 1994.
619. Cusack JC, Zhang, WW, Roth JA. High efficiency in vivo gene transduction following intralesional solid tumor injection of a recombinant adenovirus vector. Cancer Gene Ther, 1994. e-Pub 1994.
620. Roth JA. Gene replacement strategies for the prevention and therapy of lung cancer. Texas Division ACS - Excalibur: Day of Science Program, 1994. e-Pub 1994.
621. Owen-Schaub L, Zhang WW, Cusack J, Fujiwara T, Roth JA, Angelo LS. Regulation of Fas/APO-1 induced apoptosis in malignant cells. Symposium on Fundamental Cancer Res(47), 1994. e-Pub 1994.
622. Schneider PM, Holscher AH, Mizumoto S, Dittler HJ, Nekarda H, Becker K, Fink U, Bollschweiler E, Siewert JR, Roth JA. Involvement of p53 mutations in the pathogenesis of Barrett’s carcinoma. 4th International Polydisciplinary Congress A226:147, 1993. e-Pub 1993.
623. Zhang Y, Mukhopadhyay T, Georges R, Roth JA. Gene therapy approach of human lung cancer with retroviral vector-mediated transduction of K-ras antisense RNA. The Molecular Basis of Cancer:71, 1993. e-Pub 1993.
624. Zhang W, Roth JA. Propagation of recombinant p53 adenovirus and evaluation of its effect on human lung cancer cell lines. The Molecular Basis of Cancer:72, 1993. e-Pub 1993.
625. Cai DW, Mukhopadhyay T, Liu Y, Fujiwara T, Mountain CF, Roth JA. Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Proc Am Assoc Cancer Res 34:505, 1993. e-Pub 1993.
626. Casson AG, Manolopoulos B, Van Meyel D, Sorsdahl K, Troster M, Chambers A, Roth JA, Finley R, Inculet R. p53 gene mutations in Barrett’s epithelium and esophageal cancer. Proc Am Assoc Cancer Res 34:224, 1993. e-Pub 1993.
627. Fujiwara T, Grimm EA, Mukhopadhyay T, Cai D, Morris, DK, Roth JA. Retroviral-mediated transduction of p53 gene regulates TGF-alpha gene expression and secretion in a human glioblastoma cell line. Proc Am Assoc Cancer Res 34:449, 1993. e-Pub 1993.
628. Georges RN, Zhang Y, Mukhopadhyay T, Roth JA. In vivo retroviral transduction of antisense K-ras suppresses tumor growth in an orthotopic lung cancer model. Proc Am Assoc Cancer Res 34:336, 1993. e-Pub 1993.
629. Mukhopadhyay T, Roth JA. p53 regulates the transcription of human cytokeratin 8 gene in human lung cancer cell lines. Proc Am Assoc Cancer Res 34:509, 1993. e-Pub 1993.
630. Roth JA. Use of retroviral vectors for the delivery of antisense constructs. Proc Am Assoc Cancer Res 34:594-595, 1993. e-Pub 1993.
631. Schneider PM, Stoehr N, Boehm J, Manning J, Fink U, Praeuer HW, Roth JA. Differential transcriptional and posttranscriptional regulation of neu gene expression in all major histological types of human lung cancer. Proc Am Assoc Cancer Res 34:532, 1993. e-Pub 1993.
632. Srinivasin R, Maxwell SA, Roth JA. Binding of cellular proteins to a conformational domain of p53. Proc Am Assoc Cancer Res 34:535, 1993. e-Pub 1993.
633. Casson AG, Sorsdahl K, Manolopoulos B, Troster M, Chambers A, Roth JA. Clinical implications of p53 gene mutation and expression in the progression of Barrett’s epithelium to invasive esophageal cancer. Digestive Disease Weekly A-264, 1993. e-Pub 1993.
634. Georges RN, Zhang Y, Mukhopadhyay T, Roth JA. Suppression of tumor growth in the lungs of nude mice by retroviral transduction of antisense K-ras. The Society of Black Academic Surgeons (SBAS) 3:15, 1993. e-Pub 1993.
635. Fujiwara T, Grimm EA, Cai DW, Mukhopadhyay T, Roth JA. Retrovirus-mediated transfer of wild-type p53 gene inhibits TGF-alpha-dependent growth of human lung cancer spheroids. Proc J Cell Biochem 17E:196, 1993. e-Pub 1993.
636. Roussel E, Gingras MC, Grimm EA, Roth JA. Cell adhesion molecule expression and lymphokine gene activation in tumor infiltrating lymphocytes from lung adenocarcinomas. Proc J Cell Biochem 17A:335, 1993. e-Pub 1993.
637. Jr PJ, Suell DM, McMurtrey MJ, Ryan B, Walsh G, Roth JA. Esophagectomy: comparison of three techniques from one institution with a residency training program. Proc Ann Thorac Surg A34:104, 1993. e-Pub 1993.
638. Gingras MC, Roussel E, Grimm EA, Bruner JM, Moser RP, Roth JA. Expression of cell adhesion molecules and lymphokine gene activation in glioblastoma infiltrating lymphocytes. Proc J Cell Biochem 17A:333, 1993. e-Pub 1993.
639. Roth JA. Molecular strategies for the prevention and therapy of lung cancer. Lung Cancer:23-24, 1993. e-Pub 1993.
640. Roth JA. New insights into selecting patients likely to benefit from resection of pulmonary metastases. Lung Cancer:50-51, 1993. e-Pub 1993.
641. Mukhopadhyay T, Roth JA. p53 as transactivator in human cytokeratin 8 gene expression and its effect on cellular physiology. Proc J Cell Biochem 17E:197, 1993. e-Pub 1993.
642. Zhang Y, Mukhopadhyay T, Georges R, Roth JA. Retroviral vector-mediated antisense gene delivery: a novel approach for gene modulation. 1993 Science, Engineering & Technology Seminars (SETS) 1:4-5, 1993. e-Pub 1993.
643. Cai DW, Mukhopadhyay T, Roth JA. A novel ribozyme for modification of mutated p53 pre-mrna in non-small cell lung cancer cell lines. 3rd Antisense Workshop, 1993. e-Pub 1993.
644. Roussel E, Gingras MC, Ro JY, Branch C, Grimm EA, Roth JA. Lung tumor aberrancy in cell adhesion molecule expression correlates with poor activation of tumor infiltrating lymphocyte-T. MDACC Symposium on Fundamental Cancer Res: Immunobiology of Cancer Cellular and Moleular Mechanisms A47:297, 1992. e-Pub 1992.
645. Zhang Y, Mukhopadhyay T, Donehower LA, Georges RN, Roth JA. Retrovirus-vector-mediated transduction of Ki-ras antisense RNA into human lung cancer cell inhibits expression of the malignant phenotype. Proc Gene Ther, 1992. e-Pub 1992.
646. Ajani J, Roth JA, Putnam BJ, Rodman H, Ryan B, Walsh G, Lynch P, Gould P. Feasibility of five preoperative chemotherapy courses for resectable adenocarcinoma of the esophagus and Ge junction. Proc Am Assoc Cancer Res 33:218, 1992. e-Pub 1992.
647. Roussel E, Gingras MC, Grimm EA, McIntyre BW, Moser RP, Roth JA. Unique expression pattern of cell-adhesion molecules defines the tumor-infiltrating-T lymphocytes of primary tumors. Proc Am Assoc Cancer Res 33:297, 1992. e-Pub 1992.
648. Schneider PM, Spies M, Stoenr M, Boenm J, Fink U, Mung MC, Praeuer MW, Roth JA. Transcriptional and post-transcriptional modification of neu gene expression in small cell (SCLC) and non-small cell (NSCLC) lung cancer in vitro and in vivo. Proc Am Assoc Cancer Res 33:374, 1992. e-Pub 1992.
649. Kim Y, Ajani J, El-Naggar A, Roth JA, Lynch P, Ota D. Potentially resectable upper gastrointestinal adenocarcinomas (PRUGCs): evaluation of prognostic factors. Proc Am Soc Clin Oncol 11:181, 1992. e-Pub 1992.
650. Ajani JA, Ota DM, Roth JA. Systemic chemotherapy for potentially resectable adenocarcinoma of the esophagus and gastroesophageal junction. Interdisciplinary World Congress on Antimicrobial and Anticancer Drugs, 1992. e-Pub 1992.
651. Komaki R, Glisson BS, Shin D, Lee JS, Fossella FV, Oswald MJ, Greenberg J, Hong WK, Roth JA, Peter LJ. Comparison of treatment’s results between interdigitating and simultaneous chemotherapy and radiotherapy for limited small cell lung cancer. 2nd IASLC Workshop on Combine Radiotherapy and Chemotherapy Modalities in Lung Cancer, 1992. e-Pub 1992.
652. Jr PJ, Macris MP, Roth JA. Extended resection of pulmonary metastases: Is the risk justified?. Proc Ann Thorac Surg 90, 1992. e-Pub 1992.
653. Mukhopadhyay T, Cavender A, Roth JA. Antisense p53 RNA reduces the tumor suppressor function in human lung cancer cell lines carrying wild type or mutated p53 gene. Proc J Cell Biochem, 1992. e-Pub 1992.
654. Maxwell SA, Roth JA. Retinoic acid-induced changes in the expression of retinoblastoma and p53 proteins in non-small cell lung carcinoma lines. Proc J Cell Biochem, 1992. e-Pub 1992.
655. Roth JA. Tumor biology of lung cancer. American College of Chest Physicians, 1992. e-Pub 1992.
656. Roth JA. Therapy for stage I and stage II non-small cell lung cancer. American College of Chest Physicians, 1992. e-Pub 1992.
657. Macris MP, Walsh GL, Nesbitt JC, Roth JA, Jr PJ. Video-assisted thoracoscopy in thoracic surgical oncology. Proc Ann Thorac Surg, 1992. e-Pub 1992.
658. Lanza LA, Natarajan G, Roth JA, Jr PJ. Long-term survival following resection of pulmonary metastases from cancer of the breast. Southern Thoracic Surgical Association, 38th Annual Meeting A31:84, 1991. e-Pub 1991.
659. Roth JA. Molecular and cellular biology of lung cancer. Radiation Research: A Twentieth-Century Perspective 1:12, 1991. e-Pub 1991.
660. Yang S, Branch C, Grimm EA, Roth JA. Low dose OKT3 prior to IL-2 and TNF-alpha induces and enhances activation of cytotoxic lymphocytes in vivo. Proc Am Assoc Cancer Res 32:249, 1991. e-Pub 1991.
661. Yang S, Harris B, Grimm E, Hong W, Roth JA. Combination immunotherapy using low-dose OKT3, IL-2 and TNF in patients with advanced lung cancer. Proc Am Soc Clin Oncol 10:215, 1991. e-Pub 1991.
662. Ajani J, Roth JA, Ryan B, Jr PJ, Pazdur R, Faintuch J, Dumas P, Levin B, McMurtrey M, Gutterman J. High dose chemotherapy with GM-CSF for resectable adenocarcinoma of the esophagus. Proc Am Soc Clin Oncol 10:151, 1991. e-Pub 1991.
663. Schneider PM, Spies M, Boehm J, Praeuer HW, Hung MC, Fink U, Hoefler H, Siewert JR, Roth JA. Comparison of neu (c-erbB-2) mRNA and protein (p185) expression in small cell (SCLC) and non-small cell (NSCLC) lung cancer. Proc Am Assoc Cancer Res 32:290, 1991. e-Pub 1991.
664. Putnam EA, Gallick GE, Steck PA, Yen N, Fang K, Roth JA. Mechanisms of autocrine growth stimulation for non-small cell lung cancer (NSCLC) cells by TGF-alpha and the EGF receptor (EGF-R). Proc Am Assoc Cancer Res 32:43, 1991. e-Pub 1991.
665. Mukhopadhyay T, Cavender AC, Roth JA. Overexpression of wild-type p53 (wtp53) gene in non-small cell lung cancer (NSCLC) cells carrying normal p53 allele does not alter the malignant phenotype. Proc Am Assoc Cancer Res 32:303, 1991. e-Pub 1991.
666. Maxwell SA, Mukhopadhyay T, Cavender A, Johnson M, Roth JA. Changes in retinoblastoma expression correlate with retinoic acid-induced increase in proliferation of non-small cell line H460. Proc Am Assoc Cancer Res 32:301, 1991. e-Pub 1991.
667. Lazenby AW, Owen-Schaub LB, Grimm EA, Roth JA. Interleukin-1 coregulates TNF secretion and TNF-R expression for peripheral blood lymphocytes (PBL). Proc Am Assoc Cancer Res 10:266, 1991. e-Pub 1991.
668. Fossella FV, Ryan B, Dhingra H, Lee JS, Jr PJ, Murphy WK, Hong WK, Roth JA. Interim report of a prospective randomized trial of neoadjuvant chemotherapy plus surgery vs. surgery alone for IIIa non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 10:240, 1991. e-Pub 1991.
669. Heyne K, Lee J, Glisson B, Roth JA, Hong WK. Small cell lung cancer (SCLC): analysis of long-term survivors (LTS). Proc Am Soc Clin Oncol 10:245, 1991. e-Pub 1991.
670. Fang K, Li L, Jansen J, Fidler I, Roth JA. Brain metastatic variants of human lung cancer cells acquire independence from autocrine growth stimulation by TGF-alpha. Proc Am Assoc Cancer Res 32:51, 1991. e-Pub 1991.
671. Casson AG, Mukhopadhyay T, Cleary KR, Ro J, Roth JA. Evaluation of single-strand conformation polymorphism analysis for screening human lung cancer cell lines and esophageal tumors for p53 point-mutations. Proc Am Assoc Cancer Res 32:305, 1991. e-Pub 1991.
672. Casson AG, Mukhopadhyay T, Cleary K, Ro J, Levin B, Roth JA. Mutation of the p53 oncogene in Barrett’s epithelium and carcinoma of the esophagus. Proc Am Soc Clin Oncol 10:78, 1991. e-Pub 1991.
673. Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Cafferty SA, Roth JA. Oncogene activation in esophageal cancer. Proc Am Assoc Thorac Surg, 1991. e-Pub 1991.
674. Yang SC, Grimm EA, Roth JA. Immunomodulatory therapy of lung cancer. Proc J Cell Biochem 15F:18, 1991. e-Pub 1991.
675. Roth JA, Mukhopadhyay T, Yen N, Putnam E, Casson A. Molecular approaches to lung cancer therapy. Proc J Cell Biochem 15F:4, 1991. e-Pub 1991.
676. Mukhopadhyay T, Cavender AC, Branch CD, Roth JA. Expression and regulation of wild type p53 gene (Wtp53) in human non-small cell lung cancer (NSCLC) cell lines carrying normal or mutated p53 gene. Proc J Cell Biochem 15F:22, 1991. e-Pub 1991.
677. Maxwell SA, Mukhopadhyay T, Cavender A, Johnson M, Roth JA. Effect of retinoic acid on growth of non-small cell lung cancer cell lines and expression of the retinoblastoma protein. Proc J Cell Biochem 15F:25, 1991. e-Pub 1991.
678. Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Roth JA. Point-mutation of p53, BUT NOT ras, detected in Barrett’s epithelium, squamous cell and adenocarcinoma of the esophagus. Proc J Cell Biochem 15F:21, 1991. e-Pub 1991.
679. Casson AG, Mukhopadhyay T, Cleary K, Ro J, Levin B, Roth JA. Mutation of the p53 gene detected in Barrett’s epithelium, squamous cell and adenocarcinoma of the esophagus. Clin Invest Med 14:A42, 1991. e-Pub 1991.
680. Putnam EA, Gallick GE, Steck PA, Yen N, Roth JA. Autocrine growth regulation of non-small cell lung carcinomas by transforming growth factor-alpha and the epidermal growth factor receptor. Symposium on Fundamental Cancer Research A59:40, 1990. e-Pub 1990.
681. Mukhopadhyay T, Cavender AC, Fang K, Roth JA. Retinotic acid pretreatment enhances tumorigenicity of human NSCLC cells and increased the level of epidermal growth factor receptor on their surface. Symposium on Fundamental Cancer Research A66:99, 1990. e-Pub 1990.
682. Maxwell SA, Mukhopadhyay T, Cavender A, Johnson M, Roth JA. Effect of retinotic acid on the expression of tumor suppressor gene products in lung cancer cells. Symp on Fundamental Cancer Res A67:97, 1990. e-Pub 1990.
683. Fang K, Li L, Jansen J, Fidler I, Roth JA. Highly metastatic variants of human lung cells acquire independence from autocrine growth stimulation by transforming growth factor-a. Symposium on Fundamental Cancer Research A69:84, 1990. e-Pub 1990.
684. Pogrebniak HW, Roth JA, Steinberg SM, Rosenberg SA, Pass HI. Re-operative pulmonary resection in patients with metastatic soft tissue sarcoma. Southern Thoracic Surgical Association Meeting 52:197-203, 1990. e-Pub 1990.
685. Gorenstein LA, Putnam JB, Balch CM, Roth JA. Improved survival following resection of pulmonary metastases from malignant melanoma. Southern Thoracic Surgical Association Meeting 16:50, 1990. e-Pub 1990.
686. Morice RC, Peters EJ, Ryan MB, Putnam JB, Ali MK, Roth JA. Exercise testing in the evaluation of patients at high risk for lung resection. American College of Chest Physicians 56th Annual Scientific Assembly 98(2):54S, 1990. e-Pub 1990.
687. Yang SC, Grimm EA, Roth JA. Effects of low dose OKT3 induction on the anti-tumor immune response in cancer patients receiving interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF). American College of Surgeons, 1990. e-Pub 1990.
688. Roth JA, Ajani J. Multidisciplinary therapy for esophageal cancer. J Cancer Res Clin Oncol 116:800, 1990. e-Pub 1990.
689. Schneider PM, Praeuer HW, Fink U, M-C H, Siewert JR, Roth JA. Variation of neu (cerbB2) gene expression in small cell lung cancer (SCLC) compared to non-small cell lung cancer (NSCLC). J Cancer Res Clin Oncol 116:112, 1990. e-Pub 1990.
690. Mukhopadhyay T, Cavender A, Tainsky M, Roth JA. Antisense K-ras RNA causes partial reversion of transformed phenotype in a human lung cancer cell line containing a spontaneous K-ras mutation. 6th Annual Meeting on Oncogenes A60:339, 1990. e-Pub 1990.
691. Putnam EA, Roth JA. Analysis of the effects of suramin on non-small cell lung carcinoma cell lines. First Annual Meeting on the Molecular Basis of Human Cancer A59:40, 1990. e-Pub 1990.
692. Pass HI, Evans S, Matthews WA, Perry R, Roth JA, Smith P. In vitro, in vivo phototherapy of transfected human lung cancer. Proc Am Assoc Thorac Surg F8:58, 1990. e-Pub 1990.
693. Yang SC, Grimm EA, Roth JA. Anti-CD3 activation prior to interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF) enhances immunodulatory activity in vivo. Proc Am Assoc Cancer Res 31:237, 1990. e-Pub 1990.
694. Yang S, Grimm E, Hong W, Parkinson D, Roth JA. Immunologic effects of combined immunotherapy with OKT3, interleukin-2 (IL-2) tumor necrosis factor-? (TNF) in patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 9:248, 1990. e-Pub 1990.
695. Holoye P, Ellerbroek N, Komaki R, Roth JA, McMurtrey M, Ryan B, DeCaro L, Glisson B, Pang A, Hong W. Sequential chemotherapy (Ct), surgery (S), alternating Ct and twice daily radiotherapy (Xrt) in limited disease (Ld), small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 9:241, 1990. e-Pub 1990.
696. Yang SC, Owen-Schaub L, Mendiguren-Rodriguez A, Grimm EA, Hong WK, Roth JA. Combination immunotherapy for non-small cell lung cancer: Results using interleukin-2 and tumor necrosis factor-alpha. Proc Am Assoc Thorac Surg, 1990. e-Pub 1990.
697. Schneider PM, Praeuer HW, Fink U, M-C H, Siewert JR, Roth JA. Comparison of neu (c-erbB2) gene expression in small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and normal lung. Proc Am Assoc Cancer Res 31:312, 1990. e-Pub 1990.
698. Mukhopadhyay T, Cavender A, Tainsky M, Roth JA. Expression of antisense K-ras message in a human lung cancer cell line with a spontaneous activated K-ras oncogene alters the transformed phenotype. Proc Am Assoc Cancer Res 31:304, 1990. e-Pub 1990.
699. Lazenby AW, Roth JA, Yang SC, Grimm EA. Interleukin-1 (IL-1) nonapeptide (B163-171), VQGEESNDK, synergizes with interleukin-2 (IL-2) in the generation of lymphokine activated killer cell activity (LAK). Proc Am Assoc Cancer Res 31:241, 1990. e-Pub 1990.
700. Fang K, Jansen JG, Roth JA. Purification and characterization of tumor stasis factor. Proc Am Assoc Cancer Res 31:58, 1990. e-Pub 1990.
701. Ajani J, Roth JA, Ryan B, Jr PJ, Pazdur JR, Faintuch J, Jackson D, Rodriguez A, Levin B, DeCaro L, McMurtrey M, Gutterman J. Feasibility and toxicities of Gm-csf given with high-dose chemotherapy for resectable adenocarcinoma of the esophagus. Proc Am Soc Clin Oncol 9:118, 1990. e-Pub 1990.
702. Dhingra H, DeCaro L, Roth J, Hong W. Possible down staging of stage III(A) non-small cell lung cancer (NSCLC) in a randomized trial of surgery neoadjuvant chemotherapy (NA CHEMO) with cyclophosphamide (C), etopside (E), and cisplatin (P). Proc Am Soc Clin Oncol 9:242, 1990. e-Pub 1990.
703. Lazenby AW, Owen-Schaub LB, Branch C, Carinhaus J, Grimm EA, Roth JA. Interleukin-1 synergizes with interleukin-2 in the up-regulation of tumor necrosis factor receptor expression. Symp on Fundamental Cancer Res A67:94, 1990. e-Pub 1990.
704. Yang SC, Owen-Schaub L, Mendiguren-Rodriguez A, Grimm EA, Hong WK, Roth JA. Combination immunotherapy for non-small-cell lung cancer: Results using interleukin-2 (IL-2) and tumor necrosis factor-alpha. Resp Dis Digest 7:20-21, 1990. e-Pub 1990.
705. Yang SC, Grimm EA, Roth JA. Alternative pathways for generating cytotoxic lymphocytes in vivo using anti-CD3, interleukin-2 (IL-2) and tumor necrosis factor-alpha. Proc J Cell Biochem 14B:41, 1990. e-Pub 1990.
706. Yang SC, Grimm EA, Roth JA. Immunodulatory effects of combination immunotherapy with low-dose interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF) in patients with non-small cell lung cancer (NSCLC). J Cell Biochem 14B:111, 1990. e-Pub 1990.
707. Jr PJ, Roth JA. Prognostic indications in patients with pulmonary 92% metastases. Oncology Digest Series 6(5):261-6, 1990. e-Pub 1990.
708. Jr PJ, Lammermeier DE, McMurtrey MJ, Roth JA. Predicted postoperative pulmonary function correlates with operative mortality and long-term survival following pneumonectomy in patients with primary lung carcinoma. Southern Thoracic Surgical Association, 1989. e-Pub 1989.
709. Roth JA, Ajani J, McMurtrey M, Ryan MB, Natarajan G, Mendiguren-Rodriguez A, Faintuch J, Levin B. Pilot study of pre- and postoperative combination chemotherapy for resectable adenocarcinoma of the esophagus. 4th World Congress of the International Society for Diseases of the Esophagus, 1989. e-Pub 1989.
710. Yang SC, Grimm EA, Roth JA. Successful combination immunotherapy of murine pulmonary metastases using anti-CD3, interleukin-2 and tumor necrosis factor-alpha. Society of Surgical Oncology, 1989. e-Pub 1989.
711. Yang S, Licciardello J, Owen-Schaub L, Grimm E, Hong W, Roth JA. Evaluation of combination low dose tumor necrosis factor-alpha (TNF) and interleukin-2 (IL-2) for advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 8:226, 1989. e-Pub 1989.
712. Ajani J, Roth JA, Ryan B, McMurtrey M, DeCaro L, Rich T, Abbruzzese J, Jackson D, Rodriguez A, Faintuch J. Pre- and postoperative chemotherapy for operable adenocarcinoma of the esophagus (ACE). Proc Am Soc Clin Oncol 8:121, 1989. e-Pub 1989.
713. Yang S, Rodriguez MA, Owen-Schaub L, Grimm E, Hong W, Roth JA. Combination low dose tumor necrosis factor-alpha (TNF) and interleukin-2 (II-2) for non-small cell lung cancer: clinical and in vitro effects. American College of Chest Physicians 96:118S, 1989. e-Pub 1989.
714. Schneider PM, Hung MC, Chiocca SM, Roth JA. Alterations in epidermal growth factor receptor (EGFR) and new gene expression in human non-small cell lung cancer (NSCLC). Proc Am Assoc Cancer Res 30:441, 1989. e-Pub 1989.
715. Perry RR, Rosenberg SA, Venzon D, Roth JA, Pass HI. Survival after surgical resection for high-grade chest wall sarcomas. Ann Thorac Surg A39:46, 1989. e-Pub 1989.
716. Lammermeier DE, Jr PJ, McMurtrey MJ, Roth JA. Predicted postoperative pulmonary function correlates with operative mortality and long-term survival following pneumonectomy in patients with primary lung carcinoma. Ann Thorac Surg A27:72, 1989. e-Pub 1989.
717. Fang KL, Li YL, Roth JA. Purification and characterization of a human tumor stasis factor. Proc Am Assoc Cancer Res 30:81, 1989. e-Pub 1989.
718. Slater JD, Ellerbroek NA, Barkley HT, McMurtrey M, Mountain C, Oswald MJ, Roth JA, Peters LJ. Radiation therapy following resection of non-small cell bronchogenic carcinoma. American Society for Therapeutic Radiology and Oncology, 1988. e-Pub 1988.
719. Ajani J, McMurtrey M, Rich T, Roth JA, Blackburn R, DeCaro L, Faintuch J, Levin B, Ryan B, Mountain C. Prolonged chemotherapy (CT) of locally advanced squamous carcinoma of the esophagus (SCCE). 2nd International Congress on Neo-adjuvant Chemotherapy, 1988. e-Pub 1988.
720. Yang SC, Owen-Schaub L, Grimm EA, Roth JA. In vitro cytolysis of human primary lung tumors by cytotoxic lymphoyctes: synergistic effects with interleukin-2, tumor necrosis factor-alpha, and OKT3. Proc Am Assoc Cancer Res 29:403, 1988. e-Pub 1988.
721. Schneider PM, M-C H, Tainsky MA, Ames RS, Roth JA. Epidermal growth factor receptor and neu gene abnormalities in human non-small cell lung cancer. Proc Am Assoc Cancer Res 29:450, 1988. e-Pub 1988.
722. Ames RS, North SN, Nicolson GL, Roth JA. Expression of differentiation antigen gp74 by oncogene transformed rat cells and relationship to spontaneous metastatic potential. Proc Am Assoc Cancer Res 29:444, 1988. e-Pub 1988.
723. Pogrebniak HW, Stovroff M, Roth JA, Pass HI. Melanoma metastasectomy results of a 16-year experience. Southern Thoracic Surgical Association, 1987. e-Pub 1987.
724. Roth JA, Lanza LA, Ames RS, Fry K, Becker D, Lee H. Immunotoxin 5-2D9 can mediate successful therapy of pulmonary metastases in vivo with potentiation by systemic monensin. 2nd International Conference on Monoclonal Antibody Immunoconjugates for Cancer, 1987. e-Pub 1987.
725. Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC, Steinberg S. Neoadjuvant chemotherapy with cisplatinum, vindesine and bleomycin (DVB) for epidermoid carcinoma of the esophagus. Proc Am Soc Clin Oncol 6:75, 1987. e-Pub 1987.
726. Roth JA, Lanza LA, Ames RS, Fry K, Becker D, Lee H. Therapeutic efficacy of ricin-A-chain immunotoxin 45-2D9-RTA for established pulmonary metastases. Proc Am Assoc Clin Res 28:391, 1987. e-Pub 1987.
727. Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC, Steinberg S. Randomized clinical trial of neoadjuvant chemotherapy with cisplatin, vindesine and bleomycin (DVB) for epidermoid carcinoma of the esophagus. Proc Am Assoc Thorac Surg 67:1158, 1987. e-Pub 1987.
728. Fang KL, Roth JA. Isolation and characterization of tumor stasis factor. Proc Am Assoc Cancer Res, 1986. e-Pub 1986.
729. Rizzoni W, Pass HI, Wesley M, Rosenberg SA, Roth JA. Reoperative pulmonary metastasectomies in patients with adult soft tissue sarcomas. Society of Surgical Oncology, 1986. e-Pub 1986.
730. Reynolds JC, Carrasquillo JA, Lora ME, Sugarbaker P, Abrams P, Foon K, Roth JA, Colcher D, Schlom J, Larson SM. Anti-murine antibodies in patients undergoing immunoscintography or therapy with radiolabeled antibodie. International Conference on Monoclonal Antibody Immunoconjugates for Cancer 79, 1986. e-Pub 1986.
731. Miser J, Kinsella T, Tsokes M, Triche T, Horvath C, Roth JA, Pass H, Forquer R. High response rate of recurrent childhood tumors to etoposide (VP16), Ifosphamide (IFOS) and mesra (Mes) unprotection. Proc Am Assoc Cancer Res 5:206, 1986. e-Pub 1986.
732. Ames RS, Pass HI, Lee HM, Scannon PJ, Roth JA. Immunodiagnostic and therapeutic potential of a monoclonal antibody to a c-Ha-ras linked human tumor-associated antigen. Proc J Cell Biochem 10A:31, 1986. e-Pub 1986.
733. Ames RS, Roth JA. Monoclonal antibody 45-2D9 recognizes a cell surface epitope common to a c-Ha-ras transfected NIH 3T3 cell line and human tumors. FASEB J 45:1133, 1986. e-Pub 1986.
734. Roth JA, Pass HI, Wesley MN, White D, Putnam JB, Seipp C. Comparison of median sternotomy and thoracotomy for resection of pulmonary metastases in patients with adult soft tissue sarcomas. Southern Thoracic Surgical Association, 1985. e-Pub 1985.
735. Pass HI, Rosenberg SA, Baker AR, Miser J, Wesley M, Roth JA. Chest wall resection for primary, locally recurrent, and metastatic sarcomas. Society of Surgical Oncology, 1985. e-Pub 1985.
736. Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC, Wesley R. Randomized trial of Pre- and Post-operative Cisplantin, Vindesine, and Bleomycin Chemotherapy in Epidermoid Carcinoma of the esophagus. University of Tokyo Press, Editor, Joji Ishigami, Proc 14th Intl Congress of Chemotherapy 1158, 1985. e-Pub 1985.
737. Roth JA, Ames RS, Restrepo C, Pass HI, Scannon PJ, Lee HM. Cells transformed by a human oncogene (c-Ha-ras) and human tumors express a common cell surface antigen. Proc Am Assoc Cancer Res 26:294, 1985. e-Pub 1985.
738. Roth JA, Ames RS, Restrepo C, Aaronson S, Srivastava S, Scuderi P, Westin E. Detection of new cell surface determinants on cells transformed by human oncogenes. Proc J Cell Biochem 9A:90, 1985. e-Pub 1985.
739. Roth JA, Ames RS, Restrepo C, Scuderi P, Scannon PJ, Lee HM. Human tumor antigen expression is induced on murine 3T3 cells following transformation by human oncogenes. FASEB J A22:550, 1985. e-Pub 1985.
740. Leong SPL, Noguchi PD, Cunningham RE, Ames RS, Roth JA. Expression of a membrane antigen associated with transformation by a human oncogene (c-Ha-ras) is cell cycle dependent. Proc Am Assoc Cancer Res 26:264, 1985. e-Pub 1985.
741. Grimm EA, Roth JA. Purified rIL-2 causes the differentiation of null cells into killer lymphocytes. Proc J Cell Biochem 9A:108, 1985. e-Pub 1985.
742. Roth JA, Putnam, JB, Wesley MN, Rosenberg SA. Differing determinants of prognosis following resection of pulmonary metastases from osteogenic and soft tissue sarcoma patients. Society of Surgical Oncology, 1984. e-Pub 1984.
743. Roth JA. Cell surface glycoprotein associated with oncogene transformation. UCLA Symposium on Molecular and Cellular Biology, Regulation of the Immune System, 1984. e-Pub 1984.
744. Potter D, Pass H, Shelhamer J, Macher A, Ognibene F, Fauci A, Longo D, Masur H, Roth JA. Diagnostic efficiency of open lung biopsy in the AIDS patient. American College of Chest Physicians 86:330, 1984. e-Pub 1984.
745. Pass HI, Dwyer A, Makuch R, Roth JA. Nodule analysis in metastatic sarcoma: superiority of CAT-scans over conventional linear tomography. American College of Chest Physicians 86:304, 1984. e-Pub 1984.
746. Roth JA, Scuderi P, Westin E, Restrepo C, Gallo RC. Production of a monoclonal antibody recognizing a cell surface glycoprotein associated with transformation by a human oncogene. Proc Am Assoc Cancer Res 25:250, 1984. e-Pub 1984.
747. Roth JA, Scuderi P, Westin E, Gallo R. A novel approach to production of anti-tumor monoclonal antibodies: antibody to a cell surface glycoprotein associated with transformation by a human oncogene. Proc J Cell Biochem 8A:149, 1984. e-Pub 1984.
748. Jr PJ, Roth JA. Characterization of a tumor-derived immunosuppressive factor from murine melanoma: identification, characterization, and modulation of immunization and tumor growth in vivo. Proc Am Assoc Cancer Res 25:230, 1984. e-Pub 1984.
749. Funkhouser WK, Neckers LM, Ames RS, Carney DN, Trepel JB, Roth JA. Induction of tumor cell cytostasis by polypeptides isolated from human tumor cells. Proc Am Assoc Cancer Res 25:34, 1984. e-Pub 1984.
750. Roth JA, Scuderi P, Baldwin RW. Common antigens expressed by human primary and metastatic osteogenic sarcomas detected by monoclonal antibodies. 5th International Congress of Immunology, 1983. e-Pub 1983.
751. Jr PJ, Roth JA, Wesley MN, Johnston MR, Rosenberg SA. Analysis of prognostic factors in patients undergoing resection of pulmonary metastases from soft tissue sarcomas. Year Book of Cancer:201-203, 1983. e-Pub 1983.
752. Roth JA, Davidson DD, Ames RS, Schneider PD. Tumor stasis factor (TSF): A possible mechanism for the regulation of tumor cell proliferation. Association for Academic Surgery, 1982. e-Pub 1982.
753. Roth JA, Osborne BA. Detection of an immunosuppressive immunoregulatory factor in the sera of sarcoma patients by enzyme-linked immuno-assay and correlation with clinical course surgical forum. American College of Surgeons, 1982. e-Pub 1982.
754. Roth JA, Grimm EA, Ames RS. Suppression of adherent cell function by human tumor-derived immunoregulatory factors (IRF). 9th International Research Congress, 1982. e-Pub 1982.
755. Roussel E, Gingras MC, McIntyre BW, Grimm EA, Roth JA. Infammatory response in primary lung tumor is characterized by a unique pattern of til and lymph node infiltrating-T-cel expression of cell-adhesion molecules and lymphokine gene activation. Proc J Cell Biochem, 1982. e-Pub 1982.
756. Roth JA, Ames RS. Shared antigens on paired primary and metastatic human sarcomas detected by autologous humoral immune responses. Proc Am Assoc Cancer Res 23:276, 1982. e-Pub 1982.
757. Jr PJ, Roth JA. Identification and characterization of a murine immunosuppressive factor from a UV-induced melanoma k-1735. FASEB J 41:818, 1982. e-Pub 1982.
758. Davidson DD, Sugarbaker PA, Roth JA. Inhibition of murine mixed lymphocyte reaction (MLR) and cell-mediated cytotoxicity (CMC) by extracts of fresh human tumor. FASEB J 41:818, 1982. e-Pub 1982.
759. Roth JA. Humoral immune responses to human primary and metastatic sarcomas detected by an enzyme-linked immunoabsorbant solid-phase assay. Surgical Forum, American College of Surgeons, 1981. e-Pub 1981.
760. Roth JA, Grimm E, Ames R, Trahan E. Characteristics of immunoregulatory factors extracted from histological distinct tumors. Proc Am Assoc Cancer Res 22:318, 1981. e-Pub 1981.
761. Roth JA, Grimm EA, Gupta RK, Sugarbaker PH, Ames R. Suppression of lymphocyte proliferative and cytotoxic responses by human tumor-associated immunoregulatory factors. Immunobiology 159:190, 1981. e-Pub 1981.
762. Roth JA, Grimm EA, Gupta RK, Ames R, Trahan E. Presence of immunoregulatory factors in extracts from several histologically distinct human malignancies. FASEB J 40:1089, 1981. e-Pub 1981.
763. Roth JA, Grimm EA, Gupta RK, Morton DL. Characterization and purification of an immunosuppressive factor in extracts of lung carcinoma. 4th International Congress of Immunology, 1980. e-Pub 1980.
764. Roth JA, Grimm EA, Gupta RK, Morton DL. Characterization of an immunoregulatory factor in extracts of lung carcinoma. National Student Research Forum, 1980. e-Pub 1980.
765. Roth JA, Grimm E, Gupta RK, Morton DL, Eilber FR. Purification of an immunoregulatory factor in extracts of lung carcinoma. Proc Am Assoc Cancer Res 21:222, 1980. e-Pub 1980.
766. Roth JA. In vitro tests of human tumor immunity. National Cancer Institute, 1979. e-Pub 1979.
767. Roth JA, Cudingnan R, Scott CR. Use of activated clotting time to monitor heparin during cardiac surgery. American College of Surgeons, Southern CA Chapter, 1978. e-Pub 1978.
768. Roth JA, Chee D, Morton DL, Holmes EC. Inhibition of concanaval A-mediated lymphocyte stimulation by extracts of lung carcinomas. Proc Am Assoc Cancer Res 19:135, 1978. e-Pub 1978.
769. Roth JA. Effect of adriamycin and high-dose methotrexate chemotherapy on in vivo and in vitro cell-mediated immunity in cancer patients. Society of Surgical Oncology, 1977. e-Pub 1977.
770. Roth JA, Zuckerbraun L, Cohn D. Lymphosarcoma presenting as a parotid mass. American College of Surgeons, Southern CA Chapter, 1977. e-Pub 1977.
771. Roth JA, Chee DO, Morton DL, Holmes EC. In vitro lymphocyte stimulation by melanoma-associated antigens derived from fresh tumors and tissue culture cell lines. Proc Am Assoc Cancer Res 18:174, 1977. e-Pub 1977.
772. Roth JA, Morton DL, Holmes EC. Lymphocyte protein and nucleic acid synthesis in response to autologous and allogenic tumor associated antigens. Proc Am Assoc Cancer Res 17:92, 1976. e-Pub 1976.
773. Roth JA, Holmes EC, Reisfeld R, Morton DL. Immune responses to human lung carcinoma-associated antigens. Proc Am Assoc Thorac Surg, 1975. e-Pub 1975.
774. Roth JA. Isolation of soluble tumor-associated antigen from human melanoma. James Ewing Society, 1975. e-Pub 1975.
775. Roth JA, Golub SH, Holmes EC, Morton DL. Effect of BCG immunotherapy on lymphocyte function in melanoma patients. Society of University Surgeons, 1975. e-Pub 1975.
776. Roth JA, Eilber FR, Morton DL. The Role of radioisotope scintiscanning in the initial evaluation of melanoma patients. American College of Surgeons Regional Meeting, 1975. e-Pub 1975.
777. Roth JA, Holmes EC, Reisfeld RA, Morton DL, Eilber FR. Purification of human melanoma associated antigen. Proc Am Assoc Cancer Res 16:146, 1975. e-Pub 1975.
778. Roth JA, Golub SH, Grimm E, Eilber FR, Morton DL. Effects of surgery on in vitro lymphocyte function. Surg Forum, 1974. e-Pub 1974.
779. Waldman SR, Roth JA, Silverstein MJ, Pilch YH. Hematologic and immunologic effect of leukapheresis of cancer patients. Clin Res 22:497A, 1974. e-Pub 1974.
780. Roth JA, Silverstein MJ, Morton DL. Do metastases metastasize?. James Ewing Society, Maui, HI, 1974. e-Pub 1974.
781. Roth JA, ter Haar AM, Krajewski CA, Williams GM. Nucleic acid synthesis in allograft endothelium. Surg Forum 22:264-266, 1971. e-Pub 1971.

Book Chapters

1. Tsao A, Roth JA. 31Novel Emerging Agents in NSCLC (including gene therapy). In: Lung Cancer. 4th. Wiley-Blackwell Health Sciences, 479-487, 2014.
2. Sobol RE, Guan YS, Li LJ, Zhang WW, Peng Z, Menander KB, Chada S, Zumstein LA, Maneval DC, Horowitz JA, Warren R, Clayman GL, Swisher SG, Goodman WJ, Nemunaitis J, Roth JA. p53 Gene Therapy for Cancer Treatment and Prevention. In: p53 In the Clinics. Springer, 189-208, 2013.
3. Mehran R, Roth JA. Resection of pulmonary metastases. In: Atlas of Advanced Operative Surgery. 1st. Elsevier, Inc, 43-49, 2013.
4. Shirvani SM, Chang JY, Roth JA. Can stereotactic body radiation therapy (SBRT) in early stage lung cancers produce comparable success as surgery?. In: Thoracic Surgery Clinics - Lung Cancer, Part II: Surgery and Adjuvant Therapies. Elsevier Publishers, 369-381, 2013.
5. Roth JA, Chang JY. An Issue of Thoracic Surgery Clinics. In: Thoracic Surgery Clinics, devoted to Lung Cancer, Part II: Surgery and Adjuvant Treatment. Elsevier, 2013.
6. Kuroda S, Yokoyama T, Tam JO, Scott AW, Ma LL, Shanker M, Roth JA, Sokolov K, Johnston KP, Ramesh R. Multifunctional tumor-targeted nanoparticles for lung cancer. In: Pulmonary Nanomedicine: Diagnostic, Imaging and Therapeutics. Pan Stanford Publishing PTE Ltd, 15-44, 2012.
7. Ji L, Jayachandran G, Roth JA. High throughput profiling of serum phosphoproteins/peptides using the SELDI-TOF-MS platform. In: SELDI-TOF Mass Spectrometry: Methods in Molecular Biology. Chapter 14. Humana Press, 2012.
8. Jayachandran G, Roth J, Ji L. Analysis of Protein-Protein Interaction Using ProteinChip Array-Based SELDI-TOF Mass Spectrometry. In: SELDI-TOF Mass Spectrometry: Methods in Molecular Biology. Chapter 15. Humana Press, 2012.
9. Ramesh R, Shanker M, Jin J, West S, Roth JA. Lipid-based nanocarriers for cancer gene therapy. In: Lipid Nanocarriers in Cancer Diagnosis and Therapy. iSmithers-Creative Publishing Solutions, 169-188, 2011.
10. Allen M, Cerfolio R, Darling G, Deslauriers J, Duranceau A, Ferguson M, Finley R, Johnston M, Krasna M, Lerut T, Luketich J, Mathisen D, McKenna R, Pearson G, Reed C, Roth J, Rusch V, Sugarbaker D, Ximenes M, Yim A. Building a successful career: Advice from leaders in thoracic surgery. In: Thoracic Surgery Clinics. Elsevier, 395-415, 2011.
11. Ramesh R, Ioannides CG, Roth JA, Chada S. Adenovirus-Mediated Interleukin (IL)-24 Immunotherapy for Cancer. In: Methods Mol Biol. Humana Press, 241-70, 2010.
12. Roth JA. Cancer of the Lung. In: Cancer Medicine. 8th, 999-1043, 2010.
13. Lu C, Onn A, Vaporciyan AA, Chang JY, Glisson BS, Komaki R, Wistuba II, Roth JA, Herbst Roy S. Cancer of the Lung. In: Cancer Medicine. 8th, 999-1043, 2010.
14. Nemunaitis J, Roth JA. Gene-Based Therapies for Lung Cancer. In: Lung Cancer: Prevention, Management and Emerging Therapies. Springer, 305-330, 2009.
15. Nemunaitis J, Roth J. Vaccine Therapy for Lung Cancer. In: Lung Cancer. Springer, 279-304, 2009.
16. Roth JA. Gene Therapy Approaches for Lung Cancer. In: Molecular Pathology of Lung Diseases. Springer, 219-225, 2008.
17. Fang B, Roth JA. Tumor-suppressor gene replacement therapy. In: Viral Therapy of Cancer. John Wiley & Sons, Ltd, 229-239, 2008.
18. Fang B, Roth JA. Adenovector-mediated cancer gene therapy. Chapter 1. In: Cancer Drug Discovery and Development: Gene Therapy for Cancer, 3-22, 2007.
19. Chang JY, Komaki R, Roth JA, Jr HR, Cox JD. Image guidance of combined modality management of NSCLC. In: Image-guided radiation therapy for lung cancer. US Books and Journals, 1-14, 2007.
20. Chada S, Bocangel D, Pataer A, Mhashilkar AM, Inoue S, Miyahara R, Roth JA, Grimm EA, Swisher SG, Hunt KK, Ramesh R. MDA-7/IL-24 as a multi-modality therapy for cancer. Chapter 23. In: Cancer Drug Discovery and Development: Gene Therapy of Cancer. Humana Press, Inc, 413-434, 2007.
21. Roth JA. Targeted genetic therapy for lung cancer. In: Lung Cancer. 3rd. Blackwell Scientific Publishers, 411-420, 2007.
22. Chada S, Bocangel D, Menander K, Roth JA. Apoptosis modulators: p53 targeting. In: Targeted Therapies in Oncology. Informa Healthcare USA, Inc. – New York, London - Health Science Division of Taylor and Francis Group, 177-195, 2007.
23. Chang JY, Roth JA. Stereotactic body radiation therapy for stage I non-small cell lung cancer. In: Thorac Surg Clin. 2. Elsevier, 251-260, 2007.
24. Mehran R, Roth JA. Resection of pulmonary metastases (open/thorascopic). In: Atlas of Advanced Operative Surgery. Elsevier, Inc, 2007.
25. Chada S, Menander KB, Roth J, Ramesh R. Targeting cancer with tumor suppressor genes. In: Gene Therapy. Medical View Co. Ltd, 266-278, 2007.
26. Roth JA. Gene therapy for lung cancer. Chapter 36. In: Tumors of the chest: biology, diagnosis, and management. 1st. Springer Verlag, 431-435, 2006.
27. Moon C, Lee J, Par, Roth JA. . Current status of gene therapy for lung cancer and head and neck cancer. In: About Cancer in Africa. Instut National du Cancer, 673-703, 2006.
28. Onn A, Vaporciyan AA, Chang JY, Komaki R, Roth JA, Herbst R. Cancer of the lung. Chapter 7. In: Cancer Medicine. Williams & Wilkins, 1179-1225, 2005.
29. Roth JA, Grammer SF. Tumor suppressor gene replacement for cancer. Chapter 3. In: Contemporary Cancer Research Cancer Gene Therapy. 1st. Humana Press Inc, 19-33, 2005.
30. Roth JA. Genetics and molecular biology of lung cancer. In: Encyclopedia of Molecular Cell Biology and Molecular Medicine. 2nd Fung-Grow. Wiley-VCH Verlag GmbH & Co. KGaA, 353-368, 2004.
31. Roth JA, Grammer SF, Merritt JA, Swisher SG. Gene therapy clinical trials for cancer: replacement of tumor suppressor gene, p53 Chapter 38. In: Gene and Cell Therapy. 2nd. Marcel Dekker, Inc, 743-752, 2004.
32. Roth JA Grammer SF. Tumor suppressor gene therapy, Regulation, Function and Medicinal Applications. In: Methods in Molecular Biology. Humana Press, Inc, 577-598, 2003.
33. Vaporciyan AA, Kies M, Stevens C, Komaki R, Roth JA. Cancer of the lung. In: Cancer Medicine. BC Decker Inc, 1385-1446, 2003.
34. Putnam JB, Roth JA. Pulmonary metastases. In: Surgical Oncology: Multidisciplinary Approach to Difficult Problems. Arnold Publishers, 742-764, 2002.
35. Roth JA, Grammer SF, Merritt J, Swisher SG. Gene therapy clinical trials for cancer: replacement of tumor suppressor gene p53. In: Gene and Cell Therapy Therapeutic Mechanisms and Strategies. 2nd. Marcel Dekker, Inc, 743-752, 2002.
36. Swisher SG, Roth JA. Adenoviral p53 gene therapy strategies in non small-cell lung cancer, Chapter 19. In: Chemoradiation in Cancer Therapy. Humana Press, Inc, 349-358, 2002.
37. Fang B, Roth JA. Gene therapy. In: Molecular Basis of Cancer. 2nd. WB Saunders Company, 589-604, 2001.
38. Roth JA. Gene therapy approaches for the management of cancer. In: ASCO Spring Education Book, 558-5645, 2001.
39. Roth JA, Grammer SF. Gene therapy: tumor suppressor gene replacement and oncogene suppression, Chapter 98. In: The Cancer Handbook. MacMillan, 1521-1531, 2001.
40. Swisher SG, Grammer SF, Roth JA. Ad-p53 gene transfer strategies for non-small-cell lung cancer. In: American Society of Clinical Oncology, 412-417, 2001.
41. Roth JA. Lung Cancer "Biology of Lung Cancer" Chapter 31. In: Thoracic Surgery. Elsevier, 772-783, 2001.
42. Fang B, Roth JA. Gene therapy using direct in vivo gene injection. In: Principles and Practice of the Biologic Therapy of Cancer. 3rd. Lippincott Williams & Wilkins, 796-810, 2000.
43. Roth JA, Molldrem J, Smythe R. The current status of cancer gene therapy trials Chapter 13. In: Cancer: Principles & Practice of Oncology. 2nd. Lippincott-Raven, 2-15, 2000.
44. Vaporciyan AA, Nesbitt JC, Lee JS, Stevens C, Komaki R, Roth JA. Cancer of the lung. In: Cancer Medicine. 5th. Decker Inc, 1227-1292, 2000.
45. Roth JA. Cancer Biology. In: Thoracic Surgery Esophageal Surgery. 2nd. WB Saunders Co, 637-647, 1999.
46. Pollock RE, Balch CM, Roth JA, McPeek B, Mosteller F. Formulating an initial research plan. In: Surgical Research: Basic Principles and Clinical Practice. Third. Springer, 363-365, 1998.
47. Mukhopadhyay T, Roth JA. Ribozymes in targeting tumor suppressor genes. In: Ribozymes in the Gene Therapy of Cancer. RG Landes Co, 175-182, 1998.
48. Roth JA. The molecular biology of lung cancer. In: The Encyclopedia of Molecular Biology. Chernow Editorial Services, Inc, 1998.
49. Roth JA. Genetic manipulations for the treatment of lung cancer. In: Lung Cancer. Blackwell Science Inc, 369-381, 1998.
50. Roth JA. Defective tumor suppressor gene replacement and oncogene inactivation for the treatment of cancer. In: Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors. Marcel Dekker, Inc, 279-294, 1998.
51. Schrump DS, Roth JA. Gene therapy of lung cancer. In: Biology of Lung Cancer. Marcel Dekker, Inc, 171-185, 1998.
52. Swisher SG, Roth JA. Role of gene therapy in lung cancer. In: Advanced Therapy in Thoracic Surgery. Marcel Decker, Inc, 139-145, 1998.
53. Cristiano RJ, Nguyen D, Spitz F, Roth JA. Gene therapy: its interactions with chemotherapy. In: Infusion chemotherapy-irradiation interactions. Elsevier Science, 175-182, 1998.
54. Maxwell SA, Roth JA. Oncogene interactions with tumor suppressor genes. In: Encyclopedia of Cancer. Academic Press, Inc, 1161-1171, 1997.
55. Mukhopadhyay T, Roth JA. Isolation of total RNA from tissues or cell lines: visualization in Gel. In: Methods in Molecular Biology: RNA Isolation and Characterization Protocols. Humana Press Inc, 55-59, 1997.
56. Jr PJ, Morris P, Roth JA. Esophageal carcinoma. In: Difficult Problems in Surgical Oncology. Chapman & Hill, 1997.
57. Zhang WW, Roth JA. Methods for cancer gene therapy using tumor suppressor genes. In: Gene Therapy Protocols. Humana Press, 403-418, 1997.
58. Ajani JA, Roth JA, Ryan B, McMurtrey M, Rich TA. Resectable adenocarcinoma of the esophagus: a study of pre- and postoperative chemotherapy. In: Adjuvant Therapy of Cancer VI. WB Saunders Co, 396-404, 1996.
59. Balch CM, Milton GW, Roth JA. Surgery for metastatic melanoma. In: Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. JB Lippincott Co, 1996.
60. Nesbitt JC, Lee JS, Komaki R, Roth JA. Cancer of the Lung. In: Cancer Medicine. Williams & Wilkins, 3-83, 1996.
61. Roth JA. Gene replacement strategies for prevention and treatment of aerodigestive tract cancers. In: Accomplishments in Cancer Research. JB Lippincott Co, 188-199, 1996.
62. Roth JA. Lung cancer, molecular biology of. In: Encyclopedia of Molecular Biology and Molecular Medicine. VCH Verlagsesellschaft, 491-497, 1996.
63. Roth JA, Mukhopadhyay T, Casson AG, Chung KY. Molecular strategies for the prevention and therapy of cancer. In: Gene Therapy of Cancer. Appleton and Lange, 1996.
64. Roth JA, Putnam Jr JB. Pulmonary resection for metastatic disease. In: Difficult Problems in Surgical Oncology. Chapman and Hill, 1996.
65. Roth JA, Jr PJ, Rich TA, Forastiere AA. Cancer: cancer of the esophagus. In: Cancer: Principles and Practices of Oncology. Lippincott – Raven Press, 980-1010, 1996.
66. Ajani JA, Kelsen DP, Rich TA, Roth JA. Chemotherapy and combined modality therapy for squamous cell carcinoma and adenocarcinoma of the esophagus and gastroesophageal junction. In: Anonymous Thoracic Oncology. WB Saunders, 433-441, 1995.
67. Nesbitt JC, Jr PJ, Walsh GL, Ryan MB, Roth JA. Malignant diseases of the lung. In: Current Practice of Surgery. Churchill Livingstone, Inc, 1-54, 1995.
68. Jr PJ, Roth JA. Neoplasms of the esophagus. In: Digestive Tract Surgery: A Text and Atlas. Lippincott-Raven, 43-76, 1995.
69. Roth JA. The molecular biology of lung cancer. In: Molecular Biology and Molecular Medicine. VCH Publishers, Inc, 518-521, 1995.
70. Roth JA. Molecular biology and biotechnology. In: Lung Cancer, Molecular Biology of. VCH, 518-521, 1995.
71. Roth JA, Mukhopadhyay T, Zhang WW, Fujiwara T, Georges R. Gene replacement strategies for the prevention and therapy of cancer. In: The Internet Book of Gene Therapy Cancer Therapeutics. Appleton & Lange, 229-234, 1995.
72. Roth JA, Putnam JB. Surgery for carcinoma of the esophagus. In: Anonymous Thoracic Oncology. WB Saunders, 397-413, 1995.
73. Schrump DS, Roth JA. Clinical implications of molecular events in lung cancer. In: Molecular Basis of Oncology. Blackwell Scientific Publications, Inc, 295-316, 1995.
74. Schrump DS, Roth JA. Molecular biology and immunology of lung and esophageal cancer. In: Glenn’s Thoracic and Cardiovascular Surgery. 6. Appleton & Lange, 331-343, 1995.
75. Walsh GL, Roth JA. General principles and surgical considerations in the management of mediastinal masses. In: Thoracic Oncology. 2nd. WB. Saunders, 445-467, 1995.
76. Roth JA. Molecular genetic strategies for the prevention and therapy of lung cancer. In: Lung Cancer: Frontiers in Science and Treatment. Grafica L.P, 83-90, 1994.
77. Jr PJ, Roth JA. Secondary tumors in the lungs. In: General Thoracic Surgery. Williams & Wilkins, 1334-1352, 1994.
78. Putnam JB, Roth JA. Surgical resection of pulmonary metastases. In: Cancer Surgery. JB Lippincott Co, 337-350, 1994.
79. Roth JA. The esophageal mucosa. In: Anonymous O.E.S.O. Elsevier, 1093-1096, 1994.
80. Roth JA. Is an initial multifocal or diffuse appearance characteristics of adenocarcinoma in CLE?. In: The Esophageal Mucosa. Elsevier, 1093-1996, 1994.
81. Roth JA, Mukhopadhyay T, Casson AG, Chung KY. Molecular strategies for early detection, prevention and therapy cancer. In: Early Detection of Cancer: Molecular Markers. Armok, Futura Publishing Company, Inc, 45-52, 1994.
82. Roth JA, Jr PJ. New insights into selecting patients likely to benefit from resection of pulmonary metastases. In: Lung Cancer: Frontiers in Science and Treatment, 473-482, 1994.
83. Zhang Y, Mukhopadhyay T, Georges R, Roth JA. Molecular targeting of cancer: retroviral vector-mediated antisense nucleic acid therapy. In: Gene Therapy: From Lab to the Clinic. World Scientific Publishing Company, 70-106, 1994.
84. Mukhopadhyay T, Roth JA. p53 gene mutations in human premalignant and malignant tissues. In: Methods in Molecular Genetics. Academic Press, Inc, 104-128, 1993.
85. Jr PJ, Roth JA. Neoplastic diseases of the esophagus. In: Digestive Tract Surgery: A Text and Atlas. JB Lippincott, 43-75, 1993.
86. Putnam JB, Ryan MB, Walsh GL, Roth JA. Malignant disease of the lung. In: Current Practices of Surgery. Churchill Livingstone, Inc, 1-44, 1993.
87. Roth JA. The biology of lung cancer. In: Thoracic Surgery, 637-647, 1993.
88. Roth JA. Advances in cell and molecular biology of non-small cell lung cancer. In: Advances in Diagnosis and Therapy of Lung Cancer. Blackwell Scientific, 85-104, 1993.
89. Roth JA, Jr PJ. Cancer of the esophagus. In: Cancer: Principles & Practice of Oncology. JB Lippincott Co, 776-817, 1993.
90. Yang SC, Grimm E, Roth JA. Immunotherapy of lung cancer. In: Advances in Diagnosis and Therapy of Lung Cancer. Blackwell Scientific, 379-390, 1993.
91. Putnam JB, Roth JA. Resection of pulmonary metastases. In: Current Therapy in Oncology. BC Becker, 197-201, 1992.
92. Roth JA, Sugarbaker PH, Baker AR. Radical forequarter amputation with chest wall resection. In: Anonymous Musculoskeletal Surgery for Cancer. Thieme Medical Publishers, Inc, 317-324, 1992.
93. Pollock RE, Balch CM, Roth J, McPeek B, Mosteller F. Formulating an initial research plan. In: Principles and Practices of Research: Strategies for Surgical Investigators. Second. Springer-Verlag, 88-90, 1991.
94. Roth JA. Treatment of metastatic cancer: treatment of metastatic cancer to lung. In: Cancer: Principles and Practice of Oncology. JB Lippincott Co, 2261-2275, 1989.
95. Roth JA. Solitary pulmonary nodule. In: Common Problems in Gastrointestinal Surgery. Year Book Medical Publishers, 53-58, 1989.
96. Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC, Steinberg S. Clinical trials with cisplatin, vindesine, and bleomycin neoadjuvant chemotherapy for epidermoid carcinoma of the esophagus. In: Gastrointestinal Cancer: Current Approaches to Diagnosis and Treatment. University of Texas Press, 253-259, 1989.
97. Sugarbaker PH, Roth JA. Specialized techniques of cancer management: endoscopy. In: Cancer: Principles and Practice of Oncology. JB Lippincott Co, 423-440, 1989.
98. Moody FG, Roth JA. The esophagus and diaphragmatic hernias. In: Hardy’s Textbook of Surgery. 2nd. James D. Hardy, 485-513, 1988.
99. Roth JA. Prognostic indicators for soft tissue sarcoma patients with pulmonary metastases. In: Recent Concepts in Sarcoma Treatment. Kluwer Academic Publishers, 191-196, 1988.
100. Roth JA. Resection of pulmonary metastases. In: Thoracic Oncology. WB Saunders Co, 619-630, 1988.
101. Roth JA, Kelsen DP. Surgery and adjuvant chemotherapy for carcinoma of the esophagus. In: Thoracic Oncology. WB Saunders Co, 379-394, 1988.
102. Ajani JA, McMurtrey MJ, Rich TA, Blackburn R, Chang-Tung E, Levin B, Roth JA, Mountain CF. Carcinoma of the esophagus: Contribution of chemotherapy. In: Gastrointestinal Cancer: Current Approaches to Diagnosis and Treatment. University of Texas Press, 273-281, 1988.
103. Kern KA, Pass HI, Roth JA. Surgical treatment of pulmonary metastases. In: Surgical Treatment of Metastatic Cancer. JB Lippincott Co, 69-100, 1987.
104. Ognibene FP, Pass HI, Roth JA, Shelhamer JH. The diagnosis and therapy of respiratory disease in the immunosuppressed host. In: The Critically Ill Immunosuppressed Patient. Aspen Publications, 39-80, 1987.
105. Pass HI, Roth JA. Diagnosis of pulmonary metastases. In: Surgical Treatment of Metastatic Cancer. JB Lippincott Co, 36-67, 1987.
106. Roth JA. Oncogenes and monoclonal antibodies. In: Monoclonal Antibodies for the Diagnosis and Therapy for Cancer. Futura Publishing Co, Inc, 289-321, 1987.
107. Grimm EA, Roth JA, Yagita M. Effect of OK-432 activated cytolytic lymphocytes on NK resistant fresh tumor cells. In: Host Defense Mechanisms and Immunopotentiators. University of Tokyo Press, 67-74, 1986.
108. Roth JA. Oncogenes and monoclonal antibodies. In: Monoclonal Antibodies in Cancer: Advances in Diagnosis and Treatment. Futura Publishing Company, Inc, 1986.
109. Balch CM, Milton GW, Roth JA. Diagnosis of metastatic melanoma at distant sites. In: Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. JB Lippincott Co, 221-250, 1985.
110. Rosenberg JC, Roth JA, Lichter AS, Kelsen DP. Cancer of the esophagus. In: Cancer: Principles and Practice of Oncology. JB Lippincott Co, 621-657, 1985.
111. Roth JA. Treatment of pulmonary metastases. In: Cancer: Principles and Practices of Oncology. JB Lippincott Co, 2117-2131, 1985.
112. Roth JA. Treatment of metastatic cancer: treatment of metastatic cancer to lung. In: Cancer: Principles and Practice of Oncology. JB Lippincott Co, 2104-2117, 1985.
113. Roth JA. Endoscopy for thoracic oncologic diseases. In: Cancer: Principles and Practices of Oncology. JB Lippincott Co, 353-406, 1985.
114. Sugarbaker PH, Roth JA. Specialized techniques of diagnosis: endoscopy. In: Cancer: Principles and Practices of Oncology. JB Lippincott Co, 353-374, 1985.
115. Roth JA, Sugarbaker PH, Baker AR. Radical forequarter amputation with chest wall resection. In: Atlas of Extremity Sarcoma Surgery. JB Lippincott Co, 177-191, 1984.

Books (edited and written)

1. Roth JA, Komaki R, Hong WK. Lung Cancer. Ed(s) 4th. Wiley-Blackwell Health Sciences, 2014.
2. Albelda SM, Andreef M, Aref I, Barton K, Brown S, Chiocca EA, Curiel DT, Dembinski J, Desai A, Ekmekcioglu S, Ellerhorst J, Elshaikh M, Freytag SO, Fueyo J, Fujiwara T, Gerson S, Grimm EA, Haas AR, Hall B, Ji L, Jiang H, Kaur B, Kidd S, Kim JH, Kim K, Klopp A, Lang F, Lin Y, Ling X, Lopez-Berestein G, Lu M, Mangala LS, Marini F, Moon EK, Mora EM, Movsas B, Nemunaitis J, Poindexter N, Pollock RE, Price RL, Ramesh R, Rao DD, Roth JA, Senzer N, Shay JW, Siddiqui F, Singhal S, Sood AK, Spaeth E, Sterman DH, Stricker H, Studeny M, Thacker EE, Torres KE, Vorhies JS, Zeng Z. Gene-Based Therapies for Cancer. Ed(s) 1st. Springer, 2010.
3. Roth JA, Hong WK, Cox CD. Lung Cancer. Ed(s) 3rd. Blackwell Scientific Publishers, 2007.
4. Roth JA, Hong WK, Cox CD. Lung Cancer. Ed(s) 2nd. Blackwell Scientific Publishers, Inc, 1998.
5. Roth JA, Ruckdeschel J, Weisenburger T. Thoracic Oncology. Ed(s) 2nd. WB Saunders Co, 1995.
6. Mukhopadhyay T, Maxwell SA, Roth JA. p53 Suppressor Gene. RG Landes Co, 1995.
7. Roth JA, Hong WK, Cox CD. Lung Cancer. Ed(s) 1st. Blackwell Scientific Publishers, Inc, 1993.
8. Roth JA, Ruckdeschel J, Weisenburger T. Thoracic Oncology. Ed(s) 1st. WB Saunders Co, 1988.
9. Roth JA. Monoclonal Antibodies for the Diagnosis and Therapy of Cancer. Futura Publishing Company, Inc, 1987.

Patents

1. Ji LX, Fang B, Roth JA. Novel hTMC promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes. Patent Number: 8,658,778.
2. Roth J, Ji L. Methods and Compositions for TUSC2 Immunotherapy. Patent Number: 2017342364.
3. Roth JA, Li J. Methods and Compositions for TUSC2 Immunotherapy. Patent Number: ZL 201780076886.X.
4. Roth JA, Ji L. Methods and compositions for TUSC2 immunotherapy. Patent Number: 11278592.
5. Roth JA, Ji L. Methods and Compositions for TUSC2 Immunotherapy. Patent Number: 7041136.
6. |Roth J, Ji L. Methods and Compositions for TUSC2 Immunotherapy. Patent Number: 2755903.
7. Roth J, Stewart D, Lu C, Wistuba I, Nunez M. FUS1/TUSC2 Therapies. Patent Number: 2,864,394.
8. Gentile E, Ji L, Roth JA. Cationic Liquid Crystalline Nanoparticles. Patent Number: 3 634 386.
9. Ji L, Minna JD, Roth J, Lerman M. Chromosome 3p21.3 Genes Are Tumor Suppressors. Patent Number: 9,944,951.
10. Lin J, Arlinghaus R, Sun T, Ji L, Ozpolat B, Lopez-Berestein G, Roth JA. Bioactive FUS1 peptides and nanoparticle-polypeptide complexes. Patent Number: 8,859,727.
11. Roth J, Stewart D, Lu C, Wistuba II, Yan S, Nunez MI. TUSC2 Therapies. Patent Number: 9,675,663.
12. Roth J, Stewart D, Lu C, Wistuba I, Yan S, Nunez MI. TUSC2 Therapies. Patent Number: 2741784.
13. Ramesh R, Roth JA, Saeki T, Wilson DR. Methods and compositions for non-viral gene therapy for hyperproliferative disease. Patent Number: 60030970.3.
14. Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Compositions comprising DNA damaging agents and p53. Patent Number: 69535684.4-08.
15. Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Compositions comprising DNA damaging agents and p53. Patent Number: 1157702.
16. Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Compositions comprising DNA damaging agents and p53. Patent Number: AT383167.
17. Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Compositions comprising DNA damaging agents and p53. Patent Number: 0760675B2.
18. Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Compositions comprising DNA damaging agents and p53. Patent Number: 2160707.
19. Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Compositions comprising DNA damaging agents and p53. Patent Number: 69521994.4.
20. Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Compositions comprising DNA damaging agents and p53. Patent Number: 0760675.
21. Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Compositions comprising DNA damaging agents and p53. Patent Number: AT203675.
22. Zhang WW, Roth JA. Recombinant p53 adenovirus methods and compositions. Patent Number: 222981.
23. Zhang WW, Roth JA. Recombinant p53 adenovirus methods and compositions. Patent Number: 288790.
24. Zhang WW, Roth JA. Recombinant p53 adenovirus methods and compositions. Patent Number: 812631.
25. Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and p53. Patent Number: 43917.
26. Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and p53. Patent Number: 185749.
27. Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and p53. Patent Number: ZL95192776.0.
28. Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and p53. Patent Number: 325560.
29. Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and p53. Patent Number: 221279.
30. Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and p53. Patent Number: 295144.
31. Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and p53. Patent Number: 284709.
32. Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and p53. Patent Number: 2146149.
33. Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and p53. Patent Number: 694216.
34. Zhang WW, Roth JA. Recombinant p53 adenovirus methods and compositions. Patent Number: ZL94194354.2.
35. Zhang WW, Roth JA. Recombinant p53 adenovirus methods and compositions. Patent Number: 698437.
36. Zhang WW, Roth JA. Recombinant p53 adenovirus methods and compositions. Patent Number: 186151.
37. Zhang WW, Roth JA. Recombinant p53 adenovirus methods and compositions. Patent Number: 2222600.
38. Zhang WW, Roth JA. Recombinant p53 adenovirus methods and compositions. Patent Number: 73265.
39. Zhang WW, Roth JA. Recombinant p53 adenovirus methods and compositions. Patent Number: 275356.
40. Roth JA, Leman MI, Ji L, Minna JD. Chromosome 3p21.3 genes are tumor suppressors. Patent Number: 7,977,468.
41. Ramesh R, Roth JA, Saeki T, Wilson DR. Methods and compositions for non-viral gene therapy for hyperproliferative disease. Patent Number: 1180016.
42. Roth JA, Leman MI, Ji L, Minna JD. Chromosome 3p21.3 genes are tumor suppressors. Patent Number: 2000127337.
43. Zhang WW, Roth JA. Recombinant p53 adenovirus methods and compositions. Patent Number: 2,174,556.
44. Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and p53. Patent Number: 5,747,469.
45. Mukhopadhyay T, Roth JA. 2-methoxyestradiol-induced apoptosis in cancer cells. Patent Number: 5,958,892.
46. Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang W, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and p53. Patent Number: 6,069,134.
47. Fang B, Roth JA. Diminishing viral gene expression by promoter replacement. Patent Number: 6,110,744.
48. Zhang WW, Roth JA. Tumor regression by adenovirus expression of wild-type p53. Patent Number: 6,143,290.
49. Ji L, Roth JA. P16 expression constructs and their application in cancer therapy. Patent Number: 6,251,871.
50. Zhang WW, Roth JA. Recombinant P53 adenovirus compositions. Patent Number: 6,410,010.
51. Zhang WW, Roth JA. Recombinant p53 adenovirus methods and compositions. Patent Number: 6,511,847.
52. Roth JA, Mukhopadhyay T, Tainsky M. Inhibition of cellular proliferation using ras antisense molecules. Patent Number: 6,627,189.
53. Fang B, Roth JA. Diminishing viral gene expression by promoter replacement. Patent Number: 6,630,344.
54. Zhang WW, Roth JA. Recombinant P53 adenovirus methods and compositions. Patent Number: 6,740,320.
55. Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and P53. Patent Number: 6,797,702.
56. Zhang WW, Roth JA. Recombinant P53 adenovirus methods and compositions. Patent Number: 6,830,749.
57. Zhang WW, Roth JA. Recombinant p53 adenovirus methods and compositions. Patent Number: 6,905,873.
58. Roth JA, Mukhopadhyay T, Tainsky MA. Cancer treatment with retroviral vectors comprising wild-type p53. Patent Number: 6,998,117.
59. Ji L, Roth JA. p16 expression constructs and their application in cancer therapy. Patent Number: 7,163,925.
60. Roth JA, Cai DW, Mukhopadhyay T. Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme A. Patent Number: 6,482,803.
61. Zhang WW, Roth JA. Methods for the administration of adenovirus p53. Patent Number: 6,805,858.
62. Wilson DR, Lapadat-Tapolsky M, Timmons TM, Lee JA, Almond BD, Roth JA. Inhibition of cell growth by an anti-proliferative factor. Patent Number: 6,133,416.
63. Fang B, Roth JA. Diminishing viral gene expression by promoter replacement. Patent Number: 7,244,617.
64. Zhang WW, Roth J. Adenovirus supervector system. Patent Number: 7,252,989.
65. Mukhopadhyay T, Chada S, Mhashilkar A, Roth JA. Antihelminthic drugs as a treatment for hyperproliferative diseases. Patent Number: 7,423,015.
66. Ji L, Minna JD, Roth J, Lerman M. Chromosome 3p21.3 genes are tumor suppressors. Patent Number: 7,902,441.
67. Zhang WW, Roth JA. Recombinant P53 adenovirus methods and compositions. Patent Number: 7,033,750.
68. Roth JA, Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB. Methods and compositions comprising DNA damaging agents and p53. Patent Number: 7,109,179.
69. Lin J, Arlinghaus RB, Sun T, Ji L, Ozpolat B, Lopez-Berestein G, Roth JA. Bioactive FUS1 peptides and nanoparticle-polypeptide complexes. Patent Number: 8,338,366.